

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
 International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/52, 9/00, C12Q 1/25</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/60091</b> <b>(43) International Publication Date:</b> 12 October 2000 (12.10.00)
<b>(21) International Application Number:</b> PCT/US00/09154 <b>(22) International Filing Date:</b> 6 April 2000 (06.04.00)  <b>(30) Priority Data:</b> 60/127,977                      6 April 1999 (06.04.99)                      US  <b>(71) Applicant:</b> OKLAHOMA MEDICAL RESEARCH FOUNDATION [US/US]; 825 N.E. Thirteenth Street, Oklahoma City, OK 73104 (US).  <b>(72) Inventors:</b> SAUER, Brian, Lee; 601 Robert S. Kerr Avenue, Apartment 109, Oklahoma City, OK 73102 (US). RUFER, Andreas, Walter; 125 N.W. Fifteenth Street, Apartment 604, Oklahoma City, OK 73103 (US).  <b>(74) Agents:</b> PABST, Patrea, L. et al.; Arnall Golden & Gregory, LLP, 2800 One Atlantic Center, 1201 West Peachtree Street, Atlanta, GA 30309-3450 (US).	<b>(81) Designated States:</b> AU, CA, IL, JP, ZA, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
<b>(54) Title:</b> METHOD FOR SELECTING RECOMBINASE VARIANTS WITH ALTERED SPECIFICITY  <b>(57) Abstract</b> <p>Disclosed are variants of Cre recombinase that have broadened specificity for the site of recombination. Specifically, the disclosed variants mediate recombination between sequences other than the loxP sequence and other lox site sequences on which wild type Cre recombinase is active. In general, the disclosed Cre variants mediate efficient recombination between lox sites that wild type Cre can act on (referred to as wild type lox sites), between variant lox sites not efficiently utilized by wild type Cre (referred to as variant lox sites), and between a wild type lox site and a variant lox site. Also disclosed are methods of recombining nucleic acids using the disclosed Cre variants. For example, the disclosed Cre variants can be used in any method or technique where Cre recombinase (or other, similar recombinases such as FLP) can be used. In addition, the disclosed Cre variants allow different alternative recombinations to be performed since the Cre variants allow much more efficient recombination between wild type lox sites and variant lox sites. Control of such alternative recombination can be used to accomplish more sophisticated sequential recombinations to achieve results not possible with wild type Cre recombinase.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

## METHOD FOR SELECTING RECOMBINASE VARIANTS WITH ALTERED SPECIFICITY

### BACKGROUND OF THE INVENTION

Recombinases, integrases and resolvases (collectively referred to herein  
5 as recombinases) mediate the site-specific recombination of DNA. These  
recombinases were first identified in phage that integrate into host  
chromosomes. Such integration allows the phage to remain latent in the cell as  
a prophage.

Site-specific recombinases catalyze conservative DNA rearrangements  
10 at specific target sequences. The 38 kDa Cre recombinase (cyclization  
recombination), derived from the bacteriophage P1, is a well characterized and  
widely used enzyme of the Integrase family (reviewed by Sauer, *Methods*,  
14:381-392 (1998)). Cre plays two essential roles in the life cycle of P1: First,  
it provides a host-independent mechanism for P1's genome cyclization after  
15 infection, which can be important when the recombination system of the host is  
compromised. Second, Cre resolves dimerized P1 prophage plasmids to  
guarantee proper segregation during cell division.

Cre acts on a 34 bp sequence located on both ends of the linear P1  
genome, that is called *loxP* (locus of crossover of P1; Sternberg and Hamilton,  
20 *J. Mol. Biol.*, 150:467-486 (1981)), *loxP* consists of two 13 bp inverted repeats  
flanking a non-palindromic 8 bp core that defines the assigned direction of the  
sequence (as shown on the upper part of Figure 1). Depending on this direction,  
recombination catalyzed by Cre leads to excision of insertion of DNA flanked  
by *loxP* sites orientated in the same direction (indicated by *loxP*<sup>2</sup>), but leads to  
25 inversion when oriented in the opposite direction (Figure 2).

In general, Cre-recombination involves the following four events: (i)  
DNA binding, (ii) synapsis (as defined below), (iii) cleavage, and (iv) strand  
exchange. To study this process in greater detail, mutants defective for each  
step have been isolated using several screening procedures (Wierzbicki et al., *J.*  
30 *Mol. Biol.*, 195:785-794 (1987)). In addition, the crystal structure of Cre  
complexed with an artificial suicide substrate has been recently resolved,  
providing additional insights into site-specific recombination (Guo et al.,



*Nature*, 389:40-46 (1997)). From these studies, the following has been proposed: Four interacting Cre molecules are necessary for recombination between two *lox* sites, with each enzyme binding one inverted repeat plus the two outermost bp of the non-symmetric core region (DNA binding). This leads to the formation of a clamp, allowing DNA contacts in the major, as well as in the minor groove. In the step referred to as synapsis, the two *lox* sites with the bound Cre molecules, are aligned in parallel leading to an approximate 100° bending of the DNA. In the following step of strand cleavage, one of the two Cre molecules on each *lox* site causes a staggered cut in the core region, as indicated by the vertical arrows in Figure 1. This leads to a 6 bp 5' overhang and a covalent 3' phosphotyrosine linkage between the catalytic residue tyrosine 324 of Cre and the guanine (position 4) at the cleaving site of *loxP*. The created phosphotyrosine intermediate is thought to provide the energy for the reaction, thereby explaining why Cre does not require an external energy source. In the next step, the first strand is exchanged between the two nicked *lox* sites, creating an intermediate, named Holliday structure (Sigal and Alberts, *J. Mol. Biol.*, 71:789-793 (1972)). Of note, this first strand exchange is asymmetric, since the bottom strand (Figure 1) is always exchanged first (Hoess et al., *Proc. Natl. Acad. Sci. USA*, 84:6840-6844 (1987)). During the final step, the second strand is exchanged and Cre released from its substrate.

Because of the simplicity and the ability of Cre to function in yeast and mammalian cells (Sauer, B., *Mol. Cell. Biol.*, 7:2087-2096 (1987); Sauer and Henderson, *Proc. Natl. Acad. Sci. USA*, 85:5166-5170 (1988), Sauer and Henderson, *Nucl. Acids Res.*, 17:147-161 (1989), and Sauer and Henderson, *The New Biologist*, 2:441-449 (1990), Cre assisted site-specific recombination has become an important tool for efficient, specific, and conditional manipulations of eukaryotic genomes (Lakso et al., *Proc. Natl. Acad. Sci. USA*, 89:6232-6236 (1992)); Kilby et al., *Genet.*, 9:413-421 (1993); Sauer, B., *Meth. enzymol.*, 225:890-900 (1993); Kühn et al., *Science*, 269:1427-1429 (1995); Metzger et al., *Pro. Natl. Acad. Sci. USA*, 92:6991-6995 (1995).

However, there are some inconveniences for the successful use of Cre-related technologies, that include the following: (i) *lox* sites need to be

introduced by homologous recombination at the desired region into the genome before Cre can be used, (ii) the frequency of correct site-specific recombination due to Cre expression is not 100%, and consequently, (iii) selectable markers are necessary in most strategies involving Cre for genome manipulation in higher eukaryotes. These markers, e.g. *neo* or TK, may introduce problems in subsequent studies, particular in those related to animal development. The number of available selectable markers that can be used is limited also. Additional site-specific recombinases that also function efficiently in eukaryotic systems, but recognize different sites from *lox* would be helpful. Similar inconveniences limit the usefulness of other recombinases.

Therefore, it is an object of the present invention to provide a method of identifying variant recombinases that can mediate recombination between variant recombination sites.

It is another object of the present invention to provide variant recombinases that can mediate recombination between variant recombination sites.

It is another object of the present invention to provide a method of recombining nucleic acid molecules *in vitro* and *in vivo*.

It is another object of the present invention to provide Cre variants that recognize variant recombination sites.

#### BRIEF SUMMARY OF THE INVENTION

Disclosed is a method for identifying variant forms of recombinases that can mediate recombination between variant recombination sites. The method involves producing mutant recombinases and testing the mutant recombinases with specially designed constructs. The constructs contain variant recombination sites that are not recognized by non-mutant recombinase but will undergo recombination in the presence of a mutant recombinase with altered specificity. Recombination at the variant recombination sites can be monitored or detected by any suitable means. It is preferred that recombination is detected by screening or selection based on the expression or lack of expression of a reporter gene. This can be accomplished by using constructs containing a reporter gene associated with the variant recombination sites such that the

reporter gene is rearranged or deleted, or a spacer sequence interrupting the reporter gene is rearranged or deleted, as a result of recombination at the recombination sites. Recombination of such constructs will result in a loss of expression of the reporter gene, where the construct contained a functional reporter gene, or in a gain in expression of the reporter gene, where the construct contained a non-functional reporter gene.

The disclosed method also involves determining whether a variant recombinase retains the ability to mediate recombination at recombination sites recognized by non-variant recombinase. This can be accomplished by using constructs containing recombination sites recognized by non-variant recombinase. Recombination at these recombination sites can be monitored or detected by any suitable means. It is preferred that recombination is detected by screening or selection based on the expression or lack of expression of a reporter gene. This can be accomplished by using constructs containing a reporter gene associated with the recombination sites recognized by non-variant recombinase such that the reporter gene is rearranged or deleted, or a spacer sequence interrupting the reporter gene is rearranged or deleted, as a result of recombination at the recombination sites. Recombination of such constructs will result in a loss of expression of the reporter gene, where the construct contained a functional reporter gene, or in a gain in expression of the reporter gene, where the construct contained a non-functional reporter gene.

When variant recombinases are tested for activity on both variant recombination sites and recombination sites recognized by non-variant recombinase in the same system or at the same time, it is preferred that two different reporter genes, which can be separately detected or monitored, be used. In this case, the first reporter gene can be associated with the variant recombination sites and the second reporter gene can be associated with recombination sites recognized by non-variant recombinase.

Recombination between two recombination sites requires (1) that the recombinase recognize the sites as recombination sites, and (2) that the sequences of the two sites is sufficiently similar. It has been discovered that recombination between two recombination sites (both of which are recognized

by a recombinase) can be substantially reduced or prevented by using different compatibility sequences for the recombination sites (the recognition sequences can also differ if the recombinase can recognize different sequences). Thus, it is also preferred that the variant recombination sites be made incompatible with the recombination sites recognized by non-variant recombinase by using different compatibility sequences for the two sets of recombination sites.

Compatibility sequences in a recombination site are those sequences in the recombination site, other than the sequences required for recognition of the site by the recombinase, that must be similar in a pair of recombination sites for recombination to occur between them. Many recombination sites contain repeats of a characteristic sequence separated by spacer sequences. In such recombination sites, the spacer sequences are generally compatibility sequences and the repeats (or parts of the repeats) are recognition sequences. Recombinases require specific recognition sequences but allow wide variation in compatibility sequences. Thus, recombination sites that are recognized by a given recombinase but are incompatible with each other can be readily designed using the disclosed principles.

Also disclosed are variant recombinases made or identified by the disclosed method that have broadened specificity for the site of recombination. Specifically, the disclosed variants mediate recombination between sequences other than recombination sites on which the wild type recombinase is active. In general, the disclosed recombinase variants can mediate efficient recombination between recombination sites that wild type recombinase can act on (referred to as wild type recombination sites), between variant recombination sites not efficiently utilized by wild type recombinase (referred to as variant recombination sites), and between a wild type recombination site and a variant recombination site.

Also disclosed are methods of recombining nucleic acids using the disclosed variant recombinases. For example, the disclosed variant recombinases can be used in any method or technique where wild type recombinases can be used. In addition, the disclosed variant recombinases allow different alternative recombinations to be performed since the variant

recombinases can allow much more efficient recombination between wild type recombination sites and variant recombination sites. Control of such alternative recombination can be used to accomplish more sophisticated sequential recombinations to achieve results not possible with wild type recombinases.

- 5 The disclosed variant recombinases also allow recombination at specific genomic sites without the need to first introduce a recombination site.

Also disclosed are variants of Cre recombinase that have broadened specificity for the site of recombination. Specifically, the disclosed variants mediate recombination between sequences other than the loxP sequence and  
10 other lox site sequences on which wild type Cre recombinase is active. In general, the disclosed Cre variants mediate efficient recombination between lox sites that wild type Cre can act on (referred to as wild type lox sites), between variant lox sites not efficiently utilized by wild type Cre (referred to as variant lox sites), and between a wild type lox site and a variant lox site. Also disclosed  
15 are methods of recombining nucleic acids using the disclosed Cre variants. For example, the disclosed Cre variants can be used in any method or technique where Cre recombinase (or other, similar recombinases such as FLP) can be used. In addition, the disclosed Cre variants allow different alternative recombinations to be performed since the Cre variants allow much more  
20 efficient recombination between wild type lox sites and variant lox sites. Control of such alternative recombination can be used to accomplish more sophisticated sequential recombinations to achieve results not possible with wild type Cre recombinase.

#### BRIEF DESCRIPTION OF THE DRAWINGS

- 25 Figure 1 is a comparison of three different lox sites. loxP is the original recombination site for Cre recombinase. loxK1 and loxK2 are variant lox sites.

Figure 2 is a diagram of two different forms of construct and the resulting recombination products.

- Figure 3 is a diagram of an example of a random mutagenesis using  
30 DNA shuffling.

Figure 4 is a diagram of the selection plasmid for *loxK2* recombination, pBS584. Recombination of two *loxK2* sites by a potent Cre mutant will result

in the excision of *EGFP* and the transcriptional terminator *rrnBT<sub>1</sub>T<sub>2</sub>*.  
Subsequently, *neo* transcription can take place, rendering *E. coli* resistant to  
kanamycin. Note that the promoter (pRSV) even though of eukaryotic origin  
was shown to be functional in *E. coli* (Antonucci et al., *J. Biol. Chem.*,  
5 264:17656-17659 (1989)).

Figure 5 depicts gels of nucleic acid fragments and PCR products  
generated during the DNA shuffling process.

Figure 6 is a diagram of plasmid pBAD33 used for expression of mutant  
*cre* pools.

10 Figure 7 is a diagram of the construction of selection plasmids pBS568  
and pBS569.

Figure 8 is a diagram of the construction of selection plasmids pBS583  
and pBS584.

Figure 9 is a diagram of control plasmid pBS613.

15 Figure 10 is a diagram of the construction of screening plasmids pBS601  
and pBS602.

Figure 11 is a diagram of examples of basic types of constructs useful in  
the disclosed method. These types of constructs are: (1) interrupted constructs  
where the gene is interrupted by a nucleic acid segment (which is flanked by  
20 recombination sites) that is deleted during recombination, (2) flanked constructs  
where the gene as a unit is flanked by recombination sites and the gene is  
deleted by recombination, and (3) inverted constructs where a portion of the  
gene is on an inverted nucleic acid segment and recombination causes the  
segment to invert and reconstitute the intact gene. The type of recombination is  
25 indicated in parentheses.

Figures 12A, 12B, and 12C are diagrams of examples of constructs and  
their expected recombination when used in the disclosed method. Figure 12A  
shows examples of deletion constructs (flanked and interrupted). Figure 12B  
shows examples of inverted constructs. Figure 12C shows examples of  
30 constructs that combine through recombination to reconstitute an intact gene.

Figure 13 is a diagram showing the identified amino-acid changes in the  
six selected Cre mutants are listed according to their position in the protein's

secondary structure (silent mutations in parenthesis). Only one amino acid change, E262G, is common to all mutants with remarkably increased *loxK2* activity (R3M1, 2, 3, 5, and 6), suggesting that this mutation is essential for the observed phenotype.

5           Figure 14A is a table comparing recombination frequencies *in vivo* obtained with a variety of *lox* sites altered at positions 11 and 12. Figure 14B is a table comparing recombination frequencies *in vivo* obtained with identical and mixed *lox* sites. Wild type Cre and five different mutant enzymes were tested for their performance on different *lox*<sup>2</sup> substrates, as indicated. Given are the  
10           obtained percentages of recombination *in vivo* based on the described negative selection.

          Figure 15 is a table comparing recombination frequencies *in vitro* obtained with a variety of *lox* sites altered at positions 11 and 12.

          Figure 16 is a graph of percent of various Cre recombinases (wt, G, GA,  
15           GN, GS, R3M3) bound to various *lox* sites (*loxP*, *loxK2*, *loxK1*).

          Figure 17 shows wildtype and target FRT sites.

          Figure 18 shows the strategy for selection of altered specificity FLP mutants.

          Figure 19 shows an alternate target mutant FRT site. The design and  
20           rationale for design of the target mutant FRT site is as described in Figure 17, but the mutant FRT-M2 site differs from FRT-M by carrying a different mutational alteration in the repeat elements.

#### DETAILED DESCRIPTION OF THE INVENTION

          Disclosed is a method for identifying variant forms of recombinases that  
25           can mediate recombination between variant recombination sites. The method involves producing mutant recombinases and testing the mutant recombinases with specially designed constructs. The constructs contain variant recombination sites that are not recognized by non-mutant recombinase but will undergo recombination in the presence of a mutant recombinase with altered  
30           specificity. The disclosed method also involves determining whether a variant recombinase retains the ability to mediate recombination at recombination sites recognized by non-variant recombinase.

When variant recombinases are tested for activity on both variant recombination sites and recombination sites recognized by non-variant recombinase in the same system or at the same time, it is preferred that two different reporter genes which can be separately detected or monitored be used.

5 In this case, a first reporter gene can be associated with the variant recombination sites and a second reporter gene can be associated with recombination sites recognized by non-variant recombinase. It is also preferred that the variant recombination sites be made incompatible with the recombination sites recognized by non-variant recombinase by using different  
10 compatibility sequences for the two sets of recombination sites. This allows separate assessment of the ability of a variant recombinase to mediate recombination between variant recombination sites and recombination sites recognized by non-variant recombinase.

Also disclosed are variant recombinases made or identified by the  
15 disclosed method that have broadened specificity for the site of recombination. Also disclosed are methods of recombining nucleic acids using the disclosed variant recombinases. For example, the disclosed variant recombinases can be used in any method or technique where wild type recombinases can be used. In addition, the disclosed variant recombinases allow different alternative  
20 recombinations to be performed since the variant recombinases can allow much more efficient recombination between wild type recombination sites and variant recombination sites. Control of such alternative recombination can be used to accomplish more sophisticated sequential recombinations to achieve results not possible with wild type recombinases.

25 Also disclosed are variants of Cre recombinase that have broadened specificity for the site of recombination. Specifically, the disclosed variants mediate recombination between sequences other than the loxP sequence and other lox site sequences on which wild type Cre recombinase is active. Preferred forms of the disclosed Cre variants have the amino acid sequence  
30 SEQ ID NO:1 (top sequence, Table 11) altered by one or more amino acid substitutions, deletions, or insertions, where the glutamic acid at amino acid 262 has been substituted with an amino acid other than glutamic acid, and where the



Cre variant recognizes (that is, mediates recombination at) a variant lox recombination site. Useful Cre variants include proteins that recognize a variant lox recombination site and have the amino acid sequence SEQ ID NO:1 altered by substitution of the glutamic acid at amino acid 262 with an amino acid other than glutamic acid and one or more of the following amino acid substitutions:

5 isoleucine at amino acid 16, alanine at amino acid 29, glutamine at amino acid 101, glycine at amino acid 138, asparagine at amino acid 189, serine at amino acid 198, glutamine at amino acid 220, glutamine at amino acid 223, isoleucine at amino acid 227, glycine at amino acid 254, arginine at amino acid 255,

10 glutamine at amino acid 284, leucine at amino acid 307, and serine at amino acid 316. Preferred amino acid substitutions at amino acid position 262 include alanine, tryptophan, or glycine.

Examples of preferred Cre variants include proteins having the amino acid sequence SEQ ID NO:1 altered by substitutions E262G and D189N;

15 proteins having the amino acid sequence SEQ ID NO:1 altered by substitutions E262G and T316S; proteins having the amino acid sequence SEQ ID NO:1 altered by substitutions E262G and D29A; proteins having the amino acid sequence SEQ ID NO:1 altered by substitutions E262G, V16I, D189N, G198S, R223Q, Q255R, and P307L; proteins having the amino acid sequence SEQ ID

20 NO:1 altered by substitution E262G; proteins having the amino acid sequence SEQ ID NO:1 altered by substitution E262A; and proteins having the amino acid sequence SEQ ID NO:1 altered by substitution E262W. The substitutions above are listed using the convention where the first letter is the original amino acid (in single letter amino acid code), the number is the amino acid position in

25 the protein (in this case, using the positions of wild type Cre (SEQ ID NO:1)), and the last letter is the new amino acid (in single letter amino acid code). All of these Cre variants recognize both wild type lox sites and variant lox sites with an inverted repeat sequence NNNACNNCGTATA (SEQ ID NO:2).

The disclosed Cre variants recognize variant lox recombination sites.

30 Preferred variant lox sites are variant lox sites recognized by the Cre variant but not recognized by wild type Cre. Examples of useful variant lox sites include sites having two 13 base pair inverted repeats flanking 8 base pairs, where one

of the inverted repeats has the sequence NNNACNNCGTATA (SEQ ID NO:2); sites having the sequence  $N_1N_2N_3ACN_4N_5CGTATANNNNNNNNTATA$   $CGN_5'N_4'GTN_3'N_2'N_1'$  (SEQ ID NO:3), where  $N_1'$ ,  $N_2'$ ,  $N_3'$ ,  $N_4'$ , and  $N_5'$  are complementary to  $N_1$ ,  $N_2$ ,  $N_3$ ,  $N_4$ , and  $N_5$ , respectively; sites having the

5 sequence  $N_1N_2N_3ACN_4N_5CGTATANNNNNNNNTATACGN_5'N_4'GN_3'N_2'N_1'$  (SEQ ID NO:3), where  $N_4N_5$  are AA, TC, GT, TG, GG, or CC; and sites having the sequence GATACAACGTATATACCTTTCTATACGTTGTAT (SEQ ID NO:4).

Also disclosed is a method for producing site-specific recombination of

10 DNA in cells using the disclosed Cre variants. DNA sequences comprising first and second lox sites are introduced into cells and contacted with a Cre variant, thereby producing recombination at the lox sites. As with wild type Cre, the location and orientation of the lox sites determines the nature of the recombination.

15 As used herein, the expression "site-specific recombination" refers to three different types of recombination events:

1. deletion of a pre-selected DNA segment flanked by recombination sites,
2. inversion of the nucleotide sequence of a pre-selected DNA segment
- 20 flanked by recombination sites, and
3. reciprocal exchange of DNA segments proximate to recombination sites located on different DNA molecules.

It is to be understood that this reciprocal exchange of DNA segments can result in an integration event if one or both of the DNA molecules are

25 circular. "Nucleic acid segment" refers to a linear segment of single- or double-stranded nucleic acid, which can be derived from any source. The segment may be a fragment consisting of the segment or a segment within a larger nucleic acid fragment or molecule. The expression "nucleic acid in eukaryotic cells" includes all nucleic acid present in eukaryotic cells. The expression "nucleic

30 acid in yeast" includes all nucleic acid present in yeast cells. "DNA segment" refers to a linear segment of single- or double-stranded deoxyribonucleic acid (DNA), which can be derived from any source. The expression "DNA in

eukaryotic cells" includes all DNA present in eukaryotic cells. The expression "DNA in yeast" includes all DNA present in yeast cells. As used herein, a "gene" is intended to mean a DNA segment which is normally regarded as a gene by those skilled in the art. The expression "regulatory molecule" refers to a polymer of ribonucleic acid (RNA) or a polypeptide which is capable of enhancing or inhibiting expression of a gene.

"Regulatory nucleotide sequence," as used herein, refers to a nucleotide sequence located proximate to a gene whose transcription is controlled by the regulatory nucleotide sequence in conjunction with the gene expression apparatus of the cell. Generally, the regulatory nucleotide sequence is located 5' to the gene. The expression "nucleotide sequence" refers to a polymer of DNA or RNA, which can be single- or double-stranded, optionally containing synthetic, non-natural, or altered nucleotides capable of incorporation into DNA or RNA polymers. As used herein, a "regulatory nucleotide sequence" can include a promoter region, as that term is conventionally employed by those skilled in the art. A promoter region can include an association region recognized by an RNA polymerase, one or more regions which control the effectiveness of transcription initiation in response to physiological conditions, and a transcription initiation sequence. "Gene product" refers to a polypeptide resulting from transcription, translation, and, optionally, post-translational processing of a selected DNA segment.

## **Materials**

### **A. Recombinases**

Recombinases suitable for use in the disclosed method include any enzyme that mediates recombination at specific sites. This includes enzymes identified as recombinases as well as other enzymes that function to produce recombination such as integrases and resolvases. As used herein, recombination at specific sites does not refer only to recombination at completely defined sequences. Rather, a recombinase is considered to mediate recombination at specific sites when the sites of recombination are limited in some way by sequence. For example, wild type Cre recombinase mediates recombination between sites having the sequence  $N_1N_2N_3ACTTCGTATANNNNNNNNT$

ATACGAAGTN<sub>3</sub>'N<sub>2</sub>'N<sub>1</sub>', which includes both specific and non-specific sequences. The sequences ACTTCGTATA and TATACGAAGT (an inverted repeat of the first sequence) are recognized by the Cre recombinase. The non-specific sequences (positions with "N" in the recognition sequence), although  
5 not limited in sequence, must be compatible with the non-specific sequences of the partner recombination site in order for recombination to be efficient. The recombination sites need not have any particular number of specific nucleotides. All that is required is some constraint on the sequence of the site such that the recombinase is limited to recombination at some set of sites.

10 Examples of recombinases that can be used in the disclosed method include Cre recombinase, FLP recombinase, Beta recombinase of pSM19035 (Diaz et al., *J Biol Chem* 274: 6634-6640 (1999)), Int recombinases (Nunes-Döby et al., *Nucleic Acids Res.* 26:391-406 (1998)), and resolvases (Hallet et al., *FEMS Microbiol Rev.* 21: 157-178 (1997); Oram et al., *Curr Biol.* 5: 1106-  
15 1109 (1995); Mondragon, *Structure* 3: 755-758 (1995)).

#### **B. Recombination Sites**

Recombination sites are locations within a nucleic acid where recombination mediated by a recombinase takes place. Recombination sites generally include specific sequences, referred to as recognition sequences,  
20 through which the recombinase recognizes a given nucleotide sequence as a recombination site. Different recombinases generally recognize different recognition sequences. Recombination between two recombination sites requires (1) that the recombinase recognize the sites as recombination sites, and (2) that the sequences of the two sites are sufficiently similar. It has been  
25 discovered that recombination between two recombination sites (both of which are recognized by a recombinase) can be substantially reduced or prevented by using different compatibility sequences for the recombination sites (the recognition sequences can also differ if the recombinase can recognize different sequences). Thus, it is also preferred that the variant recombination sites be  
30 made incompatible with the recombination sites recognized by non-variant recombinase by using different compatibility sequences for the two sets of recombination sites. Compatibility sequences in a recombination site are those

sequences in the recombination site, other than the sequences required for recognition of the site by the recombinase, that must be similar in a pair of recombination sites for recombination to occur between them. Generally, recombinases require specific recognition sequences but allow wide variation in compatibility sequences. Thus, recombination sites that are recognized by a given recombinase but are incompatible with each other can be readily designed using the disclosed principles.

It should be understood that, for a given recombinase site or for a given recombinase, whether a given base position in the recombination site is a recognition sequence base or a compatibility sequence base may depend on other sequences in the recombination site. For example, a particular base may function as a compatibility sequence base in a recombination site having one sequence while the same base may function as a recognition sequence base in a recombination site having a different sequence. It should also be understood that recognition sequences and compatibility sequences do not necessarily occur in blocks within a recombination site. That is, recognition sequence base and compatibility sequence bases may be interspersed in a given recombination site. As discussed below, what is and is not a recognition sequence or a compatibility sequence in a given recombination site is determined functionally.

The disclosed variant recombination sites and the variant recombinases that can act on them allow more freedom in the selection of sites of recombination. In particular, the disclosed variant recombinases can allow amino acid changes in a protein of interest while retaining the ability to recombine at a given site.

#### **1. Recognition Sequences**

Recognition sequences are regions within a recombination site that must have a specific sequence, or defined range of sequences, for the cognate recombinase to recognize the recombination site. Recognition sequences in a recombination site need not be contiguous. Thus, required nucleotides dispersed in a recombination site are collectively considered recognition sequences. Nucleic acid segments can be said to have a defined range of sequences when every nucleotide position in the nucleic acid segment(s) is

limited to one, two, or three nucleotide bases. That is, so long as a nucleotide position cannot have one of the possible nucleotide bases, that position has a defined range of sequence. For example, a nucleotide sequence ATRVBYGC has a defined range of sequences since each nucleotide position has at least one  
5 limitation. Standard nomenclature for nucleic acid sequences is used herein. Thus, in this example, R represents A or G; V represents A, C, or G; B represents C, G, or T; and Y represents C or T.

Recognition sequences for recombinases are known or can be determined through routine analysis. In general, recognition sequences can be  
10 determined by varying the sequence of recombination sites and determining if recombination between the sites can still occur. For this purpose, the pair of sites to be recombined should be identical. That is, the same sequence changes should be made to both sites. This eliminates any incompatibility effect between the recombination sites. If recombination is eliminated or significantly  
15 reduced when a specific nucleotide is changed, then that nucleotide is required for recognition of the recombination site by the recombinase.

Examples of dissection of the critical sequences in recombination sites of recombinases are described by Hoess et al., *Nucleic Acids Res.* 14:2287-2300 (1986) (involving P1 recombinase); Sauer B., *Nucleic Acids Res.*, 24:4608-4613  
20 (1996) (involving Cre recombinase); Lee and Saito, *Gene* 216(1):55-65 (1998) (involving Cre recombinase); and Umlauf and Cox, *EMBO J* 7(6):1845-52 (1988) (involving FLP recombinase). Similar techniques can be used to determine the recognition sequences of other recombinases.

## 2. Compatibility Sequences

25 Compatibility sequences are regions in a recombination site that must be similar in a pair of recombination sites for recombination to occur between them. In general, the sequence of recombination sites must be similar for recombination to occur between them. Examples of compatibility sequences are spacer sequences between repeats in recombination sequences. All or some  
30 of the nucleotides in the recognition sequences for a recombination site may be involved in compatibility. For example, where some degeneracy of the recognition sequences is allowed, similar recognition sequences may be

required in a pair of recombination sites for recombination to occur between them. Thus, compatibility between recombination sites can be affected by using different sequences in the compatibility sequences other than the sequences required for recognition of the site by the recombinase (that is, recognition sequences), compatibility sequences that are part of the recognition sequences, or both. It is preferred that compatibility between recombination sites be altered by using different sequences in the compatibility sequences other than the sequences required for recognition of the site by the recombinase.

Compatibility sequences for many recombinases are known or can be determined through routine analysis. In general, compatibility sequences can be easily determined by varying the sequence of recombination sites and determining if recombination between the sites can still occur. For this purpose, only one of the sites in the pair of sites to be recombined should be altered. That is, the same sequence changes should not be made to both sites. This isolates incompatibility effect between the recombination sites. Further, only those nucleotide positions that are not a part of the recognition sequence of the site should be altered to avoid recognition problems. If recombination is eliminated or significantly reduced when a specific nucleotide is changed, then that nucleotide is required for compatibility of the recombination site.

Examples of dissection of the critical sequences in recombination sites of recombinases are described by Hoess et al., *Nucleic Acids Res.* 14:2287-2300 (1986) (involving P1 recombinase); Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996) (involving Cre recombinase); Lee and Saito, *Gene* 216(1):55-65 (1998) (involving Cre recombinase); and Umlauf and Cox, *EMBO J* 7(6):1845-52 (1988) (involving FLP recombinase). Similar techniques can be used to determine the compatibility sequences of other recombinases.

Recognition and compatibility sequences can be further understood using Cre recombination sites as an example. Wild type Cre recombinase mediates recombination between sites having the sequence  $N_1N_2N_3ACTTCGTATANN\text{NNNNNTATACGAAGTN}_3'N_2'N_1'$ , which includes both specific and non-specific sequences (that is, recognition sequences and compatibility sequences, respectively). The sequences

ACTTCGTATA and TATACGAAGT (an inverted repeat of the first sequence) are recognized by the Cre recombinase and are the recognition sequences in Cre recombinase sites. Variant Cre recombinases recognize sites having different recognition sequences. The non-specific sequences (positions with "N" in the recognition sequence), although not limited in sequence, must be compatible with the non-specific sequences of the partner recombination site in order for recombination to be efficient. Thus, the non-specific sequences are the compatibility sequences of a recombinase site.

### C. Recombination Constructs

Recombination constructs are designed to provide an observable change when recombination between recombination sites occurs. Preferred recombination constructs include two pairs of recombination sites, one pair having a variant sequence and another pair having a sequence recognized by non-mutant recombinase (for example, wild type recombinase). Sites in the first pair are referred to as variant recombination sites. Generally, recombination constructs include a first nucleic acid sequence that includes a first reporter gene and first and second recombination sites, where the first and second recombination sites are variant recombination sites, and a second nucleic acid sequence that includes a second reporter gene and third and fourth recombination sites, where the third and fourth recombination sites can be recombined by a non-mutant recombinase. The first and second nucleic acid sequences need not be present on the same vector or on the same nucleic acid molecule (for example, the chromosome), although this is preferred. It is preferred that recombination constructs be embodied in vectors, such as plasmids.

In one embodiment of the disclosed recombination constructs, the sequence of the recombination sites in the constructs are chosen such that the recognition sequences of the first and second recombination sites differ from the recognition sequences of the third and fourth recombination sites. The sequence of the recombination sites can also be chosen such that the compatibility sequences of the first and second recombination sites differ from the compatibility sequences of the third and fourth recombination sites such that the



first and second recombination sites cannot recombine with the third and fourth recombination sites. The sequence of the recombination sites can also be chosen such that the compatibility sequences of the first and second recombination sites are sufficiently similar to allow recombination between the first and second recombination sites, and such that the compatibility sequences of the third and fourth recombination sites are sufficiently similar to allow recombination between the third and fourth recombination sites. The above sequence relationships result in constructs where the first and second recombination sites can recombine (in the presence of a recombinase that recognizes the sites), the third and fourth recombination sites can recombine, but where neither the first nor second recombination site can recombine with either the third or fourth recombination site (since differences in the compatibility sequences prevent recombination).

Arriving at recombination sites having relationships as described above is preferably accomplished in the following way. Starting with a given recombination site sequence (which can be recombined by a non-mutant recombinase), parallel changes are made in the compatibility sequences of the first and second recombination sites. These altered recombination sites should then be tested to make sure that the non-mutant recombinase can still mediate their recombination. This helps insure that compatibility sequence changes have not inadvertently affected the function of the recombination sites. Once this is confirmed, changes can be made to the recognition sequences of the first and second recombination sites. These changes result in variant recombination sites for which variant recombinases can be identified using the method disclosed herein. The resulting recombination sites have the desired properties: incompatibility with the third and fourth recombination sites and variant recognition sequences that extend the range of recombination-competent sites.

The recombination sites can have a variety of properties and relationships that make them useful for particular purposes. For example, the recombination sites can be designed such that the first and second recombination sites cannot be recombined by non-mutant recombinase to a significant extent. This allows separate assessment of cleavage by mutant and

non-mutant recombinase. It is also useful if the first and second recombination sites have identical sequences, and the third and fourth recombination sites have identical sequences.

5       Recombination between the recombination sites can have a variety of effects that allows detection of recombination. For example, the constructs can be designed such that recombination between the first and second recombination sites alters the expression of the first reporter gene, where recombination between the first and second recombination sites is determined by determining if expression of the first reporter gene is altered; recombination  
10       between the third and fourth recombination sites alters the expression of the second reporter gene, where recombination between the third and fourth recombination sites is determined by determining if expression of the second reporter gene is altered; recombination between the first and second recombination sites allows the first reporter gene to be expressed; the first  
15       nucleic acid sequence includes a spacer sequence flanked by the first and second recombination sites, where the spacer sequence interrupts the first reporter gene such that the first reporter gene is not expressed, and where recombination of the first and second recombination sites excises the spacer sequence which allows the first reporter gene to be expressed; and/or a portion  
20       of the first reporter gene is inverted, wherein the inverted portion of the first reporter gene is flanked by the first and second recombination sites, wherein recombination of the first and second recombination sites inverts the inverted portion of the first reporter gene which allows the first reporter gene to be expressed.

25       The constructs can also be designed such that recombination between the first and second recombination sites prevents expression of the first reporter gene; the first reporter gene is flanked by the first and second recombination sites, where recombination of the first and second recombination sites excises the first reporter gene which prevents expression of the first reporter gene; a  
30       portion of the first reporter gene is flanked by the first and second recombination sites, where recombination of the first and second recombination sites inverts the flanked portion of the first reporter gene which prevents

expression of the first reporter gene: recombination between the third and fourth recombination sites allows the second reporter gene to be expressed; and/or the second nucleic acid sequence includes a spacer sequence flanked by the third and fourth recombination sites, where the spacer sequence interrupts the second reporter gene such that the second reporter gene is not expressed, and where  
5 recombination of the third and fourth recombination sites excises the spacer sequence which allows the second reporter gene to be expressed.

The constructs can also be designed such that a portion of the second reporter gene is inverted, where the inverted portion of the second reporter gene  
10 is flanked by the third and fourth recombination sites, and where recombination of the third and fourth recombination sites inverts the inverted portion of the second reporter gene which allows the second reporter gene to be expressed; recombination between the third and fourth recombination sites prevents  
expression of the second reporter gene to be expressed; the second reporter gene  
15 is flanked by the third and fourth recombination sites, where recombination of the third and fourth recombination sites excises the second reporter gene which prevents expression of the second reporter gene; and/or a portion of the second reporter gene is flanked by the third and fourth recombination sites, where  
recombination of the third and fourth recombination sites inverts the flanked  
20 portion of the second reporter gene which prevents expression of the second reporter gene.

Expression of a reporter gene can include transcription of the gene, translation of the transcript (if the gene encodes a protein), and/or production of an active protein. As used herein, whether a reporter gene is expressed depends  
25 on the context. In general, a gene is considered to be expressed if it produces the expression product to be detected. Such expression products include full or partial transcripts of the gene, full or partial proteins, including active or inactive forms of the proteins, translated from the transcript. Since the goal in using reporter genes in the disclosed method is the detection of expression, any  
30 of these forms of expression product can be the object of detection. For example, if the gene's transcript is to be detected, the gene will be considered to be expressed if it produces the transcript, regardless of whether the transcript is

translated or whether the resulting protein is active. If the an active protein encoded by the gene is to be detected, the gene is not expressed unless active protein is produced--mere transcription of the gene, or even translation to produce an inactive protein, will not be enough in this context. As a  
5 consequence, the expression product to be detected will influence the manner in which reporter genes should be interrupted or invented in the disclosed constructs. For example, nearly any interruption of a reporter gene would prevent expression of an active protein encoded by the gene. On the other hand, an interruption of the coding region will usually not prevent production of a  
10 transcript. The structure of the disclosed constructs should be designed with these principles in mind. As used herein, an inactive expression product refers to an expression product that does not have an activity exhibited by the active form of the expression product where that activity is required for detection of expression in the assay scheme being used.

15 The constructs can be designed such that the first nucleic acid sequence is a first nucleic acid construct and the second nucleic acid sequence is on a second nucleic acid construct; the first nucleic acid construct is an extrachromosomal vector and the second nucleic acid construct is in the genome of a host cell; and/or the first and second nucleic acid constructs are on the same  
20 nucleic acid construct.

#### **D. Reporter Genes**

Reporter genes are used to monitor whether recombination occurs in the disclosed constructs. Reporter genes can be any gene the expression of which can be detected either directly or indirectly. These include genes encoding  
25 enzymes, such as  $\beta$ -galactosidase, luciferase, and alkaline phosphatase, that can produce specific detectable products, and genes encoding proteins that can be directly detected. Virtually any protein can be directly detected by using, for example, specific antibodies to the protein. A preferred reporter protein that can be directly detected is the green fluorescent protein (GFP). GFP, from the  
30 jellyfish *Aequorea victoria*, produces fluorescence upon exposure to ultraviolet light without the addition of a substrate (Chalfie *et al.*, *Science* 263:802-5 (1994)). A number of modified GFPs have been created that generate as much

as 50-fold greater fluorescence than does wild type GFP under standard conditions (Cormack *et al.*, *Gene* 173:33-8 (1996); Zolotukhin *et al.*, *J. Virol* 70:4646-54 (1996)). This level of fluorescence allows the detection of low levels of expression in cells.

5 Reporter genes encoding proteins producing a fluorescent signal are useful since such a signal allows cells to be sorted using FACS. Another way of sorting cells based on expression of the reporter gene involves using the reporter protein as a hook to bind cells. For example, a cell surface protein such as a receptor protein can be bound by a specific antibody. Cells expressing such a  
10 protein can be captured by, for example, using antibodies bound to a solid substrate, using antibodies bound to magnetic beads, or capturing antibodies bound to the reporter protein. Many techniques for the use of antibodies as capture agents are known and can be used with the disclosed method.

The reporter gene can also encode an expression product that regulates  
15 the expression of another gene. This allows detection of expression of the reporter gene by detecting expression of the regulated gene. For example, a repressor protein can be encoded by the reporter gene. Loss of expression of the reporter gene (via recombination) would then result in derepression of the regulated gene. This type of indirect detection allows positive detection of loss  
20 of the expression of the reporter gene by the effector RNA molecule. One preferred form of this type of regulation is the use of an antibiotic resistance gene regulated by a repressor protein encoded by the reporter gene. By exposing the host cells to the antibiotic, only those cells in which expression of the reporter gene has been inhibited will grow since expression of the antibiotic  
25 resistance gene will be derepressed.

#### **E. Expression Sequences**

The reporter genes can be expressed using any suitable expression sequences. Numerous expression sequences are known and can be used for expression of the reporter genes. Expression sequences can generally be  
30 classified as promoters, terminators, and, for use in eukaryotic cells, enhancers. Expression in prokaryotic cells also requires a Shine-Dalgarno sequence just upstream of the coding region for proper translation initiation. Inducible

promoters are preferred for use with the first reporter gene since it is preferred that expression of the first reporter gene be adjustable.

Promoters suitable for use with prokaryotic hosts illustratively include the  $\beta$ -lactamase and lactose promoter systems, tetracycline (tet) promoter, 5 alkaline phosphatase promoter, the tryptophan (trp) promoter system and hybrid promoters such as the tac promoter. However, many other functional bacterial promoters are suitable. Their nucleotide sequences are generally known.

Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase, enolase, glyceraldehyde-3-phosphate 10 dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triphosphate isomerase, phosphoglucose isomerase, and glucokinase. Examples of inducible yeast promoters suitable for use in the disclosed vectors include the promoter regions for alcohol dehydrogenase 2, isocytochrome C, 15 acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Yeast enhancers also are advantageously used with yeast promoters.

Preferred promoters for use in mammalian host cells include promoters 20 from polymoma virus, Simian Virus 40 (SV40), adenovirus, retroviruses, hepatitis B virus, herpes simplex virus (HSV), Rous sarcoma virus (RSV), mouse mammary tumor virus (MMTV), and most preferably cytomegalovirus (CMV), or from heterologous mammalian promoters such as the  $\beta$  actin promoter. Particularly preferred are the early and late promoters of the SV40 virus and the immediate early promoter of the human cytomegalovirus, MMTV 25 LTR, RSV-LTR, and the HSV thymidine kinase promoter.

Transcription of the reporter gene by higher eukaryotes can be increased by inserting an enhancer sequence into the vector. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, 30 and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the

replication origin, the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

The disclosed vectors preferably also contain sequences necessary for accurate 3' end formation of both reporter and effector RNAs. In eukaryotic cells, this would be a polyadenylation signal. In prokaryotic cells, this would be a transcription terminator.

## **Method**

### **A. Identification of Variant Recombinases**

The disclosed method involves producing mutant recombinases and testing the mutant recombinases with specially designed constructs. The constructs contain variant recombination sites that are not recognized by non-mutant recombinase but will undergo recombination in the presence of a mutant recombinase with altered specificity. The disclosed method also involves determining whether a variant recombinase retains the ability to mediate recombination at recombination sites recognized by non-variant recombinase. This can be accomplished by using constructs containing recombination sites recognized by non-variant recombinase. Recombination at these recombination sites can be monitored or detected by any suitable means. It is preferred that recombination is detected by screening or selection based on the expression or lack of expression of a reporter gene. This can be accomplished by using constructs containing a reporter gene associated with the recombination sites such that the reporter gene is rearranged or deleted, or a spacer sequence interrupting the reporter gene is rearranged or deleted, as a result of recombination at the recombination sites. Recombination of such constructs will result in a loss of expression of the reporter gene, where the construct contained a functional reporter gene, or in a gain in expression of the reporter gene, where the construct contained a non-functional reporter gene.

#### **1. Production of Mutant Recombinases**

Mutant recombinases can be produced by any suitable technique. In general, all that is required is a method of generating a variety of recombinase proteins having a variety of amino acid sequences. the most preferred way of doing this is to mutagenize or alter nucleic acid encoding the recombinase and

then expressing the mutant recombinases. Numerous techniques for introducing alterations into nucleic acid sequences are known and can be used in the disclosed method. For example, alterations can be made by chemical mutagenesis, introduction of degenerate nucleic acid fragments into the base  
5 nucleic acid molecule, and low fidelity PCR. The goal of this mutagenesis or alteration will be the generation of a population or set of mutant recombinases having a variety of sequences. The broader the range of variants, the more raw material for the identification process.

## **2. Identification of Variant Recombinases That Recognize Variant 10 Recombination Sites**

Variant recombinases that can mediate recombination at variant recombination sites are identified in the disclosed method by selecting for, screening for, or otherwise detecting recombination of specially designed constructs having variant recombination sites. Recombination at variant  
15 recombination sites can be monitored or detected by any suitable means. It is preferred that recombination is detected by screening or selection based on the expression or lack of expression of a reporter gene. This can be accomplished by using constructs containing a reporter gene associated with the variant recombination sites such that the reporter gene is rearranged or deleted, or a  
20 spacer sequence interrupting the reporter gene is rearranged or deleted, as a result of recombination at the recombination sites. Recombination of such constructs will result in a loss of expression of the reporter gene, where the construct contained a functional reporter gene, or in a gain in expression of the reporter gene, where the construct contained a non-functional reporter gene.

## **25 3. Identification of Variant Recombinases That Recognize Non-Variant Recombination Sites**

Variant recombinases that can mediate recombination at recombination sites recognized by non-variant recombinase (non-variant recombination sites) are identified in the disclosed method by selecting for, screening for, or  
30 otherwise detecting recombination of specially designed constructs having recombination sites recognized by non-variant recombinase. Recombination at these recombination sites can be monitored or detected by any suitable means.



It is preferred that recombination is detected by screening or selection based on the expression or lack of expression of a reporter gene. This can be accomplished by using constructs containing a reporter gene associated with the recombination sites recognized by non-variant recombinase such that the  
5 reporter gene is rearranged or deleted, or a spacer sequence interrupting the reporter gene is rearranged or deleted, as a result of recombination at the recombination sites. Recombination of such constructs will result in a loss of expression of the reporter gene, where the construct contained a functional reporter gene, or in a gain in expression of the reporter gene, where the  
10 construct contained a non-functional reporter gene.

It is preferred that the ability of a variant recombinase to mediate recombination at both variant recombination sites and recombination sites recognized by non-variant recombinase be assessed in the same system (such as a cell strain) either sequentially or simultaneously. When variant recombinases  
15 are tested for activity on both variant recombination sites and recombination sites recognized by non-variant recombinase in the same system or at the same time, it is preferred that two different reporter genes which can be separately detected or monitored be used. In this case, a first reporter gene can be associated with the variant recombination sites and a second reporter gene can  
20 be associated with recombination sites recognized by non-variant recombinase.

#### **B. Use of Variant Recombinases**

Variant recombinases produced in the disclosed method can be used for any purpose that unmodified recombinases can be used. The advantage is that the variant recombinases have a different or broader site specificity. In general,  
25 the disclosed variant recombinases can be used to mediate recombination of any nucleic acid in any setting, including *in vitro*, in cell culture, and *in vivo*. Recombination can be obtained in single celled organisms, such as bacterial cells, fungal cells, yeast cells, prokaryotic cells, and archae bacterial cells, the cells of multicellular organisms, including plants and animals, both in the  
30 organism and in culture. The disclosed variant recombinases can also be used in combination with other recombinases (including other variant recombinases) having a different site specificity. Such combinations allow more complex

recombination schemes to be used. Examples of such schemes are discussed below.

For some uses of the disclosed recombinases, first, second, and fourth DNA sequences comprising a first recombination site, a second recombination site, and a third recombination site, respectively, are introduced into cells. As used herein the expression "recombination site" means a nucleotide sequence at which a recombinase or variant recombinase can catalyze a site-specific recombination.

Methods for introducing a DNA sequence into cells are known in the art. These methods typically include the use of a DNA vector to introduce the sequence into the DNA of a single or limited number of eukaryotic cells and then growing such cell or cells to generate a suitable population of cells. As used herein, the term "vector" includes plasmids, viruses, and viral vectors. Preferably, the DNA sequences are introduced by a plasmid capable of transforming a selected cell while carrying a DNA sequence. The particular vector which is employed to introduce the DNA sequence into a selected cell is not critical.

In the present method, the recombination sites are contacted with a variant recombinase, thereby producing the site specific recombination. A preferred means of contacting the DNA to be recombined with a variant recombinase is to place the DNA to be recombined into a cell expressing nucleic acid encoding the variant recombinase. Preferably, expression of the variant recombinase is under the control of a regulatory nucleotide sequence. Suitable regulatory nucleotide sequences are known in the art. The regulatory nucleotide sequence which is employed with a selected eukaryotic cell is not critical to the method. A partial list of suitable regulatory nucleotide sequences includes the long terminal repeat of Moloney sarcoma virus described by Blochlinger and Diggelmann, *Mol. Cell Bio.*, 4:2929-2931 (1984); the mouse metallothionein-I promoter described by Pavlakis and Hamer, *Proc. Natl. Acad. Sci USA*, 80:397-401 (1983); the long terminal repeat of Rous sarcoma virus described by Gorman et al., *Proc. Natl. Acad. Sci USA*, 79:6777-6781 (1982);

and the early region promoter of SV40 described by Southern and Berg, *J. Mol. Appl. Genet.*, 1:327-341 (1982).

In an embodiment where the cells are yeast, suitable regulatory nucleotide sequences include GAL1, GAL10, ADH1, CYC1, and TRP5  
5 promoters. GAL1 and GAL10 promoters are present on plasmid pBM150 which is described by Johnston and Davis, *Molec. Cell. Biol.*, 4:1440 (1984). The ADH1 promoter, also called ADC1, is present on plasmid pAAH5 which is described by Ammer, *Methods Enzymol.*, 101:192 (1983). The CYC1 promoter is described by Stiles et al., *Cell*, 25:277 (1981). The TRP5 promoter is  
10 described by Zalkin and Yanofsky, *J. Biol. Chem.*, 257:1491 (1982). Preferably, the regulatory nucleotide sequence is a GAL1 promoter.

In one embodiment where the cell is yeast, the first, second, and optionally, third and fourth DNA sequences are introduced into one strain of yeast. Alternatively, the DNA sequences are introduced into two different  
15 strains of yeast of opposite mating types which are subsequently mated to form a single strain having all three or four DNA sequences. Preferably, the plasmid contains either (1) a nucleotide sequence of DNA homologous to a resident yeast sequence to permit integration into the yeast DNA by the yeast's recombination system or (2) a nucleotide sequence of DNA which permits  
20 autonomous replication in yeast. One nucleotide sequence which permits autonomous replication in yeast is an ARS sequence described by Stinchcomb et al., *Nature*, 282:39 (1979). A partial list of plasmids capable of transforming yeast includes YIP5, YRP17 and YEP24. These plasmids are disclosed and described by Botstein and Davis, *The Molecular Biology of the Yeast*  
25 *Saccharomyces, Metabolism and Gene Expression* (ed. Strathern et al.), (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982), at page 607.

Since most recombination sites are asymmetrical nucleotide sequences, two recombination sites on the same DNA molecule can have the same or opposite orientations with respect to each other. Recombinations between  
30 recombination sites in the same orientation result in a deletion of the DNA segment located between the two recombination sites and a connection between the resulting ends of the original DNA molecule. The deleted DNA segment

forms a circular molecule of DNA. The original DNA molecule and the resulting circular molecule each contain a single recombination site (see Figure 2). Recombination between recombination sites in opposite orientations on the same DNA molecule result in an inversion of the nucleotide sequence of the DNA segment located between the two recombination sites (see Figure 2). In addition, reciprocal exchange of DNA segments proximate to recombination sites located on two different DNA molecules can occur. All of these recombination events are catalyzed by recombinases, including the disclosed variants and wild type recombinases.

Recombination using the disclosed variant recombinases can be used *in vitro* to produce site-specific recombination of nucleic acid molecules. This is useful for a wide variety of manipulations that currently employ wild type recombinases or involve traditional restriction enzyme cleavage followed by ligation. Examples include recombination of libraries of DNA fragments into vectors or in desired structures, and labeling of DNA via recombination. Recombined DNA formed by *in vitro* recombination can then be introduced into cells. For example, constructs formed *in vitro* can be introduced into cells to resolve the structures formed *in vitro* or to select active structures. In particular, large concatemers of subject DNA and spacer/vector fragments can be made, introduced into cells, and circularized into vector units in the cells. Such recombination could also be performed *in vitro* if desired.

The disclosed variant recombinases can be used to label DNA by recombining a DNA molecule of interest with a labeled DNA molecule. Use of a recombinase for labeling is advantageous since it involves fewer steps than traditional labeling via DNA synthesis or ligation. These considerations are particularly important when large DNA molecules (over 20 kb) are to be labeled since such large molecules will fragment more the more they are manipulated.

Recombination mediated by the disclosed variant recombinases and variant recombination sites can be used to manipulate a host cell genome as desired and simultaneously introduce a marker gene flanked by the recognition sites of a second recombinase. After selection, leading to an accumulation of cells carrying the desired genomic alteration, one could simply remove the

marker gene by expression of the second site-specific recombinase. A large number of recombinases suitable for this purpose exists in nature, including  $\lambda$  Integrase (Int), yeast Fip, etc. (Nunes-Döby et al., *Nucl. Acids Res.*, 26:391-406 (1998)). Variant recombinases having different site specificity can also be used.

- 5            Since the disclosed variant recombinases recognize both wild type recombination sites and variant recombination sites that are not recognized by wild type recombinase, wild type recombinase and variant recombinases can be used to mediate sequential recombination between nucleic acids containing a combination of wild type recombination sites and variant recombination sites.
- 10          For example, generation of knockout animals and plants can be made more efficient by using a structure wild type recombination site-selectable marker-wild type recombination site-endogenous gene-variant recombination site (rather than the conventional wild type recombination site-selectable marker-wild type recombination site-endogenous gene-wild type recombination site).
- 15          Such a structure allows the selectable marker to be removed by the action of wild type recombinase without disturbing the gene since wild type recombinase will not recognize the variant recombination site to any significant degree. The endogenous gene can then be removed later by the action of a variant recombinase since the disclosed variant recombinases recognize both wild type
- 20          and variant recombination sites.

- In a preferred embodiment of the disclosed method, the first and second DNA sequences are introduced into cells connected by a pre-selected DNA segment. The segment can be a gene or any other sequence of deoxyribonucleotides of homologous, heterologous or synthetic origin.
- 25          Preferably, the pre-selected DNA segment is a gene for a structural protein, an enzyme, or a regulatory molecule. If the first and second recombination sites have the same orientation, activation of the regulatory nucleotide sequence produces a deletion of the pre-selected DNA segment. If the first and second recombination sites have opposite orientation, activation of the regulatory
- 30          nucleotide sequence produces an inversion of the nucleotide sequence of the pre-selected DNA segment.

If a fourth DNA sequence (containing the third recombination site) is also introduced into cells, it is preferred that the second and fourth DNA sequences be introduced into cells connected by a second pre-selected DNA segment. The second segment can be a gene or any other sequence of deoxyribonucleotides of homologous, heterologous or synthetic origin. Preferably, the second pre-selected DNA segment is a gene for a structural protein, an enzyme, or a regulatory molecule. If the second and third recombination sites have the same orientation, activation of the regulatory nucleotide sequence produces a deletion of the second pre-selected DNA segment. If the second and third recombination sites have opposite orientation, activation of the regulatory nucleotide sequence produces an inversion of the nucleotide sequence of the second pre-selected DNA segment.

Combinations of wild type and variant recombination sites, and combinations of different orientations of the recombination sites, in DNA introduced into cells can multiply recombination options. For example, if the first and second recombination sites are wild type recombination sites and the third recombination site is a variant recombination site (all in the same orientation) then wild type recombinase can produce a deletion of the first pre-selected DNA segment (but not the second) and a variant recombinase can produce a deletion of the first, second, or both pre-selected DNA segments. This arrangement allows sequential deletion of the first and second pre-selected DNA segments.

If the first and second recombination sites are wild type recombination sites and the third recombination site is a variant recombination site, and the first recombination site has the opposite orientation from the second and third recombination sites (which, of course, have the same orientation) then wild type recombinase can produce an inversion of the first pre-selected DNA segment and a variant recombinase can produce a deletion of the second pre-selected DNA segment (and/or produce an inversion of the first pre-selected DNA segment or the entire section spanning the first, second, and third recombination sites).

If the first and third recombination sites are wild type recombination sites and the second recombination site is a variant recombination site, and the second recombination site has the opposite orientation from the first and third recombination sites (which, of course, have the same orientation) then wild type recombina-  
5 se can produce a deletion of the entire section spanning the first, second, and third recombination sites, and a Cre variant can produce an inversion of the first, second, or both pre-selected DNA segments.

If the first and third recombination sites are wild type recombination sites and the second recombination site is a variant recombination site, and the first recombination site has the opposite orientation from the second and third recombination sites (which, of course, have the same orientation) then wild type recombina-  
10 se can produce an inversion of the entire section spanning the first, second, and third recombination sites, and a variant recombina- se can produce a deletion of the second pre-selected DNA segments and an inversion of the first pre-selected DNA segment.  
15

Many more combinations of wild type and variant recombination sites and or recombination site orientations are possible. For example, the variant recombina- se can also be used with a different variant recombina- se having a different site specificity rather than wild type recombina- se. The above  
20 examples illustrate the general principles involved in designing specific recombinations that may be desired. It should be understood that the above combinations of recombination sites can be extended to the use of more recombination sites (that is more than three) and more intervening, pre-selected DNA segments.

For some uses of the disclosed recombinases, first, second, and fourth DNA sequences comprising a first lox site, a second lox site, and a third lox site, respectively, are introduced into cells. As used herein the expression "lox site" means a nucleotide sequence at which the gene product of the cre gene, referred to herein as Cre, and/or the disclosed Cre variants, can catalyze a site-  
25 specific recombination. LoxP site is a 34 base pair nucleotide sequence (Figure 1) which can be directly synthesized or isolated from bacteriophage P1 by methods known in the art. The Lox P site is an example of a wild type lox site.  
30

One method for isolating a LoxP site from bacteriophage P1 is disclosed by Hoess et al., *Proc. Natl. Acad. Sci. USA*, 79:3398-3402 (1982). The LoxP site consists of two 13 base pair inverted repeats separated by an 8 base pair spacer region. The nucleotide sequences of the insert repeats and the spacer region are as follows.

ATAACTTCGTATAATGTATGCTATACGAAGTTAT

Other wild type lox sites include LoxB, LoxL and LoxR sites which are nucleotide sequences isolated from *E. coli*. These sequences are disclosed and described by Hoess et al., *Proc. Natl. Acad. Sci. USA*, 79:3398-3402 (1982).

Preferred wild type lox sites are LoxP or LoxC2. Lox sites can also be produced by a variety of synthetic techniques which are known in the art. For example, synthetic techniques for producing lox sites are disclosed by Ito et al., *Nuc. Acid Res.*, 10:1755 (1982) and Ogilvie et al., *Science*, 214:270 (1981).

The gene product of the cre gene is a recombinase herein designated "Cre" which effects site-specific recombination of DNA at lox sites. As used herein, the expression "cre gene" means a nucleotide sequence which codes for a gene product which effects site-specific recombination of DNA in cells at lox sites. One cre gene (the wild type cre gene) can be isolated from bacteriophage P1 by methods known in the art. One method for isolating a cre gene from bacteriophage P1 is disclosed by Abremski et al., *Cell*, 32:1301-1311 (1983).

Genes engineered into cells for producing a foreign protein are often placed under the control of a highly active promoter. The activity of the promoter can result in an overproduction of the protein which interferes with the growth of the engineered cell. This overproduction of the protein can make it difficult to grow the engineered cell in sufficient quantity to make protein production economically feasible. The present invention provides a method whereby engineered cells can be grown to a desired density prior to expressing the engineered gene. The engineered gene is expressed, as desired, by activating a regulatory nucleotide sequence responsible for controlling expression of DNA encoding a variant recombinase. Methods of controlling the expression of an engineered gene include the following:



(1) A DNA segment flanked by recombination sites in the same orientation is introduced into DNA in a cell between a promoter and an engineered gene to render the promoter incapable of expressing the gene. A second DNA sequence comprising a regulatory nucleotide sequence and DNA encoding a variant recombinase is also introduced in the DNA. After the engineered cells are grown to a desired density, the regulatory nucleotide sequence is activated thereby effecting expression of the variant recombinase and producing a deletion of the DNA segment. The engineered gene would then be expressed.

(2) A gene for a regulatory molecule flanked by recombination sites in the same orientation is introduced into DNA in a cell. The regulatory molecule inhibits expression of an engineered gene. A second DNA sequence comprising a regulatory nucleotide sequence and DNA encoding a variant recombinase is also introduced into the DNA. After the engineered cells are grown to a desired density, the regulatory nucleotide sequence is activated thereby effecting expression of the variant recombinase and producing a deletion of the gene for the regulatory molecule. The engineered gene would then be expressed.

(3) An engineered gene lacking a promoter and flanked by two recombination sites in opposite orientations is introduced into DNA in a cell such that the 3' end of the gene lies adjacent to the transcription start site of a regulatory nucleotide sequence. A second DNA sequence comprising a regulatory nucleotide sequence and DNA encoding a variant recombinase is also introduced into the DNA. Since the engineered gene would be transcribed in the antisense direction, no engineered protein would be produced. After the engineered cell is grown to a desired density, the regulatory nucleotide sequence is activated thereby effecting expression of the variant recombinase and producing an inversion of the desired gene. The engineered gene could then be transcribed in the proper direction and expressed.

Numerous methods and techniques have been developed for the use of Cre recombinase and other, similar recombinases such as FLP. The disclosed variant recombinases can also be used in any of these methods. Adaptation of these methods to the use of the disclosed variant recombinases is

straightforward. Generally, all that is required is substitution of a variant recombinase (or a gene expressing a variant recombinase) for the original recombinase (or recombinase gene) and, if appropriate, substitution of variant (or wild type) recombination sites for the original recombination sites used in the method.

Examples of methods involving wild type recombinases and wild type recombination sites that can be adapted for use with the disclosed variant recombinases and recombination sites include recombination of DNA in phage packaging systems, recombination of DNA to form phage display libraries (for example, Fisch *et al.*, *Proc Natl Acad Sci U S A* 93(15):7761-6 (1996), and Waterhouse *et al.*, *Nucleic Acids Res* 21(9):2265-6 (1993), and other uses (for example, (Sauer *et al.*, *Proc. Natl. Acad. Sci. USA* 84: 9108-9112 (1987), Mullins *et al.*, *Nucleic Acids Res* 25(12):2539-40 (1997), Aoki *et al.*, *Mol Med* 5(4):224-31 (1999)).

Other examples of specific methods in which the disclosed variant recombinases can be used or substituted include methods disclosed in U.S. Patent No. 5,888,981, U.S. Patent No. 5,888,732, U.S. Patent No. 5,885,836, U.S. Patent No. 5,885,793, U.S. Patent No. 5,885,779, U.S. Patent No. 5,885,776, U.S. Patent No. 5,882,893, U.S. Patent No. 5,882,888, U.S. Patent No. 5,877,400, U.S. Patent No. 5,871,907, U.S. Patent No. 5,866,755, U.S. Patent No. 5,866,361, U.S. Patent No. 5,859,310, U.S. Patent No. 5,858,657, U.S. Patent No. 5,854,067, U.S. Patent No. 5,851,808, U.S. Patent No. 5,849,995, U.S. Patent No. 5,849,989, U.S. Patent No. 5,849,708, U.S. Patent No. 5,849,572, U.S. Patent No. 5,849,571, U.S. Patent No. 5,849,553, U.S. Patent No. 5,844,079, U.S. Patent No. 5,843,744, U.S. Patent No. 5,843,742, U.S. Patent No. 5,843,694, U.S. Patent No. 5,840,540, U.S. Patent No. 5,837,844, U.S. Patent No. 5,837,242, U.S. Patent No. 5,834,202, U.S. Patent No. 5,830,729, U.S. Patent No. 5,830,698, U.S. Patent No. 5,830,461, U.S. Patent No. 5,817,492, U.S. Patent No. 5,814,618, U.S. Patent No. 5,814,500, U.S. Patent No. 5,814,300, U.S. Patent No. 5,807,995, U.S. Patent No. 5,807,708, U.S. Patent No. 5,801,030, U.S. Patent No. 5,800,998, U.S. Patent No. 5,795,734, U.S. Patent No. 5,795,726, U.S. Patent No. 5,792,833, U.S.

Patent No. 5,792,632, U.S. Patent No. 5,789,156, U.S. Patent No. 5,777,194, U.S. Patent No. 5,776,449, U.S. Patent No. 5,773,697, U.S. Patent No. 5,770,384, U.S. Patent No. 5,767,376, U.S. Patent No. 5,763,240, U.S. Patent No. 5,756,671, U.S. Patent No. 5,744,343, U.S. Patent No. 5,744,336, U.S. Patent No. 5,736,377, U.S. Patent No. 5,733,744, U.S. Patent No. 5,733,743, U.S. Patent No. 5,733,733, U.S. Patent No. 5,731,182, U.S. Patent No. 5,723,765, U.S. Patent No. 5,723,333, U.S. Patent No. 5,723,287, U.S. Patent No. 5,721,367, U.S. Patent No. 5,721,118, U.S. Patent No. 5,700,470, U.S. Patent No. 5,686,595, U.S. Patent No. 5,679,523, U.S. Patent No. 5,677,177, U.S. Patent No. 5,658,772, U.S. Patent No. 5,656,438, U.S. Patent No. 5,654,182, U.S. Patent No. 5,654,168, U.S. Patent No. 5,650,491, U.S. Patent No. 5,650,308, U.S. Patent No. 5,650,298, U.S. Patent No. 5,643,727, U.S. Patent No. 5,641,866, U.S. Patent No. 5,641,748, U.S. Patent No. 5,639,726, U.S. Patent No. 5,635,381, U.S. Patent No. 5,629,179, U.S. Patent No. 5,629,159, U.S. Patent No. 5,614,389, U.S. Patent No. 5,612,205, U.S. Patent No. 5,596,089, U.S. Patent No. 5,591,609, U.S. Patent No. 5,589,362, U.S. Patent No. 5,539,094, U.S. Patent No. 5,530,191, U.S. Patent No. 5,527,695, U.S. Patent No. 5,510,099, U.S. Patent No. 5,478,731, U.S. Patent No. 5,441,884, U.S. Patent No. 5,434,066, U.S. Patent No. 5,378,618, U.S. Patent No. 5,354,668, U.S. Patent No. 5,334,515, U.S. Patent No. 5,300,431, and U.S. Patent No. 4,959,317.

### **1. Use of Variants Recombinases in Plants and Plant Cells**

Methods for introducing a DNA sequence into plant cells are known in the art. Nucleic acids can generally be introduced into plant protoplasts, with or without the aid of electroporation, polyethylene glycol, or other processes known to alter membrane permeability. Nucleic acid constructs can also be introduced into plants using vectors comprising part of the Ti- or Ri-plasmid, a plant virus, or an autonomously replicating sequence. Nucleic acid constructs can also be introduced into plants by microinjection or by high-velocity microprojectiles, also termed "particle bombardment" or "biolistics" (Sanford, J. C., *Tibtech* 6: 299 (1988)), directly into various plant parts. The preferred means of introducing a nucleic acid fragment into plant cells involves the use of

*A. tumefaciens* containing the nucleic acid fragment between T-DNA borders either on a disarmed Ti-plasmid (that is, a Ti-plasmid from which the genes for tumorigenicity have been deleted) or in a binary vector in trans to a disarmed Ti-plasmid. The *Agrobacterium* can be used to transform plants by inoculation of tissue explants, such as stems, roots, or leaf discs, by co-cultivation with plant protoplasts, or by inoculation of seeds or wounded plant parts.

Foreign genes can be introduced into a wide range of crop species. Thus, the disclosed variant recombinases and method are applicable to a broad range of agronomically or horticulturally useful plants. The particular method which is employed to introduce the DNA sequence into a selected plant cell is not critical. In a preferred embodiment, DNA sequences are introduced into plant cells by co-cultivation of leaf discs with *A. tumefaciens* essentially as described by Horsch et al., *Science*, 227: 1229-1231 (1985) omitting the nurse cultures.

In the present method, the recombination sites are contacted with a variant recombinase, thereby producing the site specific recombination. In one embodiment, a variant recombinase, or messenger RNA encoding a variant recombinase, is introduced into the cells directly by micro-injection, biolistics, or other protein or RNA introduction procedure. In a preferred embodiment, DNA encoding the variant recombinase is introduced into the plant cell under the control of a promoter that is active in plant cells. Suitable regulatory nucleotide sequences are known in the art. The promoter which is employed with a selected plant cell is not critical to the method of the invention. A partial list of suitable promoters include the 35S promoter of cauliflower mosaic virus described by Odell et al., *Nature*, 313: 810-812 (1985); the promoter from the nopaline synthase gene of *A. tumefaciens* described by Depicker et al., *J. of Mol. Appl. Genet.*, 1: 561-573 (1982); the promoter from a Rubisco small subunit gene described by Mazur and Chui, *Nucleic Acids Research* 13: 2373-2386 (1985); the 1' or 2' promoter from the TR-DNA of *A. tumefaciens* described by Velten et al., *EMBO J.* 12: 2723-2730 (1984); the promoter of a chlorophyll a/b binding protein gene described by Dunsmuir et al., *J. Mol. Appl. Genet.* 2: 285-300 (1983); the promoter of a soybean seed storage protein gene

described by Chen et al., *Proc. Natl. Acad. Sci. USA*, 83: 8560-8564 (1986); and the promoter from the wheat EM gene described by Marcotte et al., *Nature* 335: 454-457 (1988). Variant recombinases can be expressed throughout the plant generally in all cells at all stages of development, or expression of variant  
5 recombinases can be more specifically controlled through the use of promoters or regulatory nucleotide sequences having limited expression characteristics. Variant recombinases can be expressed in a tissue specific manner, for example only in roots, leaves, or certain flower parts. Variant recombinases can be expressed in a developmentally specific time period, for example only during  
10 seed formation or during reproductive cell formation. Expression of variant recombinases can also be placed under the control of a promoter that can be regulated by application of an inducer. In this case expression is off or very low until the external inducer is applied. Promoters active in plant cells have been described that are inducible by heat shock (Gurley et al., *Mol. Cell. Biol.* 6: 559-  
15 565 (1986)), ethylene (Bfogle et al., *Plant Cell* 1: 599-607 (1989)), auxin (Hagan and Guilfoyle, *Mol. Cell. Biol.* 5: 1197-1203 (1985)), abscisic acid (Marcotte et al., *Nature* 335: 454-457 (1988)), salicylic acid (EPO 332104A2 and EPO 337532A1), and substituted benzenesulfonamide safeners (WO 90/11361). Control of expression of variant recombinases by the safener-  
20 inducible promoter 2-2, or its derivatives, allows the expression to be turned on only when the inducing chemical is applied and not in response to environmental or phytohormonal stimuli. Thus expression can be initiated at any desired time in the plant life cycle. Preferably, the regulatory nucleotide sequence is a 35S promoter or a 2-2 promoter. The above techniques and  
25 materials can also be used to express wild type recombinase in plant cells if required by the particular recombination pattern to be accomplished.

One application of the disclosed variant recombinases is in controlling male fertility in a method for producing hybrid crops. Hybridization of a crop involves the crossing of two different lines to produce hybrid seed from which  
30 the crop plants are grown. Hybrid crops are superior in that more of the desired traits can be introduced into the production plants. For instance, quality traits such as oil content, herbicide resistance, disease resistance, adaptability to

environmental conditions, and the like, can be hybridized in offspring so that the latter are invested with the most desirable traits of its parents. In addition, progeny from a hybrid cross may possess new qualities resulting from the combination of the two parental types, such as yield enhancement resulting from the phenomenon known as heterosis. Controlled cross-fertilization to produce hybrid seeds has been difficult to achieve commercially due to competing self-fertilization, which occurs in most crop plants.

Hybrid seed production is typically performed by one of the following means: (a) mechanically removing or covering the male organs to prevent self-fertilization followed by exposing the male-disabled plants to plants with male organs that contain the trait(s) desired for crossing; (b) growing genetically male-sterile plants in the presence of plants with fertile male organs that contain the trait that is desired for crossing; or (c) treating plants with chemical hybridizing agents (CHA) that selectively sterilize male organs followed by exposing the male-disabled plants to plants with fertile male organs that contain the trait that is desired for crossing. Some disadvantages to each of these methods include: (a) applicability only to a few crops, such as corn, where the male and female organs are well separated; and it is labor intensive and costly; (b) genetically male sterile lines are cumbersome to maintain, requiring crosses with restorer lines; (c) all CHAs exhibit some degree of general phytotoxicity and female fertility reduction. Also CHAs often show different degrees of effectiveness toward different crop species, or even toward different varieties within the same species.

A molecular genetic approach to hybrid crop production applicable to a wide range of crops and involves genetic male sterility is described in EPA 89-344029. This system involves the introduction of a cell disruption gene that is expressed only in the tapetal tissue of anthers thereby destroying the developing pollen. The resulting genetically male sterile plants serve as the female parents in the cross to produce hybrid seed. This system could be highly effective and desirable. However one disadvantage is that since the male sterile parent is heterozygous for the sterility gene which acts as a dominant trait, only 50% of the plants grown from the hybrid seed are fertile, the rest retain the sterility

gene. This situation will result in reduced pollen shed in the production field which may lead to reduced seed set and yield. Addition of recombinase technology to this hybrid scheme allows restoration of fertility to a much higher percentage of plants in the production field, as well as elimination of the cell  
5 disruption gene. Placing the male sterility gene between recombination sites allows it to be deleted following introduction of a variant recombinase into the hybrid from the male parent.

Another application of the disclosed variant recombinases is in making seedless produce. Seedlessness is desirable in consumed produce for  
10 convenience and taste. Currently "seedless" watermelon is sold that actually contains some developed seed and a large number of immature seed that varies in size up to that of fully mature seed. To produce these watermelon first a hybrid cross is made between a tetraploid maternal parent and a diploid pollinator. The resulting triploid seed produces self-infertile plants that are  
15 crossed with a diploid pollinator to produce seedless fruit (Kihara, *Proc. Soc. Hort. Sci.*, 58: 217-230, (1951)). This production scheme suffers the following problems: (i) Creating a tetraploid plant, which is accomplished by a chromosome duplication method, is difficult. Also the number of seeds per fruit on this tetraploid plant must be low since this has a positive correlation with  
20 seed number in the final product (Andrus, *Production of Seedless Watermelons*, USDA Tech. Bull. No. 1425 (1971)); (ii) good combining ability of the diploid pollinator and the tetraploid plant is difficult to achieve (Henderson, *J. Amer. Soc. Hort. Sci.*, 102: 293-297 (1977)); (iii) the triploid seeds are much inferior to regular diploid seeds in vigor and germinability (Maynard, *Hort. Sci.*, 24:  
25 603-604 (1989)). These problems, together with incomplete seedlessness in the final product, make the development of seedless watermelon slow and difficult. This ploidy-based approach to seedlessness is possible only in those few species where unusual euploidy plants (tetraploid and triploid for watermelon, for example) are viable.

30 A molecular genetic approach to seedlessness involving the disclosed variant recombinases is much more efficient, resulting in a more reliably seedless product and does not involve changes in ploidy. Thus it is more

generally applicable to a wider range of species. A recombination site/polyA-inactivated cell disruption gene regulated by a seed-specific promoter is introduced into a plant. When this plant is crossed to a plant expressing a variant recombinase, the disruption gene is activated and expressed in the seed, thereby disrupting seed development. The certainty of endosperm failure (caused by the cell disruption gene product) leading to the abortion of the whole seed is very high. In most dicots, the endosperm supplies the nutrients needed for early embryo development. Endosperm abortion invariably leads to seed abortion (Brink and Cooper, *Bot. Rev.* 8: 423-541 (1947)).

10           The seed-specific promoter used can be selected from the group of promoters known to direct expression in the embryo and/or the endosperm of the developing seed, most desirably in the endosperm. Examples of seed-specific promoters include but are not limited to the promoters of seed storage proteins. The seed storage proteins are strictly regulated, being expressed almost exclusively in seeds in a highly tissue-specific and stage-specific manner (Higgins et al., *Ann. Rev. Plant Physiol.* 35: 191-221 (1984); Goldberg et al., *Cell* 56: 149-160 (1989)). Also, different seed storage proteins may be expressed at different stages of seed development and in different parts of the seed.

20           There are numerous examples of seed-specific expression of seed storage protein genes in transgenic dicotyledonous plants. These include genes from dicotyledonous plants for bean  $\beta$ -phaseolin (Sengupta-Goplalan et al., *Proc. Natl. Acad. Sci. USA* 82: 3320-3324 (1985) and Hoffman et al., *Plant Mol. Biol.* 11: 717-729 (1988)), bean lectin (Voelker et al., *EMBO J* 6: 3571-3577 (1987)), soybean lectin (Ocamuro et al., *Proc. Natl. Acad. Sci. USA* 83: 8240-8344 (1986)), soybean kunitz trypsin inhibitor (Perez-Grau and Goldberg *Plant Cell* 1: 1095-1109 (1989)), soybean  $\beta$ -conglycinin (Beachy et al., *EMBO J* 4: 3047-3053 (1985), Barker et al., *Proc. Natl. Acad. Sci.* 85: 458-462 (1988), Chen et al., *EMBO J* 7: 297-302 (1988), Chen et al., *Dev. Genet.* 10: 112-122 (1989), Naito et al., *Plant Mol. Biol.* 11: 683-695 (1988)), pea vicillin (Higgins et al., *Plant Mol. Biol.* 11: 109-123 (1988)), pea convicillin (Newbigin et al., *Planta* 180: 461 (1990)), pea legumin (Shirsat et al., *Mol. Gen. Genetics* 215:



326 (1989)), rapeseed napin (Radke et al., *Theor. Appl. Genet.* 75: 685-694 (1988)), as well as genes from monocotyledonous plants such as for maize 15-kd zein (Hoffman et al., *EMBO J* 6: 3213-3221 (1987)), barley  $\beta$ -hordein (Marris et al., *Plant Mol. Biol.* 10: 359-366 (1988)), and wheat glutenin (Colot et al., *EMBO J* 6: 3559-3564 (1987)). Moreover, promoters of seed-specific genes operably linked to heterologous coding regions in chimeric gene constructions also maintain their temporal and spatial expression pattern in transgenic plants. Such examples include Arabidopsis thaliana 2S seed storage protein gene promoter to express enkephalin peptides in Arabidopsis and Brassica napus seeds (Vandekerckhove et al., *Bio/Technology* 7: 929-932 (1989)), bean lectin and bean  $\beta$ -phaseolin promoters to express luciferase (Riggs et al., *Plant Sci.* 63: 47-57 (1989)), and wheat glutenin promoters to express chloramphenicol acetyl transferase (Colot et al., *EMBO J.* 6: 3559-3564 (1987)). Promoters highly expressed early in endosperm development are most effective in this application. Of particular interest is the promoter from the a subunit of the soybean  $\beta$ -conglycinin gene (Walling et al., *Proc. Natl. Acad. Sci. USA* 83: 2123-2127 (1986)) which is expressed early in seed development in the endosperm and the embryo.

The cell disruption gene used can be selected from a group of genes encoding products that disrupt normal functioning of cells. There are many proteins that are toxic to cells when expressed in an unnatural situation. Examples include the genes for the restriction enzyme EcoRI (Barnes and Rine, *Proc. Natl. Acad. Sci. USA* 82: 1354-1358 (1985)), diphtheria toxin A (Yamaizumi et al., *Cell* 15: 245-250 (1987)), streptavidin (Sano and Cantor, *Proc. Natl. Acad. Sci. USA* 87: 142-146 (1990)), and barnase (Paddon and Hartley, *Gene* 53: 11-19 (1987)). Most preferred for this system is the coding region of barnase which has been shown to be highly effective in disrupting the function of plant cells (EPA 89-344029).

A highly desirable seedless system is one in which fully fertile F1 seed develops, that can then be grown into plants that produce only seedless fruit. This system is economically favorable in that for each cross pollination, a large number of seedless fruits result: the number of F1 seed from one cross X the

number of fruits produced on an F1 plant. Also incorporated in this scheme are the advantages of growing a hybrid crop, including the combining of more valuable traits and hybrid vigor. This is accomplished in the same manner as described above except that the recombination site/polyA-inactivated disruption gene is expressed from a seed maternal tissue (seed coat or nucellus)-specific promoter. For example, the seed coat is the outgrowth of the integuments, a strictly maternal tissue. Therefore the hybrid cross that brings the recombination site/polyA-inactivated disruption gene together with the recombinase gene does not involve this seed coat tissue. The seed coat of the F1 seed has either recombination sites or recombinase, depending on which is used as the female parent, and thus F1 seed develop normally. After the F1 seed gives rise to a fruit-bearing F1 plant, all vegetative cells (including seed coat cells) inherit both recombination sites and recombinase from the embryo. Thus the seed coat of the F1 plant has an activated cell disruption gene.

The seed coat is an essential tissue for seed development and viability. When the seed is fully matured, the seed coat serves as a protective layer to inner parts of the seed. During seed development, the seed coat is a vital nutrient-importing tissue for the developing embryo. The seed is nutritionally "parasitic" to the mother plant. All raw materials necessary for seed growth must be imported. In seeds of dicotyledonous plants, the vascular tissue enters the seed through the funiculus and then anastomoses in the seed coat tissue. There is no vascular tissue connection or plasmodesmata linkage between the seed coat and the embryo. Therefore, all nutrient solutes delivered into the developing seed must be unloaded inside the seed coat and then move by diffusion to the embryo. Techniques have been developed to study the nutrient composition in the seed coat (Hsu et al., *Plant Physiol.* 75: 181 (1984); Thorne & Rainbird, *Plant Physiol.* 72: 268 (1983); Patrick, *J. Plant Physiol.* 115: 297 (1984); Wolswinkel & Ammerlaan, *J. Exp. Bot.* 36: 359 (1985)), and also the detailed cellular mechanisms of solute unloading (Offler & Patrick, *Aust. J. Plant Physiol.* 11: 79 (1984); Patrick, *Physiol. Plant* 78: 298 (1990)). It is obvious that the destruction of this vital nutrient-funnelling tissue causes seed abortion.

The disclosed tissue-specific and site-directed DNA recombination can be used to obtain seedless fruit production. This method is useful for the production of seedless watermelon, for example. A combination of gene expression specific for maternally inherited seed tissue and the disclosed recombina-  
5 recombina-  
The system can be universally applied to any horticultural crop in which the presence of seeds is undesirable and difficult to be eliminated through conventional breeding methods. The system also allows the normal production of F1 seeds. The ability to maintain heterosis is an advantage of producing F2  
10 seedless fruits.

The existing production of seedless watermelon indicates that seed development is not essential for the watermelon fruit development. However, conventional production of seedless watermelon using the ploidy imbalance trick has never been very popular due to the difficulty of overcoming the yield  
15 and production problems. Creating and maintaining the tetraploid (4n) female germline, and producing the triploid (3n) seeds have made the seed cost high. Cross-pollination is needed for the production of triploid seeds (4n X 2n) and seedless fruits (3n X 2n). Also triploid seed germination is usually poor due to ploidy imbalance.

20 The present approach eliminates the dependence on polyploid germplines and provides an efficient system for producing seedless fruit. The products of double fertilization of higher plants are the embryo and endosperm. The seed coat (including the integumentary tapetum) and nucellus (the tissue encompassing the embryo sac) are the remaining seed tissues that are  
25 maternally inherited. In addition to general protection, the seed coat and nucellus also play an important role in importing nutrients into the developing embryo and endosperm. Seed development will be aborted if this vital nutrient-importing mechanism of the seed coat/nucellus is debilitated. This will be accomplished by using the recombina-  
30 only in these tissues. Controlling the gene activation in a maternal tissue-specific manner allows production of normal F1 seed, but abortion of F2 seed. A seed coat or nucellus promoter is coupled to a tissue-destructive (lethal) gene

in order to prevent seeds from forming. The destructive gene is inactive in the seed parent due to the presence of a blocking transcription terminator. The terminator is flanked by recombination sites for subsequent excision by a recombinase-mediated recombination event. Expression of the recombinase is also controlled by the seed coat/nucellus-specific promoter. When plants carrying the separate recombinase and recombination site constructs are crossed, the F1 seed will be viable because seed coat/nucellus is maternal tissue, and in that tissue recombinase and recombination sites are not combined. When the F1 seed is used as planting seed, the self-pollinated or out-crossed plants will produce seedless fruits or vegetables, since in seed coat/nucellus tissues recombinase and recombination sites are combined, and the lethal gene is activated.

## **2. Use of Variant Recombinases for Phage Packaging**

The disclosed variant recombinases can also be used to aid in phage packaging. The cloning system described herein utilizes a headful in vitro packaging system to clone foreign DNA fragments as large as 95 kb which permits the isolation of DNA fragments that are at least twice the size of those that can be obtained by lambda cosmid cloning. This increased cloning capacity has the following utility:

(1) Genes in the 45-95 kb size range and, more particularly, in the 70-95 kb size range can now be directly cloned and genes in the 25-45 kb size range can be cloned more easily.

(2) Chromosomal "walking" and "jumping" techniques can be speeded up by a factor of at least two and should be more accurate because of the reduced number of contiguous segments that need to be linked together.

(3) The cloning system of the invention is useful as a means for the delivery of DNA efficiently to bacteria which otherwise do not take up DNA from solution well.

Specifically, the headful packaging system of this invention for cloning foreign DNA fragments as large as 95 kb comprises:

(a) modifying vector DNA by inserting a stuffer fragment into a blunt end producing site which is proximal to a pac site;

(b) digesting the product of step (a) to produce two vector arms each of which contains (i) a blunt end, (ii) another end which is compatible with the foreign DNA fragment which is to be cloned, and (iii) a recombination site;

(c) ligating the foreign DNA to the product of step (b) without  
5 generating concatemers;

(d) reacting the product of step (c) with pac cleavage proficient extract and head-tail proficient extract wherein the ratio of large heads to small heads in the head-tail extract is at least 5:1;

(e) infecting a bacterial strain expressing a variant recombinase with the  
10 product of step (d); and

(f) recovering the cloned DNA.

The term pac is a generic name which refers to the site needed to initiate packaging of DNA. The pac cleavage proficient extract contains the recognition proteins necessary to cleave the pac site and, thus, initiate  
15 packaging. The head-tail proficient extract contains the heads and tails needed to package the cloned DNA into a virus particle. The term concatemer means a DNA molecule consisting of repeating units arranged in a head-to-tail configuration. The term stuffer fragment refers to a DNA fragment which is inserted into the vector DNA at a unique site, and within which headful  
20 packaging is terminated. The terms bacteriophage and phage are used interchangeably herein.

Although many of the elements described herein pertain to the P1 bacteriophage cloning system, those skilled in the art will appreciate that, with the exception of the components needed to package DNA (pac and packaging  
25 extracts), many of the elements discussed below, such as plasmid replicon and a multicopy or lytic replicon, pertain to the recovery of packaged DNA and can be used to recover DNA in bacteria, such as *E. coli*, with other cloning systems, for example, bacteriophage, yeast, etc.

Bacteriophages which are suitable to practice the invention must have a  
30 large head capacity and the elements necessary for packaging DNA must be defined. For example, for phages P22 and T1, which utilize headful packaging, the necessary packaging elements are defined. However, P22 and T1 do not

have a very large head capacity. On the other hand, for phage T4, which has a large head capacity, the necessary packaging elements have not been defined.

The elements necessary for packaging DNA (i.e., an in vitro headful packaging system) are the following:

5 (1) a unique site, *pac*, which is cleaved by recognition proteins; it is the *pac* cleavage proficient extract which contains the recognition proteins necessary to cleave the *pac* site; and

(2) empty phage heads into which the DNA is packaged until the head has been completely filled, then a cleavage event is triggered (the "headful" cut) which separates the packaged DNA away from the remaining components; it is the head-tail proficient extract which contains the heads and tails needed to package the cloned DNA into virus particle.

Although initiation of packaging is site-specific (cleavage of *pac* site initiates packaging), termination of packaging is not site-specific. In other words, no unique site is recognized, as packaging will terminate at whatever point the head has been filled.

In the case of P1, the DNA substrate used in the packaging reaction during the viral life cycle is a concatemer consisting of individual units of the P1 chromosome arranged in a head-to-tail manner. Headful packaging, using either P1 phage or any other phage, is a four step process: (1) In the first step a unique site, *pac*, is recognized and cleaved by the *pac* recognition proteins (PRPs); (2) DNA on one side of the cleavage is packaged into an empty phage head until the head has been completely filled; (3) a second cleavage event is then triggered (the "headful" cut) that separates the packaged DNA away from the rest of the concatemer; and (4) initiation of a second round of DNA packaging from the free end generated by the previous "headful" cut--hence the term processive headful cutting. However, if a concatemer is not generated then processive headful packaging does not occur.

The ends of the packaged P1 DNA do not contain complementary single-stranded sequences, as do the ends of packaged bacteriophage lambda DNA, and consequently after P1 DNA is injected into a bacterium its cyclization does not occur by strand annealing but rather by recombination

between homologous sequences present at the ends of the molecule. Because of this circumstance, any vector that uses P1 packaging, or for that matter any headful packaging mechanism, must devise a means of cyclizing the linear packaged DNA by recombination. Cyclizing is accomplished by incorporating  
5 recombination sites into the vector and using a disclosed variant recombinase to cyclize the DNA after injection into gram-negative bacterial strains expressing the variant recombinase.

P1 produces two head sizes, a big head that can accommodate 105-110 kb of DNA, and a small head that can accommodate no more than 45 kb of  
10 DNA. Normally the ratio of big to small heads in a P1 wild-type infection is 10:1, however, in the cm-2 mutant of P1 used to prepare some of the packaging lysates described herein, the ratio of head sizes is 1:1. The head-tail packaging lysate prepared from the cm mutant of P1 contained the usual ratio of big to small heads which is about 10:1. This is the preferred lysate for preparing head-  
15 tail packaging extract. To ensure packaging of DNA exclusively into the big phage heads, the DNA must be bigger than that which can be accommodated by the small heads. It is generally desired that there be a large excess of big heads. However, the ratio of large heads to small heads should not fall below a ratio of about 5:1.

20

#### Illustration

The following illustration describes an example of how the disclosed method can be used to generate variant FLP recombinases with altered site specificity. As with other recombinase, the method preferably uses the following components:

25

1. An in vitro mutagenesis system;

2. A recombinase expression plasmid that allows varying levels of expression by a simple environmental control (for example, by the presence of varying amounts of an inducer substance in the growth media, by temperature, or by osmolarity);

30

3. An indicator/selector bacterial strain. The strain carries both an indicator recombination substrate for detection of recombination at the wild type recombination site and a second recombination substrate that allows

selection for recombinase mutants that have gained the ability to recognize and perform recombination at a target mutant recombination site (that is, a variant recombination site). Importantly, the wild type and target mutant sites are designed so that recombination between the mutant and wild type sites is  
5 blocked even with a mutant recombinase that can recognize both the wildtype site and also the target mutant site. This design prevents unwanted recombination between the wildtype and target mutant recombination sites that could interfere with either selection or detection of desired recombinational outcomes. The block is imposed by designing the wildtype and mutant sites to  
10 have different spacer regions (that is, different compatibility sequences), for example, the normal "wt" spacer for the wildtype recombination site, and an alternative spacer "A1" for the other recombination substrate. In an otherwise nonmutant recombination site DNA recombination proceeds efficiently both for recombination sites having the wt spacer (that is, a recombination between two  
15 wt sites) and also for sites having the A1 spacer (that is, a recombination between two A1 sites). Yet, recombination between the A1 site and the wt site is blocked (that is, recombination between a wt site and an A1 does not occur). This strategy is applicable to all recombinases that have a recombination target site displaying one or more recombinase binding sites (repeat elements) on each  
20 side of a spacer region in which recombination occurs (Nunes-Döby et al., *Nucl. Acids Res.*, 26:391-406 (1998)). Such sites display a requirement for homology in the spacer elements for optimal recombination activity and has been shown to be the case for members of the Int family of recombinases, including Cre, lambda Int, and FLP (Craig, *Ann. Rev. Genet.* 22:77-105 (1988)).

25 The preferred in vitro mutagenesis system is that of Stemmer (Stemmer, *Nature* 370:389-391 (1994)), or a variant of that strategy. After mutagenesis and assembly of fragments into a full-length FLP gene, it is cloned into the expression vector.

The expression plasmid to be used can be any of the "inducible"  
30 expression plasmids available in bacteria. For this illustration one of the pBAD plasmids for *E. coli* was chosen that allows expression of recombinase by growth on arabinose (Guzman et al., *J. Bacteriol.* 177:4121-4130 (1995)), and



which can be turned off by growth on glucose (and no arabinose). For this illustration the expression plasmid carries the replication origin of pACYC, and the FLP recombinase gene is under the control of the *E. coli* ara promoter region. In addition, the plasmid carries the selectable marker Cm<sup>r</sup> which  
5 confers resistance to the antibiotic chloramphenicol. Because the pACYC replicon is low copy, its use may be advantageous in preventing excessive expression of FLP. Alternatively, a higher copy replicon could be used, such as that of ColE1. In that case the expression level of FLP must also be carefully controlled using the inducer substance arabinose.

10 The indicator/selector bacteria carries two different reporter constructs for FLP-mediated recombination. The first reporter construct consists of two FRT sites (FLP recombination target; that is, the recombination site recognized by FLP recombinase) in direct orientation (an excision substrate) and resides on a low copy replicon that is compatible with the FLP expression construct. In  
15 this example the first substrate is integrated into the *E. coli* genome. This can be done by incorporating the FRT substrate onto phage lambda and then constructing a lambda lysogen. Alternatively the FRT substrate could reside on a low-copy replicon that is compatible with that of the FLP expression vector and which has an additional selectable marker, for example resistance to  
20 bleomycin. This FRT substrate carries two FRT sites in direct orientation flanking a gene whose presence can be easily monitored. In this illustration a constitutively expressing lacZ gene was used whose presence can be determined simply by growing colonies plates containing X-gal, upon which they will become blue in color. Loss of the lacZ gene by FLP-mediated recombination  
25 results in white colony formation on X-gal plates.

The indicator/selector bacterial strain also carries a second FRT-like substrate. This is a plasmid element having two FRT-M sites in direct orientation flanking DNA sequences (STOP) that disallow expression of a downstream selectable marker. In this example, nonexpression of the selectable  
30 marker is achieved by placing genetic elements in the following order: constitutive promoter – FRT-M – STOP – FRT-M – 'neo, where 'neo indicates the promoterless neo gene of Tn5. Hence this cassette cannot express neo and

cells are sensitive to the antibiotic kanamycin. Excision of STOP by recombination at FRT-M is designed to permit expression of neo so that cells now become resistant to kanamycin. The plasmid carries an additional selectable marker, Ap<sup>r</sup> conferring resistance to ampicillin, to maintain presence  
5 of the plasmid in *E. coli*. The STOP sequence here is the strong transcriptional terminator rrnBT1T2 (Liebke et al., *Nucleic Acids Res.* 13:5515-5525 (1985)).

Figure 17 shows wt FRT, FRT-A1, and FRT-M sites used in this illustration. Although the wildtype FRT site displays three inverted repeat elements, recombination proceeds efficiently with sites carrying two of these  
10 repeats in the inverted configuration shown (Jayaram, *Proc. Natl. Acad. Sci. USA* 82:5875-5879 (1985)). Either the full or minimal site can be used since both are recombinationally functional. The FRT-A1 site is designed to have an altered spacer but which is still functional for self X self recombination (Senecoff et al., *J. Biol. Chem.* 261:7380-7386 (1986)). The target FRT-M site  
15 is designed to carry symmetrical mutations in the repeat elements that disallow efficient FLP-mediated recombination (Senecoff et al., *J. Mol. Biol.* 201:405-421 (1988)), and also the spacer mutation of FRT-A1.

Importantly, the FRT-M site differs from the FRT site in two ways. First, both of the 13 bp inverted repeat elements (that is the recognition  
20 sequences) are mutated in a symmetrical manner such that the wt FLP enzyme does not catalyze recombination between two FRT-M sites, or does so only extremely poorly (< 0.1%). Second, the spacer region (that is, the compatibility sequence; the 8 bp region between the 13 bp inverted repeats) is replaced with an alternate spacer A1. The alternate spacer when present in an otherwise wt  
25 FRT site, which we will call FRT-A1, is permissive for FLP-mediated recombination between two FRT-A1 sites, but does not permit recombination between FRT-A1 and FRT. Use of the FRT-M site which contains the heterologous spacer prevents FLP-mediated recombination between FRT and FRT-M by FLP or a mutant FLP protein that might otherwise catalyze  
30 recombination between the wt FRT substrate and the mutant target FRT-M substrate. Unwanted recombination between the wildtype and target mutant recombination sites would decrease efficiency of the selection procedure by (a)

not limiting recombination at the target mutant site specifically to these sites and thus compromising the selection (at FRT-M sites) for mutant FLP recombinases, (b) affecting the accuracy of the specific indication of activity at the wt FRT sites, and (c) decreasing either the plasmid stability of the FRT-M selector substrate or the integrity of bacterial chromosome (or compatible plasmid) carrying the wt FRT sites.

Procedure (Figure 18): the FLP gene is mutagenized *in vitro* and then cloned into the inducible expression vector, in this case a pBAD derivative that places FLP under the control of the arabinose-inducible pBAD promoter. The pool of mutagenized FLP genes is transformed into the FRT indicator/selector strain which is pre-induced with arabinose and/or induced with arabinose during DNA transformation. Bacterial colonies are then selected to be simultaneously resistant to chloramphenicol (to retain the FLP expression plasmid), ampicillin or carbenicillin (to retain the selector plasmid) and kanamycin (to select for cells in which FRT-M X FRT-M recombination has occurred) on agar plates containing either arabinose (for continued FLP expression) or glucose (to prevent prolonged FLP expression). In some instances it may be advantageous to limit FLP expression to better enrich for those FLP mutants that either have more avidity for recombination at the FRT-M sites or to better exclude those FLP mutants that retain activity at the wildtype FRT sites. This is because prolonged or high-level FRT expression can lead to inefficient but detectable recombination at mutant sites.

Either all Kan<sup>r</sup> colonies or only those that are blue on X-gal plates are then pooled and harvested for DNA preparation. A second round of FRT gene mutagenesis and selection is then initiated by PCR amplification. Multiple rounds of mutagenesis and selection are used to obtain FRT mutants with altered site-specificity. Comparison of various individual isolates allows determination of critical amino acid residues that contribute to the desired mutant phenotype.

The same rationale and procedure can be used to generate a second class of altered FLP recombinases. The target mutant FRT site used is, however,

different. In this case the target is the FRT-M2 site (Figure 19) which carries a different binding site mutation(s) than does the FRT-M site as described above.

### Examples

#### Example 1: Selection of Variant Cre Recombinases

5           The following example describes the production and analysis of some examples of the disclosed variant recombinases. Cre mutants characterized by a wider substrate recognition were created, applying a technique called directed molecular evolution: Multiple rounds of a random mutagenesis procedure (DNA shuffling; Stemmer, W. P. C., *Proc. Natl. Acad. Sci. USA*, 91:10747-10751 (1994)) and a sensitive selection for the desired phenotypes allow to  
10           accumulate candidate mutants within the generated pools of mutated sequences. The Cre mutants created in this example showed wt-like activity on *loxP* sites. In addition, they performed on an altered substrate, called *loxK2*, that is not recognized by the wt enzyme. Two transversions from adenine (*loxP*) to  
15           thymine (*loxK2*) at positions 11' and 12' of the *lox* sequence are the barriers that inhibit wt Cre from recognizing *loxK2*: The two thymines are believed to cause repulsive forces with the acidic side chain of a glutamate residue in the J helix of wt Cre (position 262). This glutamate was found to be replaced by a glycine in all mutants with remarkably increased activity on *loxK2*. Additional  
20           site-directed mutagenesis experiments, confined to the glutamate at position 262 of Cre, could confirm that E262G but also E262W mutations alone are sufficient to increase *loxK2* activity by a factor of  $10^3$  without affecting *loxP* recognition. Other point mutations identified in the analyzed mutants may however be responsible for increasing the newly obtained specificity even  
25           further (10 fold compared to E262G alone).

### MATERIALS AND METHODS

#### General Procedures

#### Standard Reagents

30           The following reagents were used in all experiments: 10x' TBE (Tris-Borate-EDTA, pH 8.3) was purchased from Biofluids, Inc. (Rockville, MD) and diluted to 1x with deionized water prior to use. TE (Tris-HCl 10 mM, EDTA 1 mM, pH 8.0 and pH 7.5) and Tris-HCl (1 M, pH 7.5 and 8.0) came from

Quality Biological, Inc. (Gaithersburg, MD), as well as autoclaved LB (Luria-Bertani) and SOC broth. L-(+)-arabinose (>99%) was ordered from Sigma-Aldrich Fine Chemicals (St. Louis, MO) and anhydrous D-glucose from Mallinckrodt Laboratory Chemicals (Phillipsburg, NJ).

5           **Gel Electrophoresis**

For DNA electrophoresis, 0.8% agarose TBE gels were used (GTG Sea Kem Agarose (FMC, Rockland, ME)). Gels were prestained with 0.25 µg/ml EtBr (Ethidium Bromide, 10 mg/ml (Life Technologies, Inc., Grand Island, NY)). The used electrophoresis apparatus was a DNA SUB CELL™ (BioRad, Hercules, CA) with an OSP 105 (OWL, Woburn, MA) powersupply. Gels were run at 60 V (5 V/cm) as recommended by Sambrook et al., Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press (Second Edition) (1989). Occasionally, for small amounts of samples, 50 ml minigels were used under similar conditions (Hoefer HE33, Hoefer Scientific Instruments, San Francisco, CA). Molecular weight standards were λ / Hind III digest (Research Genetics, Huntsville, AL) and Ready-Load™ 100 bp DNA ladder (Life Technologies), providing a standard size range from 100 bp to 23130 bp (Figure 4). For standard fragment purification from gel, the GeneClean II® Kit (BIO 101, Inc., La Jolla, CA (11/98) was used, following the manufacturer's instructions.

20           **Minipreps and Plasmids**

Plasmids for diagnostics, cloning, and sequence analysis were prepared using the Wizard™ Minipreps Plus Kit (Promega, Wizard™ Minipres Plus DNA Purification System. Instruction Manual (Madison, WI) (1/96)). Useful ones were assigned a pBS number and stored in TE pH 8.0 at +4°C.

25           **Oligonucleotides**

All oligonucleotides used as PCR primers, for plasmid construction, or in the mutagenesis procedure, were ordered from Midland, Inc. (Midland, TX) in gel filtration (GF) quality. The lyophilized oligonucleotides were assigned a BSB number, suspended in HPLC grad water (Sigma-Aldrich) at a final concentration of 300 µM, and stored at -20°C.

### DNA Digests and Ligations

All enzymes used for DNA manipulations (restriction enzymes, T4 ligase, etc.) were purchased from New England Biolabs, Inc., Catalog. (Beverly, MA) (1998/99) and used as recommended in the manufacturer's catalog (1998/99). Briefly, for restriction enzyme digests the total reaction volume was 20 µl with approximately 10 units (U) of enzyme. For DNA fragment ligations, 10 µl with 200 U of T4 DNA ligase were used.

### *E. coli* Strains

All *E. coli* strains, except otherwise mentioned, were derived originally from DH5α: *endA1 hsdR17* ( $r_{KM}^{-}$ ) *supE44 thi-1 recA1 gyrA* (Nal<sup>R</sup>) *relA1*  $\Delta(lacIZYA-argF)$  U169 *deoR* (M80 *dlac*  $\Delta(lacZ)$ M15) (Woodcock et al., *Nucl. Acids Res.*, 17:3469-3478 (1989); Raleigh et al., In *Current Protocols in Molecular Biology*, eds. Ausubel, F.M. et. al. (New York: Publishing Associates and Wiley Interscience). Unit 1.4 (1989). After modification with  $\lambda$  prophages or plasmids, strains were catalogued by assigning them a BS number and stored at -80°C with 10% DMSO (Dimethylsulfoxide) after overnight culture in appropriate selection medium.

### Transformation of *E. coli*

For all plasmid transformations of *E. coli* strains, electroporation was preferred over chemical protocols. Electorcompetent cells were made and used for electroporation as described by Smith et al., *Focus*, 12:38-40 (1990). The appropriate cell porator and cuvettes were from Life Technologies. Depending on the selection procedure after electroporation, the time in SOC medium (Smith et al., *Focus*, 12:38-40 (1990) at 37°C under agitation (Lab-Line® Orbit Environ-Shaker, Lab Line Instruments, Inc., Melrose Park, IL) prior to plating on selection medium was 1 h for ampicillin (Ap) and 2 h or more h for kanamycin (Kan) selection. For induction of *cre* expression (as described below), the transformants were cultivated in SOB (Smith et al., *Focus*, 12:38-40 (1990)) supplemented with 0.2% of L-(+)-arabinose (Sigma-Aldrich) plus 20mM of MgCl<sub>2</sub> (referred to as induction medium) for 2.5 h and 4 h before plating on the appropriate selection media (see below). Resulting colony

numbers were counted after overnight incubation at 37°C in a gravity convection incubator (Precision Scientific, Chicago, IL).

### ***E. coli* Cultures**

LB (as mentioned above) was used as the standard medium for all *E. coli* cultures (liquid or solid). For selection and screening, the appropriate reagents at the following concentrations were added:

Table 1: List of reagents used for selection and screening of *E. coli* cultures.

	<u>Reagent</u>	<u>Concentration</u>	<u>Stock Solution</u>
10	Ampicillin (Ap)	100 µg/ml	50 mg/ml in H <sub>2</sub> O
	Chloramphenicol (Cm)	27 µg/ml	34 mg/ml in EtOH
	Kanamycin (Kan)	16 µg/ml	10 mg/ml in H <sub>2</sub> O
	X-gal	0.003%	2% in DMF (w/v)
	Z-ara	0.006%	2% in DMF (w/v)

15 The concentration of stock solutions, stored at -20°C and their dilutions in liquid LB medium or LB-agar plates is given. X-gal stands for 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside, and Z-ara for 5-bromo-3-indolyl-α-L-arabinofuranoside. All reagents, except Z-ara, were purchased from Life Technologies and aliquoted in the desired stock concentration for storage. Z-ara  
20 (Berlin and Sauer, *Anal. Biochem.*, 243:171-175 (1996)) was a generous gift from W. Berlin.

Ready-to-use solid LB-agar plates (2%) plain, or supplemented with Ap (100 µg/ml) were purchased from Digene, Inc. (Beltsville, MD). For all other reagent combinations in solid medium, plates were poured according to the  
25 needs using autoclaved 2% LB agar purchased from Biofluids.

### **Polymerase Chain Reaction (PCR)**

Standard PCR reactions were carried out in 50 µl total volume with the following reagents (all, except noted, from Perkin Elmer, Foster City, CA): 1x PE buffer II (without MgCl<sub>2</sub>), 2 mM MgCl<sub>2</sub>, 250 µM of each dNTP, 0.8 µM of  
30 each primer, ca. 50 ng of template DNA, qsp. H<sub>2</sub>O (HPLC grade, Sigma-Aldrich) to 49.5 µl. For mutagenic PCR reactions (also referred to as error-prone PCR), the amount of each dNTP was reduced to 20 µM and 0.25 mM of

MnCl<sub>2</sub> added. After denaturation at 95°C for 5 min, 0.5 µl of 5 U/µl PE Amlpi Taq Polymerase was added at approximately the annealing temperature of the primers. After mixing, the appropriate thermal cycles were carried out (as indicated individually below), using a PTC 200 thermal cycler (DNA Engine, MJ Research, Cambridge, MA). When finished, all PCR products immediately were loaded on an agarose gel, or separated from enzyme, nucleotides and primers by applying the Wizard™ PCR Preps Kit (Promega, Wizard™ Minipres Plus DNA Purification System. Instruction Manual (Madison, WI) (1/96)). PCR products were recovered using deionized water and stored frozen at -20°C.

#### 10           **Sequence Analysis**

Sequence analysis of plasmid constructions and *cre* mutants were carried out on a PE ABI PRISM™ 310 Genetic Analyzer (Perkin Elmer) according to recommendations in the manufacturer's protocol P/N 402078 Revision A (1995) for the ABI PRISM™ Dye Terminator Cycle Sequencing Kit (Perkin Elmer). Briefly, a cycle sequencing reaction contained ca. 50 ng of template DNA in miniprep quality, 4 pmol of primer, and 8 µl of the ABI Terminator Ready Reaction Mix (Perkin Elmer), in a total volume of 20 µl, and subjected to the following conditions: (96°C, 10 s; melting temperature of primer, 15 s; 60°C., 4 min) 26 times on a PTC 200 thermal cycler (MJ Research). After removal of residual primers and dye by ethanol precipitation, the DNA was resuspended in 25 µl of ABI Template Suppression Reagent (Perkin Elmer) and denatured at 95°C for 5 min before loading the ABI Genetic Analyzer. The obtained data files were examined using ABI PRISM™ Sequencing Analysis Version 3.0 Software (1996, Perkin Elmer). Gene Jockey II (1996, Biosoft, Cambridge, UK) software was used for sequence comparison, translation, and alignments.

#### **Mutagenesis Procedure**

##### **Substrate Preparation by PCR**

The *cre* gene for the following DNase I shuffling reaction was amplified by PCR using 5' forward primer BSB436 (5' AAATAATCTAGACTGAGTGTGAAATGTCC 3') and 3' reverse primer BSB376 (5' ATATATAAGCTTATCATTTACGCGTTAATGG 3'),



introducing an *Xba* I and *Hind* III cloning site, respectively (underlined).

Mutagenic and non-mutagenic PCR's were carried out: (94°C, 30 s; 52°C, 30 s; 72°C, 90 s) 45 or 30 times, respectively. The 5' primer was designed to include the endogenous Shine-Dalgarno (SD) of *cre*, whereas its three endogenous  
5 promoters were excluded (position -17, 6; positions refer to the adenine of the start codon of the *cre* coding sequence as position 1). Thus, after introducing the resulting *cre* genes into pBAD33 (see below), expression was exclusively under control of the pBAD promoter without interference or background expression due to endogenous promoters. Including the SD sequence of *cre*  
10 was necessary, since pBAD33 does not contain this sequence 5' of its multiple-cloning-site (MCS). The 3' reverse primer was designed to be homologous to the 3' untranslated region (UTR) of *cre* (position 1057, 1032). Mutagenic events were therefore permitted in 1020 bp of the entire 1026 bp *cre* coding sequence, excluding the first two codons. For the first round of the directed  
15 evolution procedure, the wt *cre* expression plasmid pBS185 (Sauer and Henderson, *The New Biologist*, 2:441-449 (1990)) served as template. In following cycles, the pool of mutated *cre* genes from the previous round was used. In all experiments, both, mutagenic and non-mutagenic PCR's were carried out in parallel using the appropriate template.

## 20 **Homologous Recombination *in Vitro***

### *DNase I digest*

Approximately 5 µg of the *cre* PCR product (ca. 1.1 kb) were digested with 0.03 U of DNase I, type IV (Sigma-Aldrich) in 20 µl total volume of 50 mM Tris-HCl pH 7.5 plus 1 mM MgCl<sub>2</sub> for 2 to 3 minutes at room temperature.

25 After digestion, samples immediately were loaded on a 2% minigel to separate the generated fragments (Figure 5). Fragments of 25 bp to 300 bp were purified from the gel by DE81 (Whatman, Maidstone, GB) extraction and ethanol precipitation (Sambrook et al., Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press (Second Edition) (1989)), before suspending in 5 µl of  
30 TE pH 8.0.

### *Self-Printing PCR*

A 60 cycle non-mutagenic PCR (as described above) was carried out without added primers, allowing the fragments to prime themselves and thereby to undergo shuffling while reassembling. Conditions for PCR were: 94°C, 90 s; (94°C, 30 s; 45°C, 30 s; 72°C, 90 s) 60 times; 72°C, 10 min.

### *Reassembling of cre*

Since the self-priming step never yielded a single size product but rather a range of fragments between 300 bp to 2000 bp (Figure 5), the self-priming PCR mixture was diluted 1/40 in a non-mutagenic PCR mix with primers BSB376 and BSB436 (see above), and subjected to an additional 20 cycles (94°C, 30 s; 52°C, 30 s; 72°C, 90 s). This additional step lead to one product of 1.1 kb size (Figure 5).

### *cre Expression*

After digesting the linkers of the generated mutant *cre* pool with *Xba* I and *Hind* III, the fragments were ligated into the identical sites of the MCS of the *cre* expression vector pBAD33 (Figure 6). Two features favored the choice of pBAD33 as the vector to express the mutant *cre* pool for the selection procedure (see below): First, its pACYC184 derived origin of replication is compatible with the ColE1 derived ones of the plasmids used in the selection procedure. Second, pBAD33 contains the promoter of the arabiniose operon (pBAD), as well as expresses the regulatory protein AraC. It is therefore possible to regulate the expression of a gene cloned into the MCS and under PBAD control, from moderately high levels to nearly complete regression, by simply changing 0.2% L-(+)-arabinose in the medium to 0.2% D-glucose (Guzman et al., *J. Bacteriol.*, 177:4121-4130 (1995) and Miyada et al., *Proc. Natl. Acad. Sci. USA*, 81:4120-4124 (1984). As indicated above, the primers for *cre* PCR were designed in order to include the endogenous SD sequence but to exclude the three *cre* promoters. *cre* expression therefore will be under complete control of the pBAD promoter. This is important for the selection procedure (see below) that was intended for few Cre molecules acting on different *lox* sites. High concentrations or long term background expression of

*cre* could eventually defeat the selection since wt Cre also catalyzes at very low frequencies recombination events between altered *lox* sites.

#### Plasmids and *E. coli* Strains Used for Selection and Screen

##### Mutant *lox* sites

5 Figure 1 compares the original *loxP* site to the two mutant sites, *loxK1* and *loxK2*, used during the described experiments. The *lox* sites with 5' *Sal* I and *Xho* I compatible, and 3' *Xba* I and *Nhe* I compatible ends were received as single stranded oligonucleotides from Midland and annealed by heating the appropriate ones together at 70°C, followed by a gradual cool down.

##### 10 Plasmids for Selection and Screening

Plasmid pBS561 was constructed using three fragments: (i) the 5' modified *neo* gene derived from pBS398 (Sauer et al., *Methods*, 4:143-149 (1992)), (ii) the RSVneo (Gorman et al., *Science*, 221:551-553 (1983) backbone without the *neo* gene, and (iii) the oligonucleotide-derived MCS (Figure 7).  
 15 The EGFP gene derived from pEGFP-N1 (Clontech, Palo Alto, CA) was then inserted into the MCS along with 5' and 3' *lox* sites orientated in the same direction to produce plasmids pBS568 (*loxK1*<sup>2</sup>) and pBS569 (*loxK2*<sup>2</sup>). Figure 8 summarizes the procedures used to construct plasmids pBS583 and pBS584. To restore the original *neo* reading frame without the 5' extension, the *loxK*<sup>2</sup>  
 20 cassettes containing *Mlu* I/*Kpn* I-fragments from pBS568 and pBS569 were ligated into the RSV neo backbone that contains *Mlu* I and *Bgl* II sites. The *Bgl* II – *Kpn* I junction was achieved by filling the 3' recessed end of *Bgl* II with Klenow (NEB) followed by a blunt-end ligation to the *Kpn* I end. This junction also was checked by sequencing and found to be correct. A transcriptional  
 25 terminator, *rrnBT1T2*, derived from pBAD33 by non-mutagenic PCR with primers BSB425 (5' ATAAGCGGCCGCTGAGCTTGGCTGTT TTGGCGG 3') and BSB426 (5' GCCGTCTCGAGAGAGTTTGTAG  
 AAACGCAAAAAGGC 3'), was inserted into the *loxK*<sup>2</sup> cassette 3' of the  
*EGFP* gene after digest of the its *Not* I and *Xho* I linkers (underlined). With this  
 30 construct, it could be predicted that a catalyzed recombination by K1<sup>+</sup> or K2<sup>+</sup> Cre mutants between the *lox* sites would result in the excision of *EGFP* and the transcriptional terminator, and thereby permit the transcription of the *neo* gene

due to the RSV promoter, located 5'. Expression of *neo* would no longer be impaired, because it is placed under control of 5' promoter elements present in RSVneo (a Kan<sup>R</sup> rendering plasmid in *E. coli*).

A similar *loxP*<sup>2</sup> cassette selection plasmid also was designed (pBS613, Figure 9), to be used as a control. Using this plasmid, the frequency of *loxP* recombination by Cre mutants could be determined in the same manner as used to evaluate *loxK1* or *loxK2* recombination by pBS583 and pBS584.

Finally, a completely different set of *loxK1*<sup>2</sup>/*K2*<sup>2</sup> cassette plasmids was created. These plasmids were no longer used for selecting mutants that recognize *loxK1* or *loxK2*, but rather were used to screen for these mutants in conjunction with a different bacterial background (see below). Figure 10 summarizes the construction process for pBS601 (*loxK1*<sup>2</sup>) and pBS602 (*loxK2*<sup>2</sup>): In a first step, the *neo* resistance marker of pBS581 and pBS582 (intermediates in the construction of pBS583 and pBS584) was removed by deleting the *Pvu* II fragment and thus restoring the possibility to use *neo* for a different selection procedure. Following this, the *EGFP* gene between the *lox* sites was replaced by the pUC19 (Yanish-Perron, *et. al.*, 1985) derived *lac* promoter with its 3' MCS. This pUC19 fragment was obtained by non-mutagenic PCR with primers BSB448 (5' GTCAAGCTAGCTAGCAGGTTT CCCGACTGG 3') and BSB449 (5' ACATTGCGGCCGCAGATCTCCTCTA GAGTCGACCTG 3'). An *Nhe* I site 5', and a *Bgl* II and a *Not* I site 3' (underlined) were introduced thereby, which made it possible to replace the *Nhe* I – *Not* I *EGFP* fragment after linker digestion. The newly generated polylinker between the two *lox* sites permitted insertion of the *Xba* I – *Bam*H I fragment of pBS481 (that carries the *abfA.st* marker gene) into its *Xba* I and *Bgl* II sites. As shown recently, *E. coli* strains expressing a recombinant  $\alpha$ -L-arabinofuranosidase gene from *Streptomyces lividans* (*abfA.st*), can be detected by eye on LB plates containing 5-bromo-3-indolyl- $\alpha$ -L-arabinofuranoside (Z-ara) Berlin and Sauer, *Anal. Biochem.*, 243:171-175 (1996). This leads to the formation of an indigo blue pigment, that is similar to the classical *lacZ*/5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-gal) marker system. It could therefore be expected that *E. coli* strains expressing mutant Cre

recombinases which allow recombination of *loxK1* or *loxK2* should lose the *abfA.st* gene and should form white colonies on Z-ara plates. All other clones, however, should be dark blue. Using *abfA.st* instead of the well established *lacZ* screen was necessary, because the *E. coli* strain (see below) used for this

5 construct expresses  $\beta$ -galactosidase endogenously.

#### *E. coli Strains for Selection and Screen*

The *E. coli* strain BS583, DH5  $\Delta$ lac ( $\lambda$ D69 *loxP*<sup>2</sup>[*lacZ* LEU2]), was chosen as the bacterial background for the selection procedure for *K1*<sup>+</sup> or *K2*<sup>+</sup> Cre mutants by plasmids pBS583 or pBS584. Due to the *loxP*<sup>2</sup>[*lacZ*] containing

10  $\lambda$  prophage, Cre activity on *loxP* can be evaluated simply by using X-gal plates. The selection strains BS1493 and BS1494 were made by introducing the selection plasmids pBS583 and pBS584 into BS583 (Table 2). The *loxP*2 plasmid pBS613, to be used as a control, needed to be in BS583 cells as well, becoming the strain BS1541 (Table 2).

15 For the screening plasmids pBS601 and pBS602, *E. coli* strain NS2300 (Sternberg et al., *J. Mol. Biol.*, 187:197-212 (1986)) was selected as host: *K12 recA::Tn10* ( $\lambda$ i<sup>434</sup> *loxP*2[*neo*]). This strategy combines a kanamycin selection for Cre enzymes, that are no longer active on *loxP* (P<sup>-</sup>), with a screen for *K1*<sup>+</sup> or *K2*<sup>+</sup> enzymes. By transforming pBS601 and pBS602 into NS2300, the P<sup>-</sup>

20 selection strains BS1523 and BS1524 were formed (Table 2).

#### **Selection and Screen for CRE Mutants**

##### *Selection for K1<sup>+</sup>/K2<sup>+</sup> and Screen for P<sup>-</sup>*

After ligation of the generated mutant *cre* pool into pBAD33 for 3 h, BS1493 or BS1494 electrocompetent cells were transformed with 2  $\mu$ l of the

25 microdialyzed reaction mixture (VS membrane, Millipore™ Bedford, MA). To induce expression of the *cre* pool, the transformed cells were incubated at 37°C in induction medium for 2.5 h and/or 4 h under agitation (as mentioned before). Cultures were diluted 1/500 or 1/5000 and grown on LB plates with the following formulation: Ap, Cm, glucose, and X-gal for determining the

30 transformation efficiency, referred to as non-selection plates. Dilutions of 1/5 and occasionally 1/50 were grown on plates with addition of Kan, used to select for *K1*<sup>+</sup> or *K2*<sup>+</sup> mutants and called selection-plates. The formulation of the

plates served the following purposes: (i) Ap and Cm were added to assure that all clones contained both, selection and expression plasmid, (ii) X-gal to distinguish between  $P^+$  and  $P^-$  clones (Table 2). After overnight incubation at 37°C, blue and white colonies were counted and pools prepared for the next round of DNA shuffling. Alternatively, certain mutants were chosen for further analysis (see below).

*Selection for  $P^-$  and Screen for  $K1^+$  or  $K2^+$*

After 2.5 h and/or 4 h of expression of the mutant *cre* pool in the transformed BS1523 and BS1524 cells, usually dilutions of  $10^{-3}$  or  $10^{-4}$  were grown on LB agar plates supplemented with the same reagents as listed above, except, that Z-ara replaced X-gal to allow the  $K1^+/K2^+$  screen. Non-selection plates were used for determining the transformation efficiency, and Kan containing plates for the  $P^-$  selection (Table 2).

**Mutant Analysis**

**wt *cre* Expression Plasmid**

With fewer cycles (15) of non-mutagenic PCR on the *cre* expression plasmid pBS185 and after linker digestion, the *cre* pool obtained was cloned into pBAD33 and transformed into BS583 cells. After 2 h of *cre* expression, the transformed cells were grown on X-gal plates. After overnight incubation at 37°C, two white colonies (indicating *loxP* recombination) were picked for plasmid preparation and complete sequencing. No point mutation was found in either one, so that each could be used as a control plasmid for wt Cre expression. One of the two was selected for further use and named pBS606.

**Functional Testing**

In order to determine the frequency of *lox* recombination of isolated mutant Cre enzymes by the described selection procedure, it is necessary to separate the *cre* candidate expression plasmid (pBAD33) from the selection plasmid of the chosen Kan<sup>R</sup> candidate. Then, the cleaned expression vector can be used to retransform the appropriate selection and screening strain BS1494, as well as BS1493 and BS1541 to determine the candidate's capacity for *loxK2*, *loxK1* and *loxP* recombination under identical conditions. By comparing the resulting frequencies of Kan<sup>R</sup> of different Cre mutants and wt Cre, all treated

identically, one can determine quantitatively how well each chosen mutant candidate really performs on the altered *lox* sites.

Therefore, overnight cultures of candidates were grown in liquid LB supplemented with Cm and Kan for plasmid minipreps yielding a mixture of both the mutant Cre expressing plasmid pBAD33 and the newly Kan<sup>R</sup> selection plasmid. In order to eliminate the latter, minipreps were digested with the restriction enzyme *Aat* II which only cuts the selection plasmid. After transformation of BS583 cells with this digestion mixture and approximately 2 h *cre* expression, different dilutions were grown on LB agar plates supplemented with Cm and X-gal to select for pBAD33. Plates with Ap plus Cm were used to determine the background of contamination with uncut selection plasmid. The next day, clones obtained by the Cm selection were tested for Ap<sup>s</sup> and Kan<sup>s</sup> to confirm the elimination of the selection plasmid. A final overnight culture, followed by a miniprep procedure, yielded the unique plasmid for functional testing, as described above.

#### Sequencing

To obtain the DNA sequence of candidate *cre* genes in pBAD33, eight primers (BSB454 to BSB461, Table 3), four for each strand, were designed so that the entire gene could be sequenced in both directions.

#### Site-Directed Mutagenesis

After identifying one essential mutation for the decrease in substrate specificity, the Stratagene QuickChange<sup>TM</sup> Site-Directed Mutagenesis Kit (Stratagene Cloning Systems, La Jolla, CA) was used to create *cre* mutants with mutations at the determined location, only. Using three different mutant primer sets (BSB 465 to BSB 470, Table 4), all steps were carried out as detailed in the manufacturer's instruction manual, except that electrocompetent BS1494 cells were used for transformation and mutant selection, replacing the provided XL1 blue cells. The made mutant candidates were subjected to functional testing and sequencing as detailed before.

In a different experiment, the DNA shuffling mutagenesis procedure was repeated on wt *cre* by adding one 5' phosphorylated strand of each set of mutant oligonucleotides (BSB465, BSB467 and BSB469) to the pool of small

fragments prior to reassembly. This allowed to incorporate them into the resulting *cre* pool. The desired mutations should consequently be introduced at much higher frequency than without the addition of oligonucleotides.

## RESULTS

### Establishment of the Selection Procedure

#### Selection Plasmids (pBS583 and pBS584)

To test the generated plasmids pBS583 and pBS584, a recombination event between their *lox* sites was mimicked by digesting pBS566 and pBS567 (intermediates of the pBS583/584 construction, containing only the 3' *lox* site) with *Sal* I and *Xho* I, followed by religation. This lead to excision of the *EGFP* gene and terminators. After deletion of *EGFP* and *rrnBT<sub>1</sub>T<sub>2</sub>*, the Kan<sup>R</sup> phenotype was observed as anticipated. In addition, the frequency of spontaneously occurring Kan<sup>R</sup> clones carrying the original plasmids was approximately 10<sup>-7</sup>. This background is inconsequential, since the transformation efficiency of BS583 cells was determined as 10<sup>7</sup> per µg of pBAD33.

The equivalent *loxP* control plasmid pBS613 was tested directly with the wt *cre* expression plasmid pBS606. After 2.5 h of *cre* expression, 94% of all clones were determined Kan<sup>R</sup> and about 6% showed blue color. Without *cre* expression, no Kan<sup>R</sup> and no white colonies were observed. This confirms that the control cell line BS1541 (Table 2) permits the combined P<sup>+</sup> selection and P<sup>-</sup> screen.

#### Screening Plasmids pBS601 and pBS602

Only pBS602 was tested before use by expression of wt Cre and a K2<sup>+</sup>/P<sup>+</sup> Cre mutant (see below). On non-selection medium, wt Cre expression resulted in more than 95%, whereas expression of the mutant Cre resulted in less than 3% of blue colonies. This indicates that excision of the *loxK2* flanked *abfA.st* marker by K2<sup>+</sup> Cre is possible. On selection medium, very few colonies could be found, since both types of *cre* have shown activity on *loxP* before (see below).



### Mutagenic vs. Non-Mutagenic PCR

The frequency of P<sup>+</sup> Cre mutants obtained after non-mutagenic and after error-prone PCR was determined by the following experiment: After one mutagenic or one non-mutagenic PCR on the wt Cre expression plasmid pBS185, the resulting *cre* pools were inserted into the expression vector pBAD33 and transformed into BS583 cells. After 2.5 h of arabinose-mediated induction or glucose-mediated repression (by SOC medium) or *cre* expression, dilutions were transferred to LB plates with Ap, Cm, glucose and X-gal. The results are presented in Table 5: Under glucose repression, exclusively blue colonies could be identified (first line in Table 5), indicating that *cre* expression is insufficient for *loxP* recombination and excision of *lacZ* of BS583. Induction with L-(+)-arabinose, however, lead to the formation of white colonies at the presented frequencies (second line). indicating that (i) the described control of *cre* expression by pBAD33 is functioning, and (ii) the mutagenic PCR conditions cause three times more impaired Cre enzymes for *loxP* recombination than the non-mutagenic conditions (60% blue colonies vs. 30%). It is worth mentioning that ligation reactions lacking *cre* insertion resulted in 50 to 100 times less blue colonies than obtained with the ligations with *cre* insertion. This phenotypically blue background of empty pBAD33 was subtracted before calculating the presented data.

Leung et al., *Technique*, 1:11-15 (1989) reported that the frequency of point mutations created by error-prone PCR is about 0.5%. If this is true, in average five point mutations should occur in each 1 kb *cre* coding sequence subjected to an error-prone PCR. By extrapolating this data to the three times less P<sup>+</sup> enzymes after a non-mutagenic PCR, one can conclude that the frequency for point mutations should also be reduced by a factor of three to 0.18%. Experiments made by Zhou et. al. (1991) showed 11% of a 633 bp marker gene phenotypically impaired after non-mutagenic PCR. About 37% of all genes in the pool, however, carried at least one point mutation. Even though the conditions for the non-mutagenic PCR were similar, the observed discrepancy between 11% and 20% of phenotypical mutants may be due to a variety of reasons, among which: (i) the size difference between the two genes

(633 bp vs. 1020 bp), (ii) different elongation times during PCR, and (iii) different sensibility of the two proteins for disabling point mutations.

#### Testing wt Cre on *loxK1*<sup>2</sup> vs. *loxK2*<sup>2</sup> Substrates

The level of *loxK1* and *loxK2* recombination due to wt *cre* expression was determined using the wt Cre control plasmid pBS606. After transformation of the cell lines BS1493 and BS1494 with pBS606 and 2.5 h and 4 h of *cre* expression, cells were grown on selection and non-selection plates (as described previously). The recombination frequency between the altered *lox*<sup>2</sup> sites was considered equal to the observed frequency of Kan<sup>R</sup> phenotype: for *loxK1*, it was about 10<sup>-5</sup> after 2.5 h and 2 X 10<sup>-5</sup> after 4 h of wt *cre* expression, for *loxK2*, it changed from about 2 X 10<sup>-5</sup> to 2 X 10<sup>-3</sup>. All colonies found were white, indicating effective *loxP* recombination by wt Cre within the allowed expression time. This result shows that long term expression of the wt enzyme permits a slight increase in recombination between the altered *lox* sites. The use of pBAD33 to avoid background *lox* recombination by suppressing *cre* expression is therefore justified. Because *loxK2* was eventually 100 fold better recognized by wt Cre than *loxK1* (but still at low frequency), first the creation of novel Cre recombinases with *loxK2* specificity was attempted.

#### Mutagenesis on *loxK2*

##### First Rounds of Directed Evolution

The result of the first four rounds of the described mutagenesis procedure on *loxK2* with selection plasmid pBS584 are presented in Table 6. The following symbols are used to describe the status of the DNA shuffling procedure for *cre*: "o" indicates a non-mutagenic PCR, "m" a mutagenic PCR, and "x" stands for the *in vitro* reassortment event. For example, mxoxox *cre* represents a *cre* pool subjected to three rounds of the directed evolution process, with a mutagenic PCR followed by *in vitro* shuffling in the first, and non-mutagenic PCRs and shuffling as mutagenic and recombinogenic events in the following two rounds. The phenotypically blue background due to empty pBAD33 was subtracted from all results by control ligations without *cre* insertion. In every round, error-prone and non-mutagenic PCR served as the necessary mutagenic event on the template pool of the previous round. After *in*

*vitro* reassortment and selection, always the larger Kan<sup>R</sup> population of the two parallel experiments was chosen as template for the next round (as indicated in the last column of Table 6). Only in the first round the error-prone PCR could lead to more candidates, whereas in all following rounds the reduced mutagenic frequency of the non-mutagenic PCR turned out to be more beneficial. The density of point mutations resulting out of two mutagenic PCR's was obviously too high to allow efficient elimination of deleterious mutations from advantageous ones during the *in vitro* shuffling step. This is confirmed by the high frequencies of blue colonies found within any pool in any round subjected to mutagenic PCR's twice. Error-prone PCR in the context of the applied selection therefore appears to be useful in the first round only, where its three times higher mutagenic frequency increases the amount of beneficial mutations compared to a non-mutagenic PCR. With increasing cycle numbers non-mutagenic PCR's should be preferred to avoid high densities of deleterious mutations.

The established directed molecular evolution process allows effective evolution of *cre*. Column five of Table 6 shows that with every round the number of Kan<sup>R</sup> colonies is increasing, while the time for *cre* expression could be lowered from 4 h to 2.5 h (column three). After only three rounds, Cre mutants capable for *loxK2* recombination at decreased concentrations due to the reduced expression time were found. However, it was not possible to isolate any blue colony on the selection plates. All identified K2<sup>+</sup> mutants therefore are also P<sup>+</sup>. As mentioned above, high densities of deleterious mutations in the *cre* pool subjected to error-prone PCR's twice could explain why no blue colonies were seen on selection plates, even with over 90% of P<sup>+</sup> candidates on non-selection plates.

#### **Evaluation of Six K2<sup>+</sup>/P<sup>+</sup> *cre* Mutants**

##### ***Functional Test***

As indicated in Table 6, 36 white Kan<sup>R</sup> colonies could be isolated from the *mxoxox cre* pool after only 2.5 h of *cre* expression with an 1/5 dilution grown on selection plates. This result indicated that competent Cre mutant capable of *loxK2* recombination were produced. Six were selected for further

analysis. After elimination of the selection plasmid from the minipreps (as described in Materials and Methods), all six of them, as well as wt Cre (pBS606) were subjected to the described functional test on *loxK2*, but also on *loxK1* and *loxP* recombination with plasmids pBS584, pBS583 and pBS613.

5 The results are presented in Table 7.

Briefly, by selecting for *loxK2* recombination, all mutants except mxoxox 4, showed significantly increased percentages of Kan<sup>R</sup> (between 3% and nearly 70%), compared to wt Cre (0.002%), as indicated in column three of Table 7. This indicates a 10<sup>3</sup> to over 10<sup>4</sup> fold increase in activity on *loxK2*.

10 On *loxP*, all (including mxoxox 4) showed recombination frequencies between 80% and 100% after 2.5 h of *cre* expression (column 4). This was expected from the results obtained with the X-gal screen for *loxP* recombination during the selection procedure. 2.5 h of induction for wt *cre* expression is therefore sufficient for almost complete *loxP* recombination, justifying 2.5 h of  
15 expression of mutant *cre* pools for selecting competent K2<sup>+</sup> Cre mutants. The observed slight decrease in *loxP* recombination with the mutants mxoxox 3 to 6 either derived from usual variations during experiments, or may indicate a slightly reduced *loxP* activity. With BS1541 blue colonies on both selection and non-selection plates were found in approximately the same frequency (2%  
20 to 20%) as kanamycin sensitivity (Kan<sup>S</sup>). This indicates competition between the *loxP*<sup>2</sup>[*lacZ*] site on the genome and the *loxP*<sup>2</sup>[*EGFP-rrnBT<sub>1</sub>T<sub>2</sub>*] sites on pBS613. Since the same Cre mutants never resulted in blue colonies during selection for *loxK2* recombination in cell line BS1494, it is possible to conclude that *loxP* is still preferred over *loxK2*. This argument is supported by higher  
25 frequencies of *loxP* recombination, close to 100%, compared to the *loxK2* recombination frequencies of 3% to 70%.

All frequencies found for *loxK1* recombination, determined by using cell line BS1493, lie below 0.01% after 2.5 h, as well as after 4 h of induction of *cre* expression (column five). This indicates that no analyzed mutant developed an  
30 increased activity on *loxK1* compared to wt Cre.

To summarize, five out of the six analyzed mutants showed a significant decrease in specificity, resulting in the possibility for *loxP* and *loxK2* recombination.

#### *Sequencing*

5        The six described mutants have been completely sequenced in both directions to determine the mutations which lead to the observed decrease in specificity. The resulting aligned *cre* coding and aa sequences of all mutants and wt Cre are represented in Tables 10 and 11. Each mutant showed between 3 and 8 point mutations, altogether 31, as listed in column two of Table 8. The  
10        overall mutagenic frequency can therefore be calculated at 0.5% (31 mutations in 6 clones of 1020 bp), which is similar to only one round of error-prone PCR (Leung et al., *Technique*, 1:11-15 (1989)). The reason for the low frequency of point mutations after three rounds of the mutagenesis procedure (i.e. nine PCR's) is the applied selection after each round, *cre* mutants with low density of  
15        point mutations seem to be favored by the stringent kanamycin selection.

26 of the 31 identified point mutations resulted in aa changes compared to the wt sequence, as indicated in column three. No deletions or frame-shift mutations, as well as no codons affected by more than one point mutation at the same time could be identified. All possible transition events could be observed,  
20        but only half of all possible transversion events (shown in Table 12). Adenine to guanine and vice versa transition events represented almost 30% of all identified point mutations. All other events occurred less frequent (10%, 7%, or never). The represented statistic may however be biased, either since only six mutants were analyzed, or due to the directed molecular evolution technique  
25        itself: The types of point mutations observed less often, may more frequently be deleterious in *cre* and were consequently removed from the pools. With more mutants to be sequenced, this question could be addressed further.

Only one point mutation, a transition event from adenine to guanine at position 785 in the *cre* coding sequence is common for all 5 mutants with  
30        remarkably increased *loxK2* activity. This mutation leads to a replacement of a glutamate residue at position 262 in the J helix of wt Cre by a glycine (indicated in column five of Table 8). This glutamate is believed to contact the *loxP*

sequence at positions 11 or 12 with its acidic side chain (Guo et al., *Nature*, 389:40-46 (1997)). Another point mutation, resulting in a conservative threonine to serine exchange at position 316 was identified in three mutants. Five point mutations were found independently in two of the six mutants, among which two types of silent mutations. Finally, eleven point mutations occurred only once (indicated in column four). Therefore, the critical mutation for *loxK2* activity appears to be E262G. Some of the additional mutations could be responsible for the observed ten fold difference in *loxK2* recombination frequency among the five E262G carrying mutants.

#### 10           **Site-Directed Mutagenesis to Verify Results**

##### **Site-Directed Mutagenesis Procedures**

To determine whether the E262G mutation alone is responsible for the increase of *loxK2* activity of the Cre mutants by at least a factor of  $10^3$ , two different experiments were made:

15           First, the described directed evolution procedure was repeated in three different sets on wt *cre*, by adding three 5' phosphorylated mutant oligonucleotides prior to reassembly: Incorporation of the first oligonucleotide (BSB465) into *cre* should lead to the E262G mutation, incorporation of the second one (BSB467) to a E262A mutation, and the equimolar mixture of random oligonucleotides (represented by BSB469) to  $20^3$  (= 8000) possible aa combinations at positions 261 to 263 of Cre. According to Stemmer, W. P. C., *Proc. Natl. Acad. Sci. USA*, 91:10747-10751 (1994), these oligonucleotides should be incorporated during reassembly and cause the desired mutations at a frequency of about 8%. After insertion of the resulting *cre* pools into pBAD33 and 2.5 h of expression, 0.8% of white Kan<sup>R</sup> colonies were found with BSB465. Therefore, the frequency of the Kan<sup>R</sup> phenotype due to *loxK2* recombination is ten times lower than the expected frequency for the E262G mutation to occur. This indicates that the E262G mutation increases the specificity for *loxK2* from 0.002% of wt Cre (see above) to approximately 10% of recombination during the standard expression experiment (2.5 h of *cre* expression prior to selection). By using the second oligonucleotide (BSB467) only 0.09% of the total white colonies showed Kan<sup>R</sup>. Thus, E262A still favors *lox K2* recombination but by

almost a factor ten less efficiently than the E262G mutation. With the random oligonucleotide mixture (BSB469), the frequency of *loxK2* recombination shrunk to 0.02%. Compared to a control experiment with no oligonucleotides added, resulting in 0.003% Kan<sup>R</sup> (consistent with the results obtained below),  
5 still some of the possible 8000 aa combinations at positions 261 to 263 of Cre are expected to favor *loxK2* recombination. Since the frequency of blue colonies on non-selection plates was about 30%, a clear indication for additional mutations, it cannot be completely excluded that some of the occurred Kan<sup>R</sup> mutants of this experiment have been carrying some additional beneficial  
10 mutations. Nevertheless, this experiment indicated that the E262G mutation is probably the basis for significant increase in *loxK2* activity.

For better defined mutations, a second experiment was done: The same oligonucleotides, now in sets for both DNA strands, were used with the Stratagene QuickChange™ Site-Directed Mutagenesis Kit as described in  
15 Materials and Methods. After transformation of the *loxK2* selection strain BS1494, the percentage of white Kan<sup>R</sup> colonies in the three different experiments could be determined as 6.2% for E262G, 0.8% for E262A and 0.6% for the 8000 different ten (10) days combinations as positions 261 to 263. Due to the QuickChange™ procedure, which eliminates parental DNA, one  
20 could expect that the desired mutations occurred in at least 50% of all clones of the three different pools. This assumption indicates that the E262G mutation alone results in approximately 12% or less recombination frequency on *loxK2* (6% out of 50% or more carrying the mutation) and the E262A exchange in 1.6% or less (under standard conditions). This calculation is not valid for the  
25 third set of oligonucleotides, because no defined mutation is introduced but rather a mixture of 8000 different ones. Blue colonies were not found during this experiment, confirming that the frequency of additional mutations altering Cre activity on *loxP* was very low.

The results of both experiments indicate consistently, that the E262G  
30 mutation alone is sufficient to increase *loxK2* recognition by approximately a factor of 10<sup>3</sup> compared to wt Cre. The ten times higher frequency observed with three of the six analyzed mutants after three rounds of the mutagenesis

procedure can only be explained with additional beneficial mutations. The E262A mutation increases the frequency of *loxK2* recombination also, but approximately by a factor of ten less effectively than E262G.

#### Sequencing and Elimination of Possible Additional Mutations

5 Two white Kan<sup>R</sup> colonies of each pool derived from the site-directed mutagenesis procedure were selected and the entire *cre* gene was sequenced. Both E262G and E262A candidates showed the desired sequence with no additional mutations. The random candidates surprised: One of them did not reveal any point mutation, representing an artifact which managed to survive the  
10 selection, whereas the other one showed nucleotide alterations from position 783 to 786. The wt sequence (781CTG GAA<sub>786</sub>) was found to be changed to (783 CTT TGG<sub>786</sub>), resulting in one silent mutation, conserving L261, and a E262W exchange. To exclude possible mutations in pBAD33 due to the PCR involved site-directed mutagenesis procedure, the three defined *cre* mutants (E262G,  
15 E262A, and E262W) were excised by *Hind* III and *Xba* I and reinserted into the MCA of fresh pBAD33.

#### Functional Testing

The three defined Cre mutants for the amino acid position 262 were subjected to a functional test for *loxK2*, *loxK1* and *loxP* recombination activity,  
20 as mentioned before. The results are summarized in Table 9. First, the results described previously for the E262G and E262A mutations were confirmed: As indicated in column three, the *loxK2* recombination frequency increased 10<sup>3</sup> fold with the E262G mutant compared to the wt enzyme, whereas the E262A mutant shows only an increase of 200 fold. Surprisingly, the E262W mutant  
25 also achieved a similar activity on *loxK2* as seen with the E262G mutant. The test for *loxP* recombination frequency with cell line BS1541 (column four) showed that the ability for *loxP* recognition is at best slightly impaired by the three different mutations (as already seen with the analyzed mxoxox mutants). Again, blue colonies could only be found with this cell line, indicating that *loxP*  
30 is preferred over *loxK2* (as described before). As expected, none of the three mutants performed significantly better on *loxK1* than wt Cre (column five). To conclude, this final experiment provides the necessary evidence that the E262G



mutation presents the basis for the observed decrease in specificity of Cre. However, additional mutations seem to be helpful to increase the newly obtained activity further. In addition, glycine at position 262 is not the only possible residue to permit a remarkable increase in *loxK2* activity.

## 5 DISCUSSION

### K2<sup>+</sup>/P<sup>+</sup> Cre Mutants

The chosen random mutagenesis procedure linked to the described selection in *E. coli* allowed the identification of Cre mutants, characterized by a wider substrate recognition. The evolved enzymes showed wt-like activity on  
10 *loxP* sites and in addition had almost the same activity on altered *lox*<sup>2</sup> sites, referred to as *loxK2*. By contrast, the wt enzyme showed only marginal activity on *loxK2*<sup>2</sup> substrates.

### *lox* Sites

*loxP* and *loxK2* differ at several locations as illustrated in Figure 1:

15 First, the three outermost bp of the inverted repeats are altered, facilitating the construction of the various plasmids used for selection. Second, the entire non-canonical 8 bp spacer is completely exchanged, and third, two transversion events (thymine to adenine) are introduced at positions 11 and 12 of the *lox* site. Only the two transversion events are considered important for inhibiting wt Cre  
20 from recognizing the site. Other investigations have shown before, that the two alterations of *loxP* mentioned first are without inhibiting effect on wt Cre (B. Sauer, unpublished results). The design of *loxK2* was based in part on so-called cryptic *lox* sites, that were identified previously in the yeast genome (Sauer, B., *J. Mol. Biol.*, 233:911-928 (1992)). Another consideration was the choice of a  
25 good starting sequence for the described mutagenesis procedure. Starting with sites that contained several and/or widespread alterations of *loxP* was avoided, because the greater the number of alterations in the substrate, the more the enzyme would have to be altered. Consequently, to most effectively use the mutagenesis procedure, the two sites presented in Figure 1, *loxK1* and *loxK2*,  
30 were designed to have only two critical alterations. In initial experiments, wt Cre was found to recombine *loxK2*<sup>2</sup> substrate pBS584 slightly better than *loxK1*<sup>2</sup> pBS583. This difference may depend on the fact that in *loxK2* the two

alternations are located next to each other. while in *loxK1* they are separated by 3 bp (positions 14 and 10). Thus, *loxK1* could interfere with wt Cre binding at two distinct DNA-protein interaction sites as compared to *loxK2*, where only one location of incompatibility is available. For this reason, *loxK2* was chosen for the initial set of experiments, described in this work.

### Cre Mutants after Three Rounds of Directed Evolution

Three iterations of the *in vitro* evolution procedure were necessary to identify 36 candidates, expressing Cre mutants that could process *loxK2* (based on the applied selection procedure in *E. coli*). Tests showed that five out of six selected ones had  $10^3$  and  $10^4$  fold increased activity on *loxK2* when compared to wt Cre. On *loxP* and *loxK1*, however, there was almost no difference between wt and the mutant enzymes. The mutants therefore had developed an increased tolerance from transversions at positions 11 and 12 (*loxK2*) of the *lox* sequence, but not for other positions like 10 and 14 (*loxK1*). To indicate this phenotype they were referred to as  $K2^+/P^+$ .

### The E262G Mutation

Sequence analysis identified that the five mutants with remarkably enhanced *loxK2* activity ( $10^3$  to  $10^4$  fold compared to wt Cre) had in common only one point mutation, leading to the aa change E262G. Site-directed mutagenesis experiments confirmed, that the E262G mutation is sufficient to increase *loxK2* activity by a factor of  $10^3$  compared to wt Cre.

Based on the recently described crystal structure (Guo et al., *Nature*, 389:40-46 (1997)) glutamate at position 262, located in the J helix of the enzyme, may be a DNA contacting residue and permit the formation of a hydrogen bond between the carboxyl group of its side chain and an amino group of one of the two adenines at positions 11' or 12' in the *loxP* sequence (Figure 1). However, changing these two bases to thymines in the *loxK2* sequence should lead to an electrostatic repulsion between their oxygens and the acidic side chain of glutamate. This could explain the observation that wt Cre is unable to catalyze a recombination between two *loxK2* sites. Exchanging glutamate for a glycine, that does not have a side chain, should remove the electrostatic repulsion and thereby permit *loxK2* binding. On the other hand,

this alteration could affect *loxP* binding because an electropositive DNA-protein interaction may be lost. Results from the mentioned experiments support this proposition: The E262G mutation alone lead to an increase in *loxK2*

recombination from 0.002% to about 2% and to a slight decrease in *loxP*

5 recombination from 94% to about 80%. The 50 times lower frequency of *loxK2* compared to *loxP* recombination may depend on the second thymine or more

likely on the complementary adenine (position 11 in *loxK2*) that could contribute to sterical repulsion between the J helix and the *loxK2* site. To prove

this hypothesis, the role of arginine at position 258, located one helix turn away

10 from the glutamate, should be further investigated by site-directed mutagenesis.

As proposed by Guo et al., *Nature*, 389:40-46 (1997), R258 is a DNA contacting residue that forms hydrogen bonds with the guanine at position 10'

of *loxP* and may also interact with the bp at position 11. There is yet no

confirmatory experimental evidence for this proposal.

15 Results from three initially isolated mutants (mxoxox 1 to 3) indicated about 50% of recombination frequency on *loxK2*. This is about ten fold higher than that obtained with the E262G mutation alone. It is therefore likely that some of the additional point mutations identified in these three mutants account for this increase in activity. Table 8 lists all point mutations that were found. If

20 silent and conservative mutations are considered not to influence specificity, only a limited number of candidates to account for the phenotype remains.

Among these, S254G and Q255R of mxoxox 2 and 3, because of their location close to the amino-terminus of the J helix, could be expected to influence DNA contacts with positions 11 or 12 of the *lox* site. The other mutations are

25 scattered in the N- and C-terminal domain of Cre. All, except R101Q of mxoxox 5, affect aa that are not located within the proximity of DNA contacting areas. Some appear independently in two mutants, e.g. D29A or D189N, that could influence protein folding or the interactions among the four Cre enzymes necessary for recombination. Such alterations could influence for example the

30 orientation of the J helix and thereby reduce remaining interference between the *loxK2* site and the enzyme. Alternatively, some mutations, also silent ones, could influence protein expression, leading to a faster accumulation of enzymes

and consequently to higher recombination frequency. This possibility should however also influence *loxP* recombination. In fact, after 2.5 h of *cre* expression, the mutants mxoxox 1 and 2 showed a slightly higher frequency of *loxP* recombination compared to wt *cre* (98% vs. 94%). This difference, on the other hand, may be attributed to the variations that occur normally within experiments. To address this question further, shorter *cre* expression times on *loxP* would be required.

When the coordinates of the crystal structure (Guo et al., *Nature*, 389:40-46 (1997)) are available (protein data bank, Brookhaven National Laboratory), it will be possible to confirm many of the tenets discussed.

Finally, the increase in *loxK2* tolerance between the E262G mutation alone and the isolated mutants carrying additional point mutations justifies the use of the DNA shuffling procedure linked to selection: Not only has it permitted the elimination of deleterious mutations from the sequence pool, but it helped to accumulate various more or less beneficial aa alterations as well.

#### **The E262A and E262W Mutations**

The mentioned site-directed mutagenesis procedure was used to generate two more defined Cre mutants, E262A and E262W. Compared to the E262G mutation, E262A permitted *loxK2* recombination ten fold less effectively. The E262W mutation however resulted in similar activity on *loxK2*.

The aliphatic side chain (a methyl group) of A262 could be the reason for slight sterical interference. This would explain the observed reduced frequency of *loxK2* activity with E262A. *loxP* recognition, however, could not be found to be affected compared to E262G. The lowered *loxK2* activity explains why no E262A mutation was identified in the small pool of six analyzed mutants: With a ten fold decrease in activity, one would expect to encounter the corresponding mutation ten times less often during selections as well.

In contrast to the small side chain of alanine, the large aromatic side chain of W262, was expected to inhibit recombination between any *lox* sites due to sterical interference. Surprisingly, this seems not to be true. A possible explanation for the observed activity on *loxP* and *loxK2* could be that the

aromatic and planar structure of the tryptophan side chain, fits better into the J helix – *lox* interface than does a methyl group. Different influences of A262 and W262 on folding of the J helix could also contribute to the observed phenotypes. The reason why the E262W mutation was not identified among the six analyzed mutants is the genetic code. Whereas for the E262G and E262A mutations only one bp in the glutamate encoding GAA codon needs to be mutated to GGA or GCA, for E262W the whole codon must be exchanged to TGG. This is unlikely to occur during the applied random mutagenesis procedure with a mutation frequency of 0.5%. Other amino acid changes due to two or three mutations of the glutamate encoding codon therefore cannot be considered to have occurred during the random mutagenesis procedure.

When the coordinates of the crystal structure are public, it will be interesting to confirm and further investigate the discussed hypothesis.

#### ABBREVIATIONS

15	5-BI-ara a.k.a Z-ara	5-bromo-3-indoyl- $\alpha$ -L-arabinofuranoside
	aa	amino acid
	Ap(Ap <sup>R</sup> , Ap <sup>S</sup> )	ampicillin
	bp	base pairs
	Cm(Cm <sup>R</sup> , Cm <sup>S</sup> )	chloramphenicol (resistant, sensitive)
20	<i>cre</i> – Cre	cyclization recombination ( <i>gene</i> – Protein)
	Da	Dalton
	DMSO	dimethylsulfoxide
	ds	double stranded
	GF	gel filtration
25	K1 <sup>+</sup> or K2 <sup>+</sup>	Cre mutant capable for <i>loxK1</i> or <i>loxK2</i> recombination
	Kan (Kan <sup>R</sup> , Kan <sup>S</sup> )	kanamycin (resistant, sensitive)
	<i>lox</i>	locus of crossover
	MCS	multiple cloning site
30	mRNA	messenger RNA
	<i>neo</i> – Neo	neophosphotransferase ( <i>gene</i> – Protein)
	P <sup>-</sup> or P <sup>+</sup>	Cre mutant defective or capable for <i>loxP</i> recombination

PCR	Polymerase Chain Reaction
SD	Shine-Dalgarno sequence
ss	single stranded
TK	thymidine kinase
5 wt	wildtype
X-gal	5-bromo-4-chloro-3-indolyl- $\beta$ -D-galactopyranoside

### Example 2: Analysis of Variant Cre Recombinases

This example describes analysis the activity of several specific variant  
10 Cre recombinases.

#### Vectors

*pBS606, 614, 626, 627, 628 and 650*: pBAD33 with wt, E262G, E262G/D29A, E262G/D189N, E262G/T316S, and R3M3 *cre* insertion used for expression of the corresponding Cre proteins in DH5 $\alpha$  for *in vivo* testing.

15 *pBS632 to pBS641*: pUC19 based plasmids for *in vivo* tests of different Cre mutants on a variety of different *lox* sites and combination of *lox* sites, all bearing the FAS1 spacer (Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996)). Recombination between two *lox* sites leads to excision of a *neo* cassette to give kanamycin sensitive *E. coli*. The same plasmids were also used for *in vitro*  
20 recombination experiments.

*pRH200*: wt Cre expression plasmid (a generous gift from Ron Hoess, DuPont, Wilmington, DE) used to overexpress wt Cre in BL21(DE3) (Novagen, Madison, WI) strain.

*pBS654 to pBS658*: wt *cre* of pRH200 was replaced with different *cre*  
25 mutants (E262G, E262G/D29A, E262G/D189N, E262G/T316S, and R3M3) using *Age* I and *Mlu* I restriction sites.

#### *E. coli* Strains

*BS583*: The *E. coli* strain BS583, DH5  $\Delta$ lac ( $\lambda$ D69 *loxP*<sup>2</sup>[*lacZ* LEU2]), was chosen as the bacterial background for the selection procedure using  
30 plasmid pBS584. Due to the *loxP*<sup>2</sup>[*lacZ*] containing  $\lambda$  prophage, Cre activity on *loxP* can be evaluated simply by using X-gal plates.

BS1494: The *E. coli* strain for selection was established by introducing the selection plasmid pBS584 into BS583. Thus, BS1494 allows a kanamycin-selection for *loxK2* and in parallel a blue/white-screen for *loxP* recombination with 5-bromo-4chloro-3-indolyl- $\beta$ -D-galactopyranoside (X-gal). Note that the spacer region of the *loxK2* site (FAS1) is different from the original one of *loxP*. Thus, recombination events between *loxP* of the  $\lambda$  prophage and *loxK2* of the selection plasmid pBS584 catalyzed by potent Cre mutants are excluded in BS1494.

BS1576 to BS1581: For the *in vivo* recombination experiments wt and mutant Cre expressing strains were generated by introducing plasmids pBS606, 614, 626, 627, 628, and 650 into DH5 $\alpha$ .

#### Transformation of *E. coli*

For plasmid transformations of *E. coli* strains, electroporation was preferred over chemical protocols. Electrocompetent cells were made and used for electroporation as described by Smith et al., *Focus*, 12:38-40 (1990). The appropriate cell porator and cuvettes were from Life Technologies (Bethesda, MD).

#### Site-Directed Mutagenesis

The QuickChange<sup>TM</sup> Site-Directed Mutagenesis Kit (Stratagene Cloning Systems, La Jolla, CA) (1997) was used to generate defined single and double mutations in the *cre* gene.

#### Overexpression and Purification of Candidate Mutants

Wild-type and five different mutant Cre proteins were overexpressed using plasmids pRH200, and pBS654 to pBS658 in conjunction with Novagen BI21 (DE3) cells. After induction for 2.5 h cells were harvested, sonicated, and Cre partially purified after DNase I digest with a single step Whatman® P11 resin (Whatman Inc., Fairfield, NJ) as described before by Wierzbicki et al., *J. Mol. Biol.*, 195:785-794 (1987). The obtained Cre preps were about 80% pure and protein concentrations ranged between 100 and 200 ng/ $\mu$ l.

#### Mutant Analysis

*In Vivo*: Plasmids pBS632 to pBS641 were transformed into Cre-expressing *E. coli* strains BS1576 (wt), BS1577 (E262G), BS1578

(E262G/D29A), BS1579 (E262G/D189N), BS1580 (E262G/T316S), and BS1581 (R3M3). After 1 hour of induction of *cre* expression with 0.2% L-(+)-arabinose,  $10^{-5}$  dilutions were plated on non-selection medium containing 0.2% D-glucose. After overnight incubation at 37°C, colonies were transformed to  
5 kanamycin-selection plates for the described negative selection for *neo* excision.

*In Vitro*: Purified Cre mutants were used for both *in vitro* recombination and gel retardation experiments as described before by Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996) and Wierzbicki et al., *J. Mol. Biol.*, 195:785-794 (1987), respectively. For the recombination reactions plasmids pBS632 to  
10 pBS641 served as substrates, whereas for the DNA binding reactions  $\gamma[^{33}\text{P}]$ -dATP (Amersham Pharmacia Biotech, Piscataway, NJ) end-labeled 35 bp oligonucleotides were used, each encoding a *lox*-halfsite and one half of the FAS1 spacer.

#### Evaluation of Six $\text{K2}^+/\text{P}^+$ *cre* Mutants

15 Six of the 36 identified single  $\text{Kan}^{\text{R}}$  colonies of the third round were chosen for further analysis and referred to as R3M1 to 6 (Round 3 Mutants 1 to 6). Retesting them in the indicator strain revealed that all but one (R3M4) show significant *loxK2* recombination and all are unbiased in their activity on *loxP* (Table 14). Sequencing analysis revealed one amino acid change common to all  
20 five mutants having increased *loxK2* activity: a glutamate to glycine exchange at position 262 (E262G) in the J helix of the Cre protein (Figure 13). A second point mutation, a conservative threonine to serine exchange at position 316 (T316S), was identified in three of the mutants with enhanced *loxK2* activity. Two non-conservative mutations (D29A and D189N) were found in two of the  
25 five mutants. In addition, ten mutations occurred only once. Therefore, the critical mutation for *loxK2* activity appears to be E262G.

#### Site-Directed Mutagenesis

To address the question of the influence of the different point mutations further, the QuickChange™ Site-Directed Mutagenesis Kit (Stratagene) was  
30 applied to generate the following Cre mutants, each confirmed by sequencing: E262G, E262G/D29A, E262G/D189N, and E262G/T316S.



### *In Vivo* Characterization

To elucidate the contribution of specific amino acid changes in conferring altered recombinational specificity to Cre, recombination assays with different *lox* sites were carried out with the following Cre enzymes: the wt enzyme, one of the originally sequenced third round mutants (R3M3), and the generated single and double mutants. All *lox* sites used for the *in vivo* tests were designed to have the same 8 bp spacer region (FAS1) so that recombinational specificity was completely dependent on Cre's recognition of the symmetrical inverted repeats of the *lox* sites. Note that wt Cre-dependent recombination between *loxP* sites bearing the FAS1 spacer does not differ from recombination between original *loxP* sites (Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996)).

Figure 14 presents the recombination frequencies of various mutant *lox*<sup>2</sup> substrates and combination of sites (*loxP* with *loxK2* and as control with *loxK1*) from the marker excision assay. Mutant *lox* sites with symmetric nucleotide substitutions at positions 11 and 12 of the *loxP* sequence were tested with the wt enzyme and the five variant Cre mutants, including the multiple mutant R3M3(A). All enzymes showed a maximum in recombination (close to 100%) with thymines at these positions, i.e. with *loxP*<sup>2</sup>. Adenines, i.e. *loxK2*<sup>2</sup>, lowered the recombination frequencies drastically for the wt enzyme, whereas the single and double mutants performed approximately 50% to 70% less effectively. R3M3, however, showed nearly *LoxP*-like activity on the *loxK2*<sup>2</sup> substrate, as seen before with the selection strain (Table 14). Altering the two thymines to guanines resulted in similar recombination frequencies as seen with adenines at these positions. Cytosines, on the other hand, did not result in similar recombination frequencies as seen with thymines, but were surprisingly the least efficiently recognized substitutions of positions 11 and 12. To conclude, it appears that the E262G mutation is necessary and sufficient to significantly increase recombination frequencies on *lox* sequences which are symmetrically altered at positions 11 and 12. Of the additional mutations tested, D29A seems to be slightly beneficial, whereas D189N and T316S appear indifferent or even slightly deleterious for recombination on the variant sites. Thus, additional

mutations of R3M3 (Figure 13) must be responsible for its further increased performance on the mutant substrates *in vivo*.

Figure 14B shows the observed recombination frequencies on mixed substrates (e.g. *loxP* with *loxK2*). For both *loxK2* and the control substrate, *loxK1*, recombination with *loxP* by wt enzyme was substantially less than for *loxP*<sup>2</sup> recombination. This recombination frequency was increased dramatically with all of the mutant Cre protein. These results hint that not only a cooperativity in binding of two Cre molecules to one *lox* site exists but moreover also cooperativity between Cre molecules binding to different sites which then are synapsed and recombined. This finding is especially useful for genomic targeting: It suggests that a targeting vector carrying a *loxP* site will be effectively recombined with the endogenous *lox*-like site by the Cre mutants as long as the spacers are compatible.

Noteworthy also is R3M3-Cre's increased ability to recombine *loxK1* by itself, whereas all the mutants, like wt, did not. Again, some additional mutations found in R3M3 (Figure 13) seem to be responsible not only for increased recombination frequencies on *loxK2* but also on *loxK1* compared to Cre bearing the E262G mutation alone or in conjunction with the D29A mutation.

#### ***In Vitro* Characterization**

***In Vitro* Recombination Assays.** For the *in vitro* recombination experiments the same substrates as *in vivo*--that is, pBS632 to pBS641--were used. An *in vitro* recombination experiment using wt, E262G, and R3M3 Cre preps on *loxP*<sup>2</sup>, *loxK2*<sup>2</sup>, and *loxK1*<sup>2</sup> substrate showed that, as seen *in vivo* before, wt Cre is capable to recombine *loxP*<sup>2</sup> substrates only. No recombination products are visible when *loxK2*<sup>2</sup> or *loxK1*<sup>2</sup> substrates were used. By introducing the E262G mutation into Cre, however, recombination of *loxK2*<sup>2</sup> substrates becomes possible at elevated frequencies, and even for *loxK1*<sup>2</sup> substrate recombination products become weakly visible *in vitro*. E262G-Cre activity on the *loxK1* control site *in vitro* but not *in vivo* probably derives from differences in ionic strength and/or enzyme concentration between the assays. Finally, with R3M3 Cre the ability for both *loxK2*<sup>2</sup> and *loxK1*<sup>2</sup> recombination is

further increased, as expected from the *in vivo* assays. As mentioned in the *in vivo* results before, guanines at positions 11 and 12 of the *lox* sequence were recognized at similar frequencies as seen with adenines (i.e. *loxK2*), whereas cytosines were clearly less tolerated by all Cre mutants. Slight differences between *in vivo* and *in vitro* recombination frequencies are probably due to differences in ionic strength, temperature, DNA condensation, enzyme concentration, etc. In general, the pattern of the *in vitro* recombination frequencies of the different Cre enzymes on the different *lox* sites mirrors the one seen *in vivo*.

**Gelshift Experiments.** Gelshift experiments were applied to address the question of *in vitro* DNA-affinities of the different Cre mutants. As expected from the previous results, all three Cre enzymes bind with similar efficiency to *loxP*, whereas to *loxK2*, only E262G and R3M3 show binding affinity. Surprisingly, R3M3 binding appears less efficient on the *loxK2* half-site than binding of E262G, and on the *loxK1* half-site only E262G does bind weakly whereas R3M3 does not.

## DISCUSSION

### *lox* sites

*loxP* and *loxK2* differ at several locations as illustrated in Figure 1:

First, the three outermost bp of the inverted repeats are altered (positions 15, 16, 17, 15', 16' and 17'). Second, the entire non-canonical 8 bp spacer is completely exchanged (positions 4 to 4'), and third, two transversion events (thymine to adenine) are introduced at positions 11 and 12 (and mirrored at 11' and 12') of the *lox* site, mimicking potential recombination targets in eukaryotes. Only the two mutations at positions 11 and 12 are considered important for inhibiting wt Cre from recognizing the site. Thus, they were the only alterations in the *loxi* sites used for the *in vivo* and *in vitro* characterization experiments. Other investigations have shown that the two alterations of *loxP* mentioned first are without inhibiting effect on wt Cre (Sauer, B., *Mol. Cell. Biol.*, 7:2087-2096 (1987) and Sauer B., *Nucleic Acids Res.*, 24:4608-4613 (1996)). Noteworthy is however that the altered 8 bp spacer region (FAS1 spacer) does not allow *loxP* - *loxK2* recombination, since the regions where the

single-strand cleavages and exchanges take place are not compatible. To allow simultaneous monitoring of Cre-mediated recombination both at the wt *loxP*<sup>2</sup> and at a mutant *lox*<sup>2</sup> substrate (*loxK2*<sup>2</sup>), incompatible spacer elements were used to prevent recombination between the two types of *lox* sites by a candidate Cre mutant with altered specificity. Such recombination might easily compromise ready detection of desired Cre specificity mutants. Incompatible spacers (original *loxP* and FAS1) formed the basis for the simultaneous selection for *loxK2* recombination and screen for *loxP* recombination with *E. coli* strain BS1494 which led to the disclosed variant Cre recombinases.

*LoxK1*, the other *lox* sequence used in this study, bears two critical bp exchanges per arm as well, however at different positions: 10 and 14. It was used as a control *lox* site, addressing the question whether the generated Cre mutants with novel specificity for *loxK2* can also tolerate adjacent alterations within the *lox* sequence.

#### Cre Mutants after Three Rounds of Directed Evolution

Three iterations of the *in vitro* evolution procedure were used to identify 36 candidates which express Cre mutants that could process *loxK2* (based on the selection), as well as *loxP* (based on the simultaneous screen). wt Cre, on the other hand, only shows marginal activity on *loxK2* when expressed at very high levels.

#### Characterization

Sequence analysis revealed that five mutants with significant *loxK2* activity had in common only one point mutation, leading to the amino acid change E262G. However, several other point mutations occurred independently twice or thrice, among which D29A, D189N, and T316S. To investigate the influence of the mentioned mutations on the observed phenotype, specific single and double mutants were generated by site-directed mutagenesis. *In vivo* and *in vitro* assays were then carried out with wt-Cre and five different mutants (R3M3, E262G, E262G/D29A, E262G/D189N, E262G/T316S) to compare their performance on a variety of different alterations of the *loxK2* site.

The *in vivo* and *in vitro* recombination assays showed a similar pattern in recombination frequencies for the different enzymes on the different sites

tested. In general, recombination frequencies on mutant substrates were distinctively the highest with R3M3. The double mutant E262G/D29A was about half as effective as R3M3, whereas the other double mutants and the single mutant E262G showed slightly further decreased recombination frequencies on the altered sites. The wt enzyme did not recombine any of the mutant substrates presented here, neither *in vivo* nor *in vitro*. With previous results showing that single D29A, D189N, and T316S mutants of Cre perform like the wt enzyme on *loxK2* and *loxK1* *in vivo* and the fact that the E262G point-mutation was the only one found independently in all the originally isolated Cre mutants with *loxK2* specificity, it is clear that E262G is a critical mutation that allows Cre to recognize *loxK2*. However, in combination with E262G, D29A permits still higher recombination frequencies on *lox* sites altered at positions 11 and 12. Since R3M3 shows even further increased recombination frequencies on the altered sites compared to E262G/D29A, other of the point mutations identified in this Cre mutant (see Figure 14) must account for this increase in activity. Because of its location close to the amino-terminus of the J helix, the Q255R mutation of R3M3 could be expected to influence DNA contacts. Other mutations may influence protein folding or protein-protein interactions which could result in a higher flexibility within the Cre-*lox* interface and thus allowing a better tolerance of alterations of the *lox* sequence. This hypothesis is also supported by the observation that R3M3 recognizes the *loxK1* site at frequencies similar to E262G recognizing *loxK2*. The double and single Cre mutants, on the other hand, did not show activity on *loxK1*. In addition, the gel-shift experiments showed that R3M3-Cre's binding affinity for *loxK2* and *loxK1* half-sites is less than E262G-Cre's and the three double mutant's. Taking these results together, other mutations of R3M3 must further influence Cre-*lox* interactions to allow enhanced recombination on *loxK2*. On the one hand, this results in less efficient binding to *lox* half-sites, on the other hand, when complete *lox* sites are available, the cooperativity phenomenon between Cre enzymes binding to the same and different *lox* sites may compensate for this loss in binding activity. Then the postulated increased flexibility between DNA and protein seems to become advantageous for

recognizing and recombining altered *lox* sites, as seen with the *in vivo* and *in vitro* recombination assays.

Alternatively, some mutations, also silent ones, could influence protein expression, leading to a faster accumulation of enzymes and consequently to higher recombination frequency. An *E. coli* codon usage table suggested, however, that none of the identified mutations should improve Cre expression in *E. coli* remarkably.

### Modeling

With the published crystal structure of four Cre molecules bound to two synapsed *loxA* sites after the first single strand cleavage (Guo et al., *Nature*, 389:40-46 (1997)) the identified point mutations were analyzed for being involved in DNA and/or protein interactions. All of them, including the E262 position in the J-helix of Cre were found to be not involved in either interactions in this state of the reaction. This observation indicates that the mutations which were found to account for the described novel substrate recognition *in vivo* and *in vitro* lead to this new phenotype in a less direct and obvious manner. As mentioned earlier, they may influence protein folding, resulting in a higher flexibility within the Cre-*lox* interface. This hypothesis is especially well supported with the described differences between binding to *lox* halvesites and recombination. Alternatively, they may still be involved in protein-protein (D29A) or protein-DNA (E262G) contacts before or after the formation of the clamp-like strand-exchange state.

### *In Vivo* and *In Vitro* Recombination

Some additional variations of the *loxK2* site were tested also. The list in Table 17 shows all the sequences of *lox* sites which were tested and assigns them a name, as well as their plasmid (pBS) number. In Figure 15 the obtained *in vivo* recombination frequencies on all the variants of *loxK2* are indicated. The additional results indicate that alterations at position 12 of the *lox* halvesite are of more importance for Cre-based recombination than ones at position 11.

The *in vitro* recombination frequencies of all six Cre enzymes tested on the *lox* sites listed above are given in table 15. The frequencies were calculated after quantitation of the brightness of fluorescence of the Ethidium-Bromide-

stained DNA fragments on agarose-gels. Differences in temperature, ionic strength, medium composition, and enzyme concentration probably account for the observed differences between *in vivo* and *in vitro* recombination results. Most strikingly, *loxP* is no longer recognized with the highest frequencies *in vitro*. However, when the ionic strength in the *in vitro* assay was increased results began to resemble the ones seen *in vivo*. Thus, efficiency of recombination with variant *lox* sites by each of the Cre mutant and the wt enzyme can be further controlled *in vitro* by adjusting ionic strength and other *in vitro* conditions.

Qualitatively, however, the *in vivo* and *in vitro* recombination frequencies mirror each other. These novel Cre mutants thus possess a specificity for substrates (*loxK2* and its derivatives) which are not recognized by the wt enzyme.

#### Gelshift Assays

DNA binding (gelshift) experiments were also done with the generated Cre double-mutants (E262G with D29A, D189N, or T316S) to analyzing binding of the variant Cre recombinases to various recombination sites. In table 16 the observed mean percentages of binding to *loxP*, *loxK2*, and *loxK1* halfsites with the five different Cre mutants and the wt enzyme are given. As shown, all mutants - in contrast to the wt enzyme - do bind to *loxK2* with similar frequencies, except R3M3 which shows surprisingly low retardation. As discussed above, this phenomenon may be explained with an increased tolerance, i.e., flexibility, of R3M3 for altered *lox* sites. On halfsites which precludes the cooperativity between Cre molecules in binding R3M3 cannot bind as tight as wt or the single and double mutants. With the *loxK1* halfsite this 'binding versus recombination' difference is even more strikingly. Whereas wt and the R3M3 mutant cannot bind to the halfsite, all the other mutants can. Yet, recombination of *loxK1* substrates was seen with R3M3 Cre, only. These results show clearly that simple DNA affinity does not correlate in a one-to-one fashion with recombination. Thus, inappropriate DNA binding by recombinases likely can lead to a block in recombination.

**Conclusions** The *in vivo* data show that:

1. The E262G mutation confers a generally elevated level of recombination at a number of variant *lox* sites, those having any of a large number of alterations at positions 11 and 12 (and mirroring 11' and 12' alterations).
- 5 2. The D189N mutation in conjunction with the E262G mutation appears to fine tune the broadened specificity of the E262G mutation by reducing recombination at the *loxK2* variants 'GG', 'TC' and 'CC' without decreasing recombination at *loxK2* and the 'GT' variant. This mutation is thus useful to limit the broadened specificity of E262G.
- 10 3. The T316S mutation when in conjunction with E262G provides a slight boost in recombination frequency with the *loxK2* variants 'GT' and 'CC', and has no deleterious effect on recombination at the other variant *loxK2* sites.
4. The D29A mutation together with E262G boosts recombination at *loxK2* and the variants 'CC' and 'GG'. D29A does not reduce recombination at the  
15 other variant *lox* sites or at *loxP*.
5. Some of the additional mutations of R3M3 must account for the further increased recombination frequency on any of the tested mutant *lox* sites, including *loxK1* but do not compromise *loxP* recognition.

The disclosed variant recombinases have a number of useful features  
20 and applications. By recognizing an altered, user-defined target site, they were designed to allow both genetic targeting events in prokaryotes and eukaryotes like wt Cre but on different sites and *in vitro* recombination strategies. With a wider variety of possible target sequences being now accessible, multiple and defined genomic alterations will now become feasible. This opens more  
25 possibilities in designing genomic manipulations in all DNA-based organisms by site-specific recombination.

With the various genome projects under way today, there will be more and more applications for site-specific recombination to study the impact of genes or genetic control elements by genomic engineering. In addition, genome  
30 manipulations are also more frequently used to express recombinant proteins within the organism of choice.



**Table 13.** Presented are the results of the first four rounds of the described mutagenesis procedure for *loxK2* specificity. Column one indicates the round of the mutagenesis procedure (round 0 indicates that no mutagenesis event has taken place yet, wt enzyme, only) and column two the allotted time for *cre* expression in induction medium. Column three presents the observed frequencies of Kan<sup>R</sup>, indicating *loxK2* recombination by a mutant candidate. Of note, all Kan<sup>R</sup> colonies found during this experiment were white, indicating effective *loxP* recombination. In column four the actual number of Kan<sup>R</sup> colonies found in each round of 1000 to 10<sup>4</sup> plated is given, and the last column presents the frequency of white colonies on non-selection plates which is decreasing with every round.

**Table 14.** Presented are the frequencies of Kan<sup>R</sup> of six chosen candidate mutants from round three of the mutagenesis procedure (R3M1 to 6) when retesting them in the indicator strain. Also, they were tested for their performance on *loxP* sites in identical fashion. The obtained Kan<sup>R</sup> frequencies indicate the percentages of recombination within the allotted induction time of 2.5 hours.

Table 2: List of Strains Used for Selection and Screen

BS #	Description	Substrates	Selection and Screen
1493	BS583 [pBS583]	<i>loxK1<sup>2</sup>/loxP<sup>2</sup></i>	<i>neo</i> selection and <i>lacZ</i> screen, respectively
1494	BS583 [pBS584]	<i>loxK2<sup>2</sup>/loxP<sup>2</sup></i>	<i>neo</i> selection and <i>lacZ</i> screen, respectively
1541	BS583 [pBS613]	<i>loxP<sup>2</sup>/loxP<sup>2</sup></i>	<i>neo</i> selection and <i>lacZ</i> screen, respectively
1523	NS2300 [pBS601]	<i>loxK1<sup>2</sup>/loxP<sup>2</sup></i>	<i>abfA.st</i> screen and <i>neo</i> selection, respectively
1524	NS2300 [pBS602]	<i>loxK2<sup>2</sup>/loxP<sup>2</sup></i>	<i>abfA.st</i> screen and <i>neo</i> selection, respectively

List of the *E. coli* strains used for the described selection and screening procedures for the desired Cre mutants. BS1493 and BS1494 served as selection strains for K1<sup>+</sup> or K2<sup>+</sup> Cre mutants, respectively. BS1541 was used as a control strain to determine *loxP* activity. BS1523 and BS1524 were used to select for P<sup>+</sup> mutants. Construction and application of the different selection procedures are explained in detail in the text.

Table 3: Sequencing Primers for *cre*

Primer BSB#	Sequence 5' - 3'	Position (5', 3') in <i>cre</i>
454	TTT GGG CTA GCG AAT TCG AG	-55, -36
455	TTT GGG CCA GCT AAA CAT GC	273, 292
456	CGG TGG GAG AAT GTT AAT CC	567, 586
457	GGA CAC AGT GCC CGT GTC	862, 879
458	TCT GCG TTC TGA TTT AAT CTG	1117, 1097
459	CCA GGC CAG GTA TCT CTG	858, 841
460	GTA CGT GAG ATA TCT TTA ACC C	563, 542
461	TTG CTG GAT AGT TTT TAC TGC C	270, 249

Presented are the eight sequencing primers used for sequencing of the entire *cre* gene in both directions and their positions within the *cre* coding sequence. Primers BSB 454 to BSB457 allow sequencing of the coding strand, whereas the four remaining primers have been designed for the non-coding strand. In order to achieve a complete sequence information in both directions, about 350 bases have to be read out of each sequencing reaction. The positions given for each primer refer to its 5' and 3' end, with position 1 referring to the adenine of the ATG start codon of *cre*.

Table 4: Primers Used in the QuickChange™ Site-Directed Mutagenesis Kit (Stratagene)

Primer BSB#	Sequence 5' - 3'	Position (5', 3') in <i>cre</i>
465	GCTATCAACTCGCGCCCTGGGAGGGATTTTGAAGCAACTCATCG	765, 809
466	GAGTTGCTTCAAAAATCCCTCCCAGGGCGCGAGTTGATAGCTGGC	805, 761
467	GCTATCAACTCGCGCCCTGGCAGGGATTTTGAAGCAACTCATCG	765, 809
468	GAGTTGCTTCAAAAATCCCTGCCAGGGCGCGAGTTGATAGCTGGC	805, 761
469	GCTATCAACTCGCGCCNNNNNNNNNATTTTGAAGCAACTCATCG	765, 809
470	GAGTTGCTTCAAAAATNNNNNNNNNGGCGCGAGTTGATAGCTGGC	805, 761

Illustrated are the mutant oligonucleotides used in the QuickChange™ Site-Directed Mutagenesis Kit (Stratagene) to introduce single point mutations (mismatches with the wt sequence are highlighted by bold letters). With BSB465/466 a E262G mutation, and with BSB467/468 a E262A mutation is introduced in Cre. The last set of primers (BSB469/470), as indicated by the bold N, represent an equimolar mixture of all possible bases at the assigned positions. This mixture results in all possible aa combinations at positions 261 to 263 of Cre. As mentioned before, the indicated positions refer to 5' and 3' end of the oligonucleotides in the *cre* coding sequence.

Table 5: Comparison of Mutagenic and Non-Mutagenic PCR on wt *cre*

Induction of <i>cre</i> Expression	Non-Mutagenic PCR		Mutagenic PCR	
	Blue	White	Blue	White
SOC, 2.5h	> 99.6%	< 0.4%	> 99.5%	< 0.5%
SOB+ara, 2.5h	19.7%	81.3%	60.8%	39.2%

The experiments presented here served two purposes: (i) to compare the influence of glucose (SOC medium) and arabinose on *cre* expression with pBAD33, (ii) to compare the frequencies of deleterious point mutations occurring during non-mutagenic and error-prone PCR. The first column indicates the medium used for repression (SOC), or induction of *cre* expression (SOB+ara). The second column compares the observed frequencies of blue and white colonies after a non-mutagenic PCR, the third column after a mutagenic PCR. Blue colonies indicate, that the *loxP*<sup>2</sup> flanked *lacZ* gene of BS583 is not excised by Cre, white ones its Cre-mediated excision. Note that the number of blue colonies resulting from empty pBAD33 vector (approximately 1% in all experiments) was subtracted before calculating the presented values. This blue background was determined with a control ligation lacking *cre* insertion. With glucose in the medium, only blue colonies are found, indicating that *cre* is not expressed. With arabinose induction, however, the frequencies of disabled Cre mutants (blue) can be determined, increasing three times under mutagenic conditions.

Table 6: The First Four Rounds on *loxK2*<sup>2</sup>

Round	Status	Induction	% White (Non-Selection)	% Kan <sup>R</sup> (White)	Nb. Kan <sup>R</sup> (White)	Nb. Pooled for the Next Round
1	ox	4 h	83.9%	0.01%	1	none
	mx	4 h	42.4%	0.16%	6	6
2	mxox	2.5 h	88.3%	0.02%	1	none
		4 h	82.5%	0.56%	47	47
	mxmx	2.5 h	13%	< 0.01%	0	none
		4 h	24%	0.3%	5	none
3	mxoxox	2.5 h	80.7%	0.2%	36	30
		4 h	85%	25%	10 <sup>4</sup>	none
	mxoxmx	2.5 h	25.7%	0.02%	1	none
		4 h	21.8%	5%	250	none
4	mxoxoxox	2.5 h	75%	4.6%	102	none
	mxoxoxmx	2.5 h	< 7.7%	0.3%	3	none

Presented are the results of the first four rounds of the described mutagenesis procedure for *loxK2* specificity. The following symbols for the status of the *cre* pools have been used: "o" indicates a non-mutagenic, "m" a mutagenic PCR, and "x" stands for the shuffling step by DNase I digest and reassembly. Column one indicates the round of the mutagenesis procedure, column two its status as mentioned above, and column three the time permitted for *cre* expression in induction medium. In column four, the calculated percentages of white colonies on non-selection plates is indicated, decreasing with every round, especially when the pools were subjected to mutagenic PCR's twice. Column five presents the observed frequencies of Kan<sup>R</sup>, indicating *loxK2* recombination by a mutant candidate. Of note, that all Kan<sup>R</sup> colonies found during this experiment were white, indicating effective *loxP* recombination. The two last columns give the actual numbers of Kan<sup>R</sup> colonies found in each round (1/5 dilution) and mark the ones used as starting material for the next round.

Table 7: Functional Evaluation of Six Selected mxoxox K2\* Mutants and wt Cre

Cre Candidate	Induction Time	% Kan <sup>R</sup> with		
		BS1494 ( <i>loxK2</i> <sup>1</sup> )	BS1541 ( <i>loxP</i> <sup>1</sup> )	BS1493 ( <i>loxK1</i> <sup>1</sup> )
wt	2.5 h	0.002%	93.9%	0.001%
	4 h	n.d.	n.d.	0.002%
mxoxox 1	2.5 h	66.4%	98.2%	0.004%
	4 h	n.d.	n.d.	0.005%
mxoxox 2	2.5 h	53.6%	98%	0.007%
	4 h	n.d.	n.d.	0.005%
mxoxox 3	2.5 h	66.5%	80.5%	0.007%
	4 h	n.d.	n.d.	0.01%
mxoxox 4	2.5 h	0.05%	80.3%	0.008%
	4 h	n.d.	n.d.	0.006%
mxoxox 5	2.5 h	15.2%	81.2%	0.006%
	4 h	n.d.	n.d.	0.009%
mxoxox 6	2.5 h	3.1%	83.7%	0.003%
	4 h	n.d.	n.d.	0.01%

The results of functional testing of the six chosen K2\*/P\* Cre candidates compared to wt Cre are listed. All enzymes were checked on *loxK2*, *loxP* and *loxK1* recombination in the selection strains BS1494, BS1493 and the control strain BS1541. In the first column the Cre candidate is indicated, in the second the allowed time for cre expression. The three following columns show the calculated percentages of Kan<sup>R</sup> when subjecting the different Cre mutants and wt Cre to the three selection strains. The frequency of the observed Kan<sup>R</sup> phenotype is considered as an indicator for the frequency of *lox* recombination: On *loxK2*, all mutants, except mxoxox 4, show remarkably increased Kan<sup>R</sup> frequencies compared to wt Cre. On *loxP*, all (including mxoxox 4), show very similar results as wt Cre, indicating, that *loxP* recombination is at best slightly affected. On *loxK1* neither mutant nor wt Cre show more than background activity, even after four hours of cre expression. The obtained mutants are therefore characterized by a broader substrate recognition compared to the wt enzyme.

Table 8: Sequence Analysis of the Six mxoxox K2'/P\* Mutants

Cre Candidate	Codon Change in <i>cre</i>		aa Change	Nb. of Isolates	Position in Cre
	Position	wt → mut			
mxoxox 1	45	CCG CCI	(P15P)	2	(N-terminal)
	86	GAC GCC	D29A	2	A
	565	GAC AAC	D189N	2	loop I - 2
	642	AGC AGI	(S214S)	1	(N-term. of I)
	679	GTC ATC	V227I	1	I
	785	GAA GGA	E262G*	5	J
mxoxox 2	45	CCG CCI	(P15P)	2	(N-terminal)
	413	GAA GGA	E138G	1	N-term. of F
	760	AGC GGC	S254G	1	loop 5 - J
	785	GAA GGA	E262G*	5	J
	861	TCI TCC	(S287S*)	2	N-term. of K
	946	ACC ICC	T316S	3	loop L - M
mxoxox 3	46	GTC ATC	V16I	1	N-terminal
	565	GAC AAC	D189N	2	loop I - 2
	592	GGC AGC	G198S	1	C-term. of 2
	668	CGA CAA	R223Q	1	I
	764	CAG CCG	Q255R	1	loop 5 - J
	785	GAA GGA	E262G*	5	J
	861	TCI TCC	(S287S*)	2	N-term. of K
	920	CCG CTG	P307L	1	L
mxoxox 4	230	TAT TGT	Y77C	1	C
	412	GAA AAA	E138K	1	N-term. of F
	851	CTG CAG	L284Q	2	loop J - K
mxoxox 5	86	GAC GCC	D29A	2	A
	302	CCG CAG	R101Q*	1	D
	659	CTG CAG	L220Q	1	I
	785	GAA GGA	E262G*	5	J
	946	ACC ICC	T316S	3	loop L - M
mxoxox 6	785	GAA GGA	E262G*	5	J
	851	CTG CAG	L284Q	2	loop J - K
	946	ACC ICC	T316S	3	loop L - M

The point mutations identified by sequence analysis in the six selected K2'/P\* mutants are listed. Column one identifies the mutants, column two the observed point mutations and their position in the *cre* coding sequence. Column three indicates the resulting aa changes and their positions in the Cre enzyme (silent mutations in parenthesis). DNA contacting residues, according to the crystal structure (Guo, *et. al.*, 1997), are marked by an asterisk. Column four indicates how often the different point mutations were independently found in the pool of the six mutants, and column five shows where the aa changes are located in the secondary structure of the protein. Of the altogether 31 point mutations listed, five are silent. Only one aa change, E262G, is common to all mutants with remarkably increased *loxK2* activity (mxoxox 1, 2, 3, 5, and 6), suggesting that this mutation is the essential one for the observed phenotype. Nine point mutations occurred twice or three times in the pool, whereas eleven were found in one mutant only. For further information, see text and appendices A, B, and C.

Table 2: Functional Evaluation of Three Defined Cre Mutants for Position 262 and wt Cre

Cre Mutant	Induction Time	% Kan <sup>R</sup> with		
		BS1494 ( <i>loxK2</i> <sup>1</sup> )	BS1541 ( <i>loxP</i> <sup>1</sup> )	BS1493 ( <i>loxK1</i> <sup>1</sup> )
wt	2.5 h	0.002%	93.9%	0.001%
E262G	2.5 h	2.2%	84.2%	0.004%
E262A	2.5 h	0.4%	82.3%	0.006%
E262W	2.5 h	2.9%	81.7%	0.003%

The results of functional testing of three defined Cre mutants for position 262 compared to wt Cre are listed. All enzymes were checked on *loxK2*, *loxP* and *loxK1* recombination in the selection strains BS1494, BS1493 and the control strain BS1541. In the first column the Cre candidate is indicated, in the second the allowed time for cre expression. The three following columns show the calculated percentages of Kan<sup>R</sup> when subjecting the different Cre mutants and wt Cre to the three selection strains. The frequency of the observed Kan<sup>R</sup> phenotype is considered as an indicator for the frequency of *lox*<sup>1</sup> recombination: On *loxK2*, E262G and E262W show approximately an 10<sup>3</sup> fold increased Kan<sup>R</sup> frequency compared to wt Cre, whereas E262A results in a 200 fold increase. On *loxP*, all show very similar results as wt Cre, indicating, that *loxP* recombination is at best slightly affected. On *loxK1* neither mutant nor wt Cre show more than background activity. This indicates, that E262G and E262W alone are sufficient to remarkably increase Cre's activity on *loxK2*, that these mutations do not increase *loxK1* recognition, and that *loxP* activity may be slightly affected.



Table 10

*In Vitro* Evolution of the Cre recombinase

wiCre	TTTGGGCTAG	CGAATTCGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mx0x0x1	TTTGGGCTAG	CGAATTCGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mx0x0x2	TTTGGGCTAG	CGAATTCGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mx0x0x3	TTTGGGCTAG	CGAATTCGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mx0x0x4	TTTGGGCTAG	CGAATTCGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mx0x0x5	TTTGGGCTAG	CGAATTCGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
mx0x0x6	TTTGGGCTAG	CGAATTCGAG	CTCGGTACCC	GGGGATCCTC	TAGACTGAGT
-55					
wiCre	GTGAAATCTC	CAATTTACTG	ACCGTACACC	AAAAATTTGCC	TGCATTACCG
mx0x0x1	GTGAAATCTC	CAATTTACTG	ACCGTACACC	AAAAATTTGCC	TGCATTACCT
mx0x0x2	GTGAAATCTC	CAATTTACTG	ACCGTACACC	AAAAATTTGCC	TGCATTACCT
mx0x0x3	GTGAAATCTC	CAATTTACTG	ACCGTACACC	AAAAATTTGCC	TGCATTACCG
mx0x0x4	GTGAAATCTC	CAATTTACTG	ACCGTACACC	AAAAATTTGCC	TGCATTACCG
mx0x0x5	GTGAAATCTC	CAATTTACTG	ACCGTACACC	AAAAATTTGCC	TGCATTACCG
mx0x0x6	GTGAAATCTC	CAATTTACTG	ACCGTACACC	AAAAATTTGCC	TGCATTACCG
-5					
wiCre	GTCGATGCAA	CGAGTGATGA	GGTTCGCAAG	AAOCTGATGG	ACATGTTTCA
mx0x0x1	GTCGATGCAA	CGAGTGATGA	GGTTCGCAAG	AAOCTGATGG	CCATGTTTCA
mx0x0x2	GTCGATGCAA	CGAGTGATGA	GGTTCGCAAG	AAOCTGATGG	ACATGTTTCA
mx0x0x3	ATCGATGCAA	CGAGTGATGA	GGTTCGCAAG	AAOCTGATGG	ACATGTTTCA
mx0x0x4	GTCGATGCAA	CGAGTGATGA	GGTTCGCAAG	AAOCTGATGG	ACATGTTTCA
mx0x0x5	GTCGATGCAA	CGAGTGATGA	GGTTCGCAAG	AAOCTGATGG	CCATGTTTCA
mx0x0x6	GTCGATGCAA	CGAGTGATGA	GGTTCGCAAG	AAOCTGATGG	ACATGTTTCA
46					
wiCre	GGATCGOCAG	GCGTTTCTG	AGCATAOCTG	GAAAAATGCTT	CTGTCCGTTT
mx0x0x1	GGATCGOCAG	GCGTTTCTG	AGCATAOCTG	GAAAAATGCTT	CTGTCCGTTT
mx0x0x2	GGATCGOCAG	GCGTTTCTG	AGCATAOCTG	GAAAAATGCTT	CTGTCCGTTT
mx0x0x3	GGATCGOCAG	GCGTTTCTG	AGCATAOCTG	GAAAAATGCTT	CTGTCCGTTT
mx0x0x4	GGATCGOCAG	GCGTTTCTG	AGCATAOCTG	GAAAAATGCTT	CTGTCCGTTT
mx0x0x5	GGATCGOCAG	GCGTTTCTG	AGCATAOCTG	GAAAAATGCTT	CTGTCCGTTT
mx0x0x6	GGATCGOCAG	GCGTTTCTG	AGCATAOCTG	GAAAAATGCTT	CTGTCCGTTT
96					
wiCre	GCCGGTCTGT	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTTCCC
mx0x0x1	GCCGGTCTGT	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTTCCC
mx0x0x2	GCCGGTCTGT	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTTCCC
mx0x0x3	GCCGGTCTGT	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTTCCC
mx0x0x4	GCCGGTCTGT	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTTCCC
mx0x0x5	GCCGGTCTGT	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTTCCC
mx0x0x6	GCCGGTCTGT	GGCGGCATGG	TGCAAGTTGA	ATAACCGGAA	ATGGTTTCCC
146					
wiCre	GCAGAACCTG	AAGATGTTCC	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mx0x0x1	GCAGAACCTG	AAGATGTTCC	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mx0x0x2	GCAGAACCTG	AAGATGTTCC	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mx0x0x3	GCAGAACCTG	AAGATGTTCC	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mx0x0x4	GCAGAACCTG	AAGATGTTCC	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mx0x0x5	GCAGAACCTG	AAGATGTTCC	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
mx0x0x6	GCAGAACCTG	AAGATGTTCC	CGATTATCTT	CTATATCTTC	AGGCGCGCGG
196					

Table 10 (cont.)

*In Vitro Evolution of the Cre recombinase*

wtCre	TCTGGCAGTA	AAAACTATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mx0x0x1	TCTGGCAGTA	AAAACTATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mx0x0x2	TCTGGCAGTA	AAAACTATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mx0x0x3	TCTGGCAGTA	AAAACTATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mx0x0x4	TCTGGCAGTA	AAAACTATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mx0x0x5	TCTGGCAGTA	AAAACTATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
mx0x0x6	TCTGGCAGTA	AAAACTATCC	AGCAACATTT	GGGCCAGCTA	AACATGCTTC
246					
wtCre	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mx0x0x1	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mx0x0x2	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mx0x0x3	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mx0x0x4	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mx0x0x5	ATCGTCAGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
mx0x0x6	ATCGTCGGTC	CGGGCTGCCA	CGACCAAGTG	ACAGCAATGC	TGTTTCACTG
296					
wtCre	GTTATGCCGC	GGATCCGAAA	AGAAAAAGTT	GATGCCGGTG	AACGTGCAAA
mx0x0x1	GTTATGCCGC	GGATCCGAAA	AGAAAAAGTT	GATGCCGGTG	AACGTGCAAA
mx0x0x2	GTTATGCCGC	GGATCCGAAA	AGAAAAAGTT	GATGCCGGTG	AACGTGCAAA
mx0x0x3	GTTATGCCGC	GGATCCGAAA	AGAAAAAGTT	GATGCCGGTG	AACGTGCAAA
mx0x0x4	GTTATGCCGC	GGATCCGAAA	AGAAAAAGTT	GATGCCGGTG	AACGTGCAAA
mx0x0x5	GTTATGCCGC	GGATCCGAAA	AGAAAAAGTT	GATGCCGGTG	AACGTGCAAA
mx0x0x6	GTTATGCCGC	GGATCCGAAA	AGAAAAAGTT	GATGCCGGTG	AACGTGCAAA
346					
wtCre	ACAGGCTCTA	GCGTTGGAAC	GCACTGATTT	CGAOCAGGTT	CGTTCACTCA
mx0x0x1	ACAGGCTCTA	GCGTTGGAAC	GCACTGATTT	CGAOCAGGTT	CGTTCACTCA
mx0x0x2	ACAGGCTCTA	GCGTTGGAAC	GCACTGATTT	CGAOCAGGTT	CGTTCACTCA
mx0x0x3	ACAGGCTCTA	GCGTTGGAAC	GCACTGATTT	CGAOCAGGTT	CGTTCACTCA
mx0x0x4	ACAGGCTCTA	GCGTTGGAAC	GCACTGATTT	CGAOCAGGTT	CGTTCACTCA
mx0x0x5	ACAGGCTCTA	GCGTTGGAAC	GCACTGATTT	CGAOCAGGTT	CGTTCACTCA
mx0x0x6	ACAGGCTCTA	GCGTTGGAAC	GCACTGATTT	CGAOCAGGTT	CGTTCACTCA
396					
wtCre	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCGCGG
mx0x0x1	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCGCGG
mx0x0x2	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCGCGG
mx0x0x3	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCGCGG
mx0x0x4	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCGCGG
mx0x0x5	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCGCGG
mx0x0x6	TGGAAAATAG	CGATCGCTGC	CAGGATATAC	GTAATCTGGC	ATTTCGCGG
446					
wtCre	ATTGCTTATA	ACACCCGTGT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mx0x0x1	ATTGCTTATA	ACACCCGTGT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mx0x0x2	ATTGCTTATA	ACACCCGTGT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mx0x0x3	ATTGCTTATA	ACACCCGTGT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mx0x0x4	ATTGCTTATA	ACACCCGTGT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mx0x0x5	ATTGCTTATA	ACACCCGTGT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
mx0x0x6	ATTGCTTATA	ACACCCGTGT	ACGTATAGCC	GAAATTGCCA	GGATCAGGGT
496					

Table 10 (con<sup>d</sup>)*In Vitro Evolution of the Cre recombinase*

wtCre	TAAAGATATC	TCACGTA	ACGGTGGAG	AATGTTAATC	CATATTGCA
mx0x0x1	TAAAGATATC	TCACGTA	ACGGTGGAG	AATGTTAATC	CATATTGCA
mx0x0x2	TAAAGATATC	TCACGTA	ACGGTGGAG	AATGTTAATC	CATATTGCA
mx0x0x3	TAAAGATATC	TCACGTA	ACGGTGGAG	AATGTTAATC	CATATTGCA
mx0x0x4	TAAAGATATC	TCACGTA	ACGGTGGAG	AATGTTAATC	CATATTGCA
mx0x0x5	TAAAGATATC	TCACGTA	ACGGTGGAG	AATGTTAATC	CATATTGCA
mx0x0x6	TAAAGATATC	TCACGTA	ACGGTGGAG	AATGTTAATC	CATATTGCA
546					
wtCre	GAACGAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mx0x0x1	GAACGAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mx0x0x2	GAACGAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mx0x0x3	GAACGAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mx0x0x4	GAACGAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mx0x0x5	GAACGAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
mx0x0x6	GAACGAAAC	GCTGGTTAGC	ACCGCAGGTG	TAGAGAAGGC	ACTTAGCCTG
596					
wtCre	GGGGTAACTA	AACCTGGTGA	GCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mx0x0x1	GGGGTAACTA	AACCTGGTGA	GCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mx0x0x2	GGGGTAACTA	AACCTGGTGA	GCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mx0x0x3	GGGGTAACTA	AACCTGGTGA	GCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mx0x0x4	GGGGTAACTA	AACCTGGTGA	GCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mx0x0x5	GGGGTAACTA	AACCTGGTGA	GCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
mx0x0x6	GGGGTAACTA	AACCTGGTGA	GCGATGGATT	TCCGTCTCTG	GTGTAGCTGA
646					
wtCre	TGATCCGAAT	AACCTACCTGT	TTTGCCGGGT	CAGAAAAAAT	GGTGTTCGCG
mx0x0x1	TGATCCGAAT	AACCTACCTGT	TTTGCCGGGT	CAGAAAAAAT	GGTGTTCGCG
mx0x0x2	TGATCCGAAT	AACCTACCTGT	TTTGCCGGGT	CAGAAAAAAT	GGTGTTCGCG
mx0x0x3	TGATCCGAAT	AACCTACCTGT	TTTGCCGGGT	CAGAAAAAAT	GGTGTTCGCG
mx0x0x4	TGATCCGAAT	AACCTACCTGT	TTTGCCGGGT	CAGAAAAAAT	GGTGTTCGCG
mx0x0x5	TGATCCGAAT	AACCTACCTGT	TTTGCCGGGT	CAGAAAAAAT	GGTGTTCGCG
mx0x0x6	TGATCCGAAT	AACCTACCTGT	TTTGCCGGGT	CAGAAAAAAT	GGTGTTCGCG
696					
wtCre	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGA	AGGGATTTTT
mx0x0x1	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
mx0x0x2	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
mx0x0x3	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
mx0x0x4	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
mx0x0x5	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
mx0x0x6	CGCCATCTGC	CACCAGCCAG	CTATCAACTC	GCGCCCTGGG	AGGGATTTTT
746				785	
wtCre	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mx0x0x1	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mx0x0x2	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mx0x0x3	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mx0x0x4	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mx0x0x5	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
mx0x0x6	GAAGCAACTC	ATCGATTGAT	TTACGGCGCT	AAGGATGACT	CTGGTCAGAG
796					

Table 10 (cont)

*In Vitro* Evolution of the Cre recombinase

wtCre	ATACCTGGCC	TGGTCTGGAC	ACAGTGCCCG	TGTCGGAGCC	GCGCGAGATA
mx0x0x1	ATACCTGGCC	TGGTCTGGAC	ACAGTGCCCG	TGTCGGAGCC	GCGCGAGATA
mx0x0x2	ATACCTGGCC	TGGTCTGGAC	ACAGTGCCCG	TGTCGGAGCC	GCGCGAGATA
mx0x0x3	ATACCTGGCC	TGGTCTGGAC	ACAGTGCCCG	TGTCGGAGCC	GCGCGAGATA
mx0x0x4	ATACCTGGCC	TGGTCTGGAC	ACAGTGCCCG	TGTCGGAGCC	GCGCGAGATA
mx0x0x5	ATACCTGGCC	TGGTCTGGAC	ACAGTGCCCG	TGTCGGAGCC	GCGCGAGATA
mx0x0x6	ATACCTGGCC	TGGTCTGGAC	ACAGTGCCCG	TGTCGGAGCC	GCGCGAGATA
846					
wtCre	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mx0x0x1	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mx0x0x2	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mx0x0x3	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mx0x0x4	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mx0x0x5	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
mx0x0x6	TGGCCCGCGC	TGGAGTTTCA	ATACCGGAGA	TCATGCAAGC	TGGTGGCTGG
896					
wtCre	ACCAATGTAA	ATATTGTCAT	GAACATATC	CGTAACTGG	ATAGTGAAAC
mx0x0x1	ACCAATGTAA	ATATTGTCAT	GAACATATC	CGTAACTGG	ATAGTGAAAC
mx0x0x2	ACCAATGTAA	ATATTGTCAT	GAACATATC	CGTAACTGG	ATAGTGAAAC
mx0x0x3	ACCAATGTAA	ATATTGTCAT	GAACATATC	CGTAACTGG	ATAGTGAAAC
mx0x0x4	ACCAATGTAA	ATATTGTCAT	GAACATATC	CGTAACTGG	ATAGTGAAAC
mx0x0x5	ACCAATGTAA	ATATTGTCAT	GAACATATC	CGTAACTGG	ATAGTGAAAC
mx0x0x6	ACCAATGTAA	ATATTGTCAT	GAACATATC	CGTAACTGG	ATAGTGAAAC
946					
wtCre	AGGGGCAATG	GTGGCGCTGC	TGGAAGATGG	CGATTAGCCA	TTAAGCGGTA
mx0x0x1	AGGGGCAATG	GTGGCGCTGC	TGGAAGATGG	CGATTAGCCA	TTAAGCGGTA
mx0x0x2	AGGGGCAATG	GTGGCGCTGC	TGGAAGATGG	CGATTAGCCA	TTAAGCGGTA
mx0x0x3	AGGGGCAATG	GTGGCGCTGC	TGGAAGATGG	CGATTAGCCA	TTAAGCGGTA
mx0x0x4	AGGGGCAATG	GTGGCGCTGC	TGGAAGATGG	CGATTAGCCA	TTAAGCGGTA
mx0x0x5	AGGGGCAATG	GTGGCGCTGC	TGGAAGATGG	CGATTAGCCA	TTAAGCGGTA
mx0x0x6	AGGGGCAATG	GTGGCGCTGC	TGGAAGATGG	CGATTAGCCA	TTAAGCGGTA
996					
wtCre	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCGTGAT
mx0x0x1	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCGTGAT
mx0x0x2	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCGTGAT
mx0x0x3	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCGTGAT
mx0x0x4	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCGTGAT
mx0x0x5	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCGTGAT
mx0x0x6	AATGATAAGC	TTGGCTGTTT	TGGCGGATGA	GAGAAGATTT	TCAGCGTGAT
1046					
wtCre	ACAGATTAAA	TCAGAACGCA	GA		
mx0x0x1	ACAGATTAAA	TCAGAACGCA	GA		
mx0x0x2	ACAGATTAAA	TCAGAACGCA	GA		
mx0x0x3	ACAGATTAAA	TCAGAACGCA	GA		
mx0x0x4	ACAGATTAAA	TCAGAACGCA	GA		
mx0x0x5	ACAGATTAAA	TCAGAACGCA	GA		
mx0x0x6	ACAGATTAAA	TCAGAACGCA	GA		
1096					

A.T.T - Start Codon  
T.A.T - Stop Codon  
T - Point Mutation

Table 11

*In Vitro* Evolution of the Cre recombinase





wtCre	MSNLLTVHQN	LPALPVDATS	DEVKKNLMDM	FRDRQAES <del>EH</del>	IWKMLLSVCB
mxoxox1	MSNLLTVHQN	LPALPVDATS	DEVKKNLMAM	FRDRQAES <del>EH</del>	IWKMLLSVCB
mxoxox2	MSNLLTVHQN	LPALPVDATS	DEVKKNLMDM	FRDRQAES <del>EH</del>	IWKMLLSVCB
mxoxox3	MSNLLTVHQN	LPALPIDATS	DEVKKNLMDM	FRDRQAES <del>EH</del>	IWKMLLSVCB
mxoxox4	MSNLLTVHQN	LPALPVDATS	DEVKKNLMDM	FRDRQAES <del>EH</del>	IWKMLLSVCB
mxoxox5	MSNLLTVHQN	LPALPVDATS	DEVKKNLMAM	FRDRQAES <del>EH</del>	IWKMLLSVCB
mxoxox6	MSNLLTVHQN	LPALPVDATS	DEVKKNLMDM	FRDRQAES <del>EH</del>	IWKMLLSVCB
1					
			A	B	
wtCre	SWAAWCKLNN	RKWFP <del>AE</del> PD	VRDYLLYLQA	BGLAVKTIQQ	HLCQLNMLHB
mxoxox1	SWAAWCKLNN	RKWFP <del>AE</del> PD	VRDYLLYLQA	BGLAVKTIQQ	HLCQLNMLHB
mxoxox2	SWAAWCKLNN	RKWFP <del>AE</del> PD	VRDYLLYLQA	BGLAVKTIQQ	HLCQLNMLHB
mxoxox3	SWAAWCKLNN	RKWFP <del>AE</del> PD	VRDYLLYLQA	BGLAVKTIQQ	HLCQLNMLHB
mxoxox4	SWAAWCKLNN	RKWFP <del>AE</del> PD	VRDYLLCLQA	BGLAVKTIQQ	HLCQLNMLHB
mxoxox5	SWAAWCKLNN	RKWFP <del>AE</del> PD	VRDYLLYLQA	BGLAVKTIQQ	HLCQLNMLHB
mxoxox6	SWAAWCKLNN	RKWFP <del>AE</del> PD	VRDYLLYLQA	BGLAVKTIQQ	HLCQLNMLHB
51					
			C	D	
wtCre	B <del>S</del> GLPRPSDS	NAVSLVMBRI	R <del>K</del> ENV <del>D</del> AGER	A <del>K</del> QALAFERT	DFDQV <del>R</del> SLME
mxoxox1	B <del>S</del> GLPRPSDS	NAVSLVMBRI	R <del>K</del> ENV <del>D</del> AGER	A <del>K</del> QALAFERT	DFDQV <del>R</del> SLME
mxoxox2	B <del>S</del> GLPRPSDS	NAVSLVMBRI	R <del>K</del> ENV <del>D</del> AGER	A <del>K</del> QALAF <del>G</del> RT	DFDQV <del>R</del> SLME
mxoxox3	B <del>S</del> GLPRPSDS	NAVSLVMBRI	R <del>K</del> ENV <del>D</del> AGER	A <del>K</del> QALAFERT	DFDQV <del>R</del> SLME
mxoxox4	B <del>S</del> GLPRPSDS	NAVSLVMBRI	R <del>K</del> ENV <del>D</del> AGER	A <del>K</del> QALAFKRT	DFDQV <del>R</del> SLME
mxoxox5	Q <del>S</del> GLPRPSDS	NAVSLVMBRI	R <del>K</del> ENV <del>D</del> AGER	A <del>K</del> QALAFERT	DFDQV <del>R</del> SLME
mxoxox6	B <del>S</del> GLPRPSDS	NAVSLVMBRI	R <del>K</del> ENV <del>D</del> AGER	A <del>K</del> QALAFERT	DFDQV <del>R</del> SLME
101					
			E	F	
wtCre	NSD <del>B</del> CQDI <del>B</del> N	LAFLGIA <del>Y</del> NT	LLFIA <del>E</del> IARI	RVKDISRTDG	GRMLIHIGRT
mxoxox1	NSD <del>B</del> CQDI <del>B</del> N	LAFLGIA <del>Y</del> NT	LLFIA <del>E</del> IARI	RVKDISRTNG	GRMLIHIGRT
mxoxox2	NSD <del>B</del> CQDI <del>B</del> N	LAFLGIA <del>Y</del> NT	LLFIA <del>E</del> IARI	RVKDISRTDG	GRMLIHIGRT
mxoxox3	NSD <del>B</del> CQDI <del>B</del> N	LAFLGIA <del>Y</del> NT	LLFIA <del>E</del> IARI	RVKDISRTNG	GRMLIHISRT
mxoxox4	NSD <del>B</del> CQDI <del>B</del> N	LAFLGIA <del>Y</del> NT	LLFIA <del>E</del> IARI	RVKDISRTDG	GRMLIHIGRT
mxoxox5	NSD <del>B</del> CQDI <del>B</del> N	LAFLGIA <del>Y</del> NT	LLFIA <del>E</del> IARI	RVKDISRTDG	GRMLIHIGRT
mxoxox6	NSD <del>B</del> CQDI <del>B</del> N	LAFLGIA <del>Y</del> NT	LLFIA <del>E</del> IARI	RVKDISRTDG	GRMLIHIGRT
151					
			G	H	1 2

Table 11 (cont)

*In Vitro* Evolution of the Cre recombinase

wtCre	KTLVSTAGVE	KALSLGVTKL	VERWISVSGV	ADDPNNYLFC	BVRKNGVAAP
mxoxox1	KTLVSTAGVE	KALSLGVTKL	VERWISISGV	ADDPNNYLFC	BVRKNGVAAP
mxoxox2	KTLVSTAGVE	KALSLGVTKL	VERWISVSGV	ADDPNNYLFC	BVRKNGVAAP
mxoxox3	KTLVSTAGVE	KALSLGVTKL	VEQWISVSGV	ADDPNNYLFC	BVRKNGVAAP
mxoxox4	KTLVSTAGVE	KALSLGVTKL	VERWISVSGV	ADDPNNYLFC	BVRKNGVAAP
mxoxox5	KTLVSTAGVE	KALSLGVTKQ	VERWISVSGV	ADDPNNYLFC	BVRKNGVAAP
mxoxox6	KTLVSTAGVE	KALSLGVTKL	VERWISVSGV	ADDPNNYLFC	BVRKNGVAAP
201					
wtCre	SATSQSLSTBA	LEGIFEATHR	LIYGAKDDSG	QBYLAWSGHS	AFVGAARDMA
mxoxox1	SATSQSLSTBA	LGGIFEATHR	LIYGAKDDSG	QBYLAWSGHS	AFVGAARDMA
mxoxox2	SATGQSLSTBA	LGGIFEATHR	LIYGAKDDSG	QBYLAWSGHS	AFVGAARDMA
mxoxox3	SATSRLSTBA	LGGIFEATHR	LIYGAKDDSG	QBYLAWSGHS	AFVGAARDMA
mxoxox4	SATSQSLSTBA	LEGIFEATHR	LIYGAKDDSG	QBYQAWSGHS	AFVGAARDMA
mxoxox5	SATSQSLSTBA	LGGIFEATHR	LIYGAKDDSG	QBYLAWSGHS	AFVGAARDMA
mxoxox6	SATSQSLSTBA	LGGIFEATHR	LIYGAKDDSG	QBYQAWSGHS	AFVGAARDMA
251					
wtCre	RAGVSIPEIM	QAGGWITVNI	VMNITBNLDS	ETGAMVRLLE	DGD-
mxoxox1	RAGVSIPEIM	QAGGWITVNI	VMNITBNLDS	ETGAMVRLLE	DGD-
mxoxox2	RAGVSIPEIM	QAGGWSNVNI	VMNITBNLDS	ETGAMVRLLE	DGD-
mxoxox3	RAGVSIPEIM	QAGGWITVNI	VMNITBNLDS	ETGAMVRLLE	DGD-
mxoxox4	RAGVSIPEIM	QAGGWITVNI	VMNITBNLDS	ETGAMVRLLE	DGD-
mxoxox5	RAGVSIPEIM	QAGGWSNVNI	VMNITBNLDS	ETGAMVRLLE	DGD-
mxoxox6	RAGVSIPEIM	QAGGWSNVNI	VMNITBNLDS	ETGAMVRLLE	DGD-
301					

G - mutated residue

T - catalytic residue

E - DNA contacting residue

— -  $\alpha$ -helix→ -  $\beta$  sheet

Table 12

Transition	Frequency	Transversion	Frequency
A - G	29 % (9)	A - C	6.5 % (2)
G - A	26 % (8)	C - A	< 3 % (0)
C - T	6.5 % (2)	A - T	9.7 % (3)
T - C	6.5 % (2)	T - A	9.7 % (3)
		C - G	< 3 % (0)
		G - C	< 3 % (0)
		G - T	6.5 % (2)
		T - G	< 3 % (0)

31 point mutations could be identified in the six analyzed mutants. The mutagenic frequency can therefore be calculated as 0.5%. No frame-shift mutations, or more than one point mutation per codon of the *cre* sequence were found. The table classifies these mutations into the different types of transition and transversion events. Given are the frequencies and in parenthesis the actual numbers which were found. Interestingly, the A to G and vice versa transisiton occurred much more often than all other possible events. On the other hand, half of the possible transversions were not identified at all.

Table 13

Round	Induction	% Kan <sup>R</sup>	Nb. Kan <sup>R</sup>	% White
0	4 h	< 0.01%	-	100%
1	4 h	0.16%	6	84%
2	4 h	0.56%	47	82%
3	2.5 h	0.2%	36	80%
4	2.5 h	4.6%	102	75%



Table 14

Mutant	% Kan <sup>R</sup>	
	<i>loxK2</i> <sup>2</sup>	<i>loxP</i> <sup>2</sup>
wt	<0.01%	94%
R3M1	66%	98%
R3M2	54%	98%
R3M3	65%	91%
R3M4	0.02%	93%
R3M5	15%	91%
R3M6	3%	94%

Table 15 In Vitro Recombination Results

% of recombination is calculated from the obtained fluorescence intensity of substrate and product on an agarose gel.

% of lox-lox recombination In vitro												
Cre	loxP	ATAACTTCGTATA						loxK2		loxK1	loxP-K2	loxP-K1
		TT	TG	GT	GG	TC	CC	AA				
R3M3	25.4	32.1	36.8	29.7	8.5	23.9	36.7	29.9	31.2	28.9		
E262G/D29A	25.4	30.4	21.4	48.4	16.6	20.4	52.4	17.7	31.0	29.7		
E262G/T316S	36.4	37.6	38.6	47.3	19.6	23.2	51.1	32.3	43.2	29.1		
E262G/D189N	35.3	33.8	34.0	59.9	16.4	24.0	65.1	31.2	46.5	35.3		
E262G	30.9	32.1	27.5	49.2	-	15.2	46.9	24.3	35.9	28.4		
wt	28.7	0	45.8	0	0	0	0	0	15.9	4.3		

Table 16      DNA Binding to lox halfsites (Gelshift)

% of gelretardation is calculated from the obtained intensity of the shifted band (Cre bound to lox halfsite) and free lox halfsites (labeled oligonucleotides). The values given here were all obtained with 0.2 pmol of lox halfsites. Without enzyme added, no retardation of either halfsite could be observed. The obtained data was normalized for better comparability to 100% retardation on loxP halfsite, for each enzyme tested.

% of lox halfsites retarded on the gel due to Cre binding			
	loxP	loxK2	loxK1
R3M3	100	14.8 ± 5.2	0.3 ± 0.2
E262G/D29A	100	36.6 ± 6.4	14.1 ± 2.7
E262G/T316S	100	40.7 ± 19.3	13.6 ± 1.7
E262G/D189N	100	44.2 ± 8.1	16.1 ± 2.9
E262G	100	34 ± 7.2	15.8 ± 6.4
wt	100	6 ± 1.3	0.8 ± 1.1
	ATAACTTCGTATA	ATAACAACGTATA	ATACCTTTGTATA

Table 17

Name	pBS#	Sequence: Halfsite - FAS1 Spacer - Inverted Halfsite					
Positions in lox:		17	12	5	4	1/1'4'	5' 11' 17'
loxP	632	ATAACTTCGTATA TACC/TTTC TATAGCAAGTTAT					
loxK2	633	ATAACAACGTATA TACC/TTTC TATAGCTTGTAT					
loxK1	634	ATACCTTTGTATA TACC/TTTC TATAGAAAGGTAT					
loxK2 'GG'	638	ATAACGGCGTATA TACC/TTTC TATAGCCCGTTAT					
loxK2 'CC'	639	ATAACCCCGTATA TACC/TTTC TATAGCGGGTTAT					
loxK2 'TC'	635	ATAACTCCGTATA TACC/TTTC TATAGCGAGTTAT					
loxK2 'GT'	636	ATAACGTCGTATA TACC/TTTC TATAGCACGTTAT					
loxK2 'TG'	637	ATAACTGCGTATA TACC/TTTC TATAGCCAGTTAT					

## CLAIMS

We claim:

1. A method of identifying variant recombinases that mediate recombination at variant recombination sites, the method comprising,

(a) bringing into contact

a mutant recombinase,

a first nucleic acid sequence comprising a first reporter gene and first and second recombination sites, wherein the first and second recombination sites are variant recombination sites, and

a second nucleic acid sequence comprising a second reporter gene and third and fourth recombination sites, wherein the third and fourth recombination sites can be recombined by a non-mutant recombinase,

(b) determining if recombination occurs between the first and second recombination sites, and determining if recombination occurs between the third and fourth recombination sites,

wherein recombination between the first and second recombination sites indicates that the mutant recombinase is a variant recombinase that mediates recombination at variant recombination sites,

wherein recombination between the third and fourth recombination sites indicates that the mutant recombinase retains the ability to mediate recombination at non-variant recombination sites.

2. The method of claim 1 wherein the recombination sites comprise recognition sequences and compatibility sequences,

wherein the recognition sequences of the first and second recombination sites differ from the recognition sequences of the third and fourth recombination sites,

wherein the compatibility sequences of the first and second recombination sites are sufficiently similar to allow recombination between the first and second recombination sites, and wherein the compatibility sequences of the third and fourth recombination sites are sufficiently similar to allow recombination between the third and fourth recombination sites, and

wherein the compatibility sequences of the first and second recombination sites differ from the compatibility sequences of the third and fourth recombination

sites such that neither the first nor the second recombination site can be recombined with either the third or the fourth recombination site.

3. The method of claim 1 wherein the first and second recombination sites cannot be recombined by non-mutant recombinase to a significant extent.

4. The method of claim 1 or 2 wherein the first and second recombination sites have identical sequences, and wherein the third and fourth recombination sites have identical sequences.

5. The method of claim 1 wherein recombination between the first and second recombination sites alters the expression of the first reporter gene, wherein recombination between the first and second recombination sites is determined by determining if expression of the first reporter gene is altered, and

wherein recombination between the third and fourth recombination sites alters the expression of the second reporter gene, wherein recombination between the third and fourth recombination sites is determined by determining if expression of the second reporter gene is altered.

6. The method of claim 5 wherein recombination between the first and second recombination sites allows the first reporter gene to be expressed.

7. The method of claim 6 wherein the first nucleic acid sequence further comprises a spacer sequence flanked by the first and second recombination sites, wherein the spacer sequence interrupts the first reporter gene such that the first reporter gene is not expressed, wherein recombination of the first and second recombination sites excises the spacer sequence which allows the first reporter gene to be expressed.

8. The method of claim 6 wherein a portion of the first reporter gene is inverted, wherein the inverted portion of the first reporter gene is flanked by the first and second recombination sites, wherein recombination of the first and second recombination sites inverts the inverted portion of the first reporter gene which allows the first reporter gene to be expressed.

9. The method of claim 5 wherein recombination between the first and second recombination sites prevents expression of the first reporter gene.

10. The method of claim 9 wherein the first reporter gene is flanked by the first and second recombination sites, wherein recombination of the first and second

recombination sites excises the first reporter gene which prevents expression of the first reporter gene.

11. The method of claim 9 wherein a portion of the first reporter gene is flanked by the first and second recombination sites, wherein recombination of the first and second recombination sites inverts the flanked portion of the first reporter gene which prevents expression of the first reporter gene.

12. The method of claim 5 wherein recombination between the third and fourth recombination sites allows the second reporter gene to be expressed.

13. The method of claim 12 wherein the second nucleic acid sequence further comprises a spacer sequence flanked by the third and fourth recombination sites, wherein the spacer sequence interrupts the second reporter gene such that the second reporter gene is not expressed, wherein recombination of the third and fourth recombination sites excises the spacer sequence which allows the second reporter gene to be expressed.

14. The method of claim 13 wherein the spacer sequence interrupts the second reporter gene such that the second reporter gene is not transcribed.

15. The method of claim 13 wherein the second reporter gene encodes a protein, wherein the spacer sequence interrupts the second reporter gene such that the protein encoded by the second reporter gene is not translated.

16. The method of claim 13 wherein the spacer sequence interrupts the second reporter gene such that the second reporter gene produces an inactive expression product.

17. The method of claim 12 wherein a portion of the second reporter gene is inverted, wherein the inverted portion of the second reporter gene is flanked by the third and fourth recombination sites, wherein recombination of the third and fourth recombination sites inverts the inverted portion of the second reporter gene which allows the second reporter gene to be expressed.

18. The method of claim 5 wherein recombination between the third and fourth recombination sites prevents expression of the second reporter gene to be expressed.

19. The method of claim 18 wherein the second reporter gene is flanked by the third and fourth recombination sites, wherein recombination of the third and

fourth recombination sites excises the second reporter gene which prevents expression of the second reporter gene.

20. The method of claim 18 wherein a portion of the second reporter gene is flanked by the third and fourth recombination sites, wherein recombination of the third and fourth recombination sites inverts the flanked portion of the second reporter gene which prevents expression of the second reporter gene.

21. The method of claim 1 wherein the first nucleic acid sequence is a first nucleic acid construct and the second nucleic acid sequence is on a second nucleic acid construct.

22. The method of claim 21 wherein the first nucleic acid construct is an extrachromosomal vector and the second nucleic acid construct is in the genome of a host cell.

23. The method of claim 1 wherein the first and second nucleic acid constructs are on the same nucleic acid construct.

24. A method for producing site-specific recombination of DNA, comprising,

contacting a variant recombinase identified by the method of claim 1 with first and second DNA sequences,

wherein the first DNA sequence comprises a first recombination site and the second DNA sequence comprises a second recombination site,

wherein the variant recombinase mediates recombination between the first and second recombination sites thereby producing the site specific recombination.

25. The method of claim 24 wherein the first recombination site, the second recombination site, or both, are variant recombination sites.

26. The method of claim 24, wherein the first and second DNA sequences are connected by a pre-selected DNA segment.

27. The method of claim 26, wherein the first and second recombination sites have the same orientation and the site-specific recombination of DNA is a deletion of the pre-selected DNA segment.

28. The method of claim 27, wherein the pre-selected DNA segment is a gene for a structural protein, an enzyme, or a regulatory molecule.

29. The method of claim 27 further comprising contacting the variant recombinase with a fourth DNA sequence comprising a third recombination site,



wherein the second and fourth DNA sequences are connected by a second pre-selected DNA segment.

30. The method of claim 29 wherein the first recombination site is a variant recombination site recognized by the variant recombinase and not by wild type recombinase, and wherein the second and third recombination sites are recombination sites recognized by wild type recombinase and by the variant recombinase.

31. The method of claim 30 further comprising, prior to contacting the variant recombinase with the first, second, and third recombination sites, contacting the recombination sites with wild type recombinase, thereby producing site specific recombination between the second and third recombination sites resulting in a deletion of the second pre-selected DNA segment.

32. The method of claim 29, wherein the second pre-selected DNA segment is a gene for a structural protein, an enzyme, or a regulatory molecule.

33. The method of claim 26, wherein the first and second recombination sites have opposite orientations and the site-specific recombination is an inversion of the nucleotide sequence of the pre-selected DNA segment.

34. The method of claim 33, wherein the first and second recombination sites are variant recombination sites recognized by the variant recombinase.

35. The method of claim 33, wherein the pre-selected DNA segment is a gene for a structural protein, an enzyme, or a regulatory molecule.

36. The method of claim 24, wherein the second and third DNA sequences are introduced into two different DNA molecules and the site-specific recombination is a reciprocal exchange of DNA segments proximate to the recombination sites.

37. The method of claim 36, wherein the first and second recombination sites are variant recombination sites recognized by the variant recombinase.

38. The method of claim 24 wherein the second DNA sequence includes a label, wherein recombination between the first and second recombination sites associates the label with the first DNA sequence.

39. The method of claim 38 wherein the first DNA sequence is a large circular DNA molecule.

40. The method of claim 24 wherein recombination occurs in a cell.

41. The method of claim 40 wherein the variant recombinase is contacted with the first and second DNA sequences by introducing into the cell a third DNA sequence comprising DNA encoding the variant recombinase.

42. The method of claim 41, wherein the third DNA sequence further comprises a regulatory nucleotide sequence and expression of the variant recombinase is produced by activating the regulatory nucleotide sequence.

43. The method of claim 40, wherein the cell is a eukaryotic cell, a mammalian cell, a yeast cell, a fungal cell, a prokaryotic cell, a bacterial cell, an archae bacterial cell, or a cell in a multicellular organism.

44. The method of claim 43 wherein the multicellular organism is a plant, an animal, or a mammal.

45. The method of claim 40, wherein the first and second DNA sequences are connected by a pre-selected DNA segment, wherein the first and second recombination sites have the same orientation and the site-specific recombination of DNA is a deletion of the pre-selected DNA segment.

46. The method of claim 45 wherein the cell is in a multicellular organism.

47. The method of claim 45, wherein the pre-selected segment is an undesired marker or trait gene.

48. The method of claim 24 wherein the variant recombinase is contacted with the recombination sites *in vitro*.

49. The method of claim 48 wherein the method further comprises introducing the recombined DNA into a cell.

50. A method for cloning large DNA fragments, the method comprising concatenating DNA fragments to be cloned with vector arms, wherein each vector arm comprises a recombination site, wherein the DNA fragments and vector arms alternate in the concatemer,

introducing the concatemer into a cell expressing a variant recombinase identified by the method of claim 1, wherein the recombinase mediates recombination of the recombination sites thereby generating circles each containing a DNA fragment and a vector arm.

51. A method for cloning large DNA fragments, the method comprising ligating a DNA fragment to be cloned to vector arms, wherein each vector arm comprises (i) a blunt end, (ii) another end which is compatible with an end of

the DNA fragment to be cloned, and (iii) a recombination site, wherein concatemers are not formed, and

introducing the ligated DNA fragment and vector arms into a cell expressing a variant recombinase identified by the method of claim 1.

52. A method for cloning large DNA fragments, the method comprising ligating a plurality of DNA fragments to be cloned with a plurality of first and second vector arms, wherein each first vector arm comprises two ligatable ends, wherein each second vector arm comprises a recombination site and one non-ligatable end,

wherein, following ligation, the DNA fragments and first vector arms alternate in concatemers, wherein the concatemers are flanked by second vector arms,

introducing the concatemers into a cell expressing a variant recombinase identified by the method of claim 1, wherein the recombinase mediates recombination of the recombination sites thereby generating circles containing the DNA fragments.

53. A variant recombinase identified by the method of claim 1.

54. A nucleic acid molecule encoding a variant recombinase identified by the method of claim 1.

55. The nucleic acid molecule of claim 54 wherein the nucleic acid molecule is a plasmid.

56. A cell containing the nucleic acid molecule of claim 54.

57. The cell of claim 56 wherein the cell is a eukaryotic cell, a mammalian cell, a yeast cell, a fungal cell, a prokaryotic cell, a bacterial cell, an archae bacterial cell, or a cell in a multicellular organism.

58. The cell of claim 57 wherein the multicellular organism is a plant, an animal, or a mammal.

59. A nucleic acid molecule having at least one variant recombination site, wherein the variant recombination site is recognized by a variant recombinase identified by the method of claim 1 and is not recognized by wild type recombinase.

60. The nucleic acid molecule of claim 59 wherein the recombination site is not recognized by wild type recombinase.

61. The nucleic acid molecule of claim 59, wherein a first recombination site and a second recombination site are connected by a pre-selected DNA segment.

62. The nucleic acid molecule of claim 59 wherein the nucleic acid molecule is a plasmid.

63. A cell containing the nucleic acid molecule of claim 59.









FIG. 2

3/25

**FIG. 3**

**FIG. 4****FIG. 6**




**FIG. 5A**

100bp



**FIG. 5B**

300bp




**FIG. 5C**

ca.2kb

300 bp




1.1kb cre



CONTINUED ON FIG. 7B

7/25



CONTINUED ON FIG. 7C





FIG. 7C

9/25



CONTINUED ON FIG. 8B

10/25






FIG. 8B


**FIG. 9**

**FIG. 10A**




CONTINUED ON FIG. 10B






CONTINUED ON FIG. 10C




**FIG. 11**


INTERRUPTED  
(DELETION)





FLANKED  
(DELETION)



INVERTED  
(INVERSION)



**FIG. 12A****DELETION**

*FIG. 12B*

INVERSION

**FIG. 12C**





FIG. 13



**FIG. 14A**

% of Cre - mediated recombination

R3M3 Cre	97	82	67	90
E262G/D29A Cre	95	37	34	47
E262G/T316S Cre	98	21	14	32
E262G/D189N Cre	93	6	5	22
E262G Cre	90	20	10	28
wt Cre	95	0	0	0
	TT	GG	CC	AA

loxHalfsite      ATA A C T T C G T A T A

**FIG. 14B**

% of Cre-mediated recombination

R3M3 Cre	97	90	95	30	82
E262G/D29A Cre	95	47	80	2	30
E262G/T316S Cre	98	32	81	1	12
E262G/D189N Cre	93	22	71	1	17
E262G Cre	90	28	78	2	20
wt Cre	95	0	18	0	5
	loxP <sup>2</sup>	loxK2 <sup>2</sup>	loxP- loxK2	loxK1 <sup>2</sup>	loxP- loxK1




**FIG. 15**% Cre-mediated  $lox^2$  recombination

R3M3 Cre	97	99	92	82	56	67	90
E262G/D29A Cre	95	95	82	37	35	34	47
E262G/T316S Cre	98	97	89	21	31	14	32
E262G/D189N Cre	93	98	68	6	9	5	22
E262G Cre	90	97	65	20	32	10	28
wt Cre	95	92	25	0	0	0	0

TT	TG	GT	GG	TC	CC	AA
----	----	----	----	----	----	----

$loxP$ Halfsite	ATAACTTCGTATA
-----------------	---------------

FIG. 16



23/25





FIG. 17

FIG. 18



wt FRT: GAAGTTCCTATTC TCTAGAAA GTATAGGAACTTC

Note - alternatively, a full site can also be used  
Having 3 repeat elements:

GAAGTTCCTATTC CGAAGTTCCTATTC TCTAGAAA GTATAGGAACTTC

